Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. by Estrada, Karol et al.
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Supplementary Table 11.  Associated top SNPs from SNP‐LS BMD association analysis using 






























Gene A1 A2 Freq1 Analysis Beta P Beta P
Known 
Locus/signal
rs2120461 1p36.23 8370309 RERE t c 0.68 Both sexes 0.048 3.91E‐08 0.035 1.44E‐04 no
rs7521902 1p36.12 22363311 WNT4 a c 0.31 Secondary signal ‐0.051 8.78E‐08 ‐0.050 1.25E‐06 yes
rs6426749 1p36.12 22584060 ZBTB40 c g 0.17 Both sexes 0.108 1.35E‐23 0.105 2.35E‐20 yes
rs12137389 1p34.1 45710973 TESK2 t c 0.02 Both sexes ‐0.127 3.05E‐06 ‐0.052 7.38E‐02 no
rs17482952 1p31.3 68411973 WLS a g 0.93 Secondary signal 0.076 2.32E‐07 0.063 7.19E‐05 yes/no
rs12407028 1p31.3 68420304 WLS t c 0.61 Both sexes 0.048 1.47E‐08 0.081 6.86E‐20 yes
rs11809524 1p21.1 103232125 COL11A1 t c 0.85 Both sexes 0.055 1.37E‐06 0.047 1.06E‐04 no
rs479336 1q24.3 170466196 DNM3 t g 0.74 Both sexes ‐0.050 1.06E‐07 ‐0.024 1.34E‐02 no
rs12120297 1q41 221617907 SUSD4 t c 0.85 Both sexes 0.042 7.95E‐04 0.065 3.05E‐06 no
rs13413210 2p23.2 29426149 ALK a c 0.91 Males ‐0.059 3.02E‐02 ‐0.130 2.65E‐06 no
rs7584262 2p21 42104053 PKDCC t c 0.23 Both sexes 0.053 1.44E‐07 0.016 1.27E‐01 no
rs4233949 2p16.2 54513211 SPTBN1 c g 0.38 Both sexes 0.032 1.49E‐04 0.062 5.01E‐12 yes
rs730402 2p16.1 59948210 BCL11A a g 0.45 Males 0.070 2.62E‐06 0.037 1.45E‐02 no
rs17040773 2q13 112216506 ANAPC1 a c 0.77 Both sexes 0.045 4.26E‐06 0.005 6.14E‐01 no
rs1878526 2q14.2 118755068 INSIG2 a g 0.22 Females 0.013 2.77E‐01 0.061 6.41E‐07 no
rs1346004 2q24.3 166309292 GALNT3 a g 0.49 Both sexes ‐0.052 1.79E‐10 ‐0.049 1.29E‐08 yes
rs11675051 2q32.2 191154675 NAB1 a g 0.32 Females 0.049 1.47E‐06 0.019 8.15E‐02 no
rs12995369 2q33.1 202535225 ALS2CR7 a g 0.55 Both sexes 0.052 1.94E‐07 0.031 4.71E‐03 no
rs6436440 2q36.1 224413150 AP1S3 a g 0.47 Females 0.046 1.17E‐06 0.033 1.10E‐03 no
rs2291296 3p24.2 25400886 RARB a g 0.17 Females ‐0.007 5.88E‐01 ‐0.061 3.76E‐06 no
rs7427438 3p24.1 29369729 RBMS3 a c 0.33 Females ‐0.047 2.29E‐06 ‐0.017 1.16E‐01 no
rs430727 3p22.1 41103568 CTNNB1 t c 0.47 Both sexes ‐0.074 9.73E‐17 ‐0.056 2.87E‐09 yes
rs1026364 3q13.2 114852700 KIAA2018 t g 0.36 Both sexes 0.041 2.01E‐06 0.019 4.29E‐02 no
rs344081 3q25.31 158038678 LEKR1 t c 0.87 Males 0.112 6.83E‐07 0.083 2.87E‐04 no
rs3755955 4p16.3 984414 IDUA a g 0.16 Both sexes ‐0.061 3.90E‐07 ‐0.068 1.35E‐07 no
rs6532023 4q22.1 88992873 MEPE t g 0.34 Both sexes 0.051 2.55E‐09 0.061 1.72E‐11 yes
rs1366594 5q14.3 88411817 MEF2C a c 0.53 Both sexes 0.092 7.38E‐29 0.019 2.90E‐02 yes
rs4957742 5q21.3 105200867 EFNA5 a g 0.77 Both sexes ‐0.044 4.74E‐06 ‐0.028 7.56E‐03 no
rs9466056 6p22.3 21492592 CDKAL1 a g 0.38 Both sexes ‐0.048 1.80E‐08 ‐0.036 6.53E‐05 no
rs11755164 6p21.1 44747162 SUPT3H t c 0.40 Both sexes ‐0.012 2.26E‐01 ‐0.052 3.52E‐07 no
rs13204965 6q22.32 127208765 RSPO3 a c 0.76 Females 0.069 2.90E‐07 0.049 8.23E‐04 yes
rs4869742 6q25.1 151949441 C6orf97 t c 0.32 Both sexes ‐0.068 3.61E‐14 ‐0.087 3.27E‐20 yes
rs7751941 6q25.1 151988351 C6orf97 a g 0.21 Secondary signal ‐0.048 5.34E‐07 ‐0.077 3.97E‐14 yes/yes
rs7788807 7p22.1_1 4734564 FOXK1 t c 0.94 Females 0.043 3.34E‐02 0.098 4.11E‐06 no
rs2008425 7p22.1_2 5786972 RNF216 t g 0.02 Females ‐0.127 2.00E‐03 ‐0.194 2.97E‐06 no










rs6959212 7p14.1 38094851 STARD3NL t c 0.34 Both sexes ‐0.030 6.36E‐04 ‐0.077 6.86E‐17 yes
rs2282930 7p12.2 50722173 GRB10 a g 0.26 Females ‐0.057 5.03E‐07 ‐0.037 2.26E‐03 no
rs4727338 7q21.3 95958611 SLC25A13 c g 0.67 Both sexes 0.081 2.99E‐20 0.074 1.11E‐15 yes
rs13245690 7q31.31 120572300 C7orf58 a g 0.65 Secondary signal 0.032 8.57E‐05 0.052 1.07E‐09 no
rs3801387 7q31.31 120762001 WNT16 a g 0.74 Both sexes ‐0.071 4.23E‐14 ‐0.083 1.35E‐16 no
rs7812088 7q36.1 150550762 ABCF2 a g 0.12 Both sexes 0.061 1.22E‐06 0.055 2.93E‐05 no
rs1670346 7q36.3 157960022 PTPRN2 a g 0.30 Both sexes ‐0.042 2.81E‐06 ‐0.020 3.49E‐02 no
rs7017914 8q13.3 71753757 XKR9 a g 0.49 Females 0.053 4.70E‐08 0.010 3.52E‐01 no
rs13272568 8q21.12 79197014 PKIA a c 0.44 Both sexes ‐0.039 2.13E‐06 ‐0.014 9.80E‐02 no
rs2062377 8q24.12 120076601 TNFRSF11B a t 0.59 Both sexes ‐0.063 2.50E‐14 ‐0.081 2.26E‐20 yes
rs4240467 9q33.2 123350111 DAB2IP c g 0.32 Males ‐0.043 6.75E‐03 ‐0.079 9.65E‐07 no
rs7851693 9q34.11 132468648 FUBP3 c g 0.63 Both sexes 0.047 3.08E‐08 0.017 5.81E‐02 no
rs3905706 10p11.23 28519948 MPP7 t c 0.23 Both sexes 0.005 6.28E‐01 0.063 2.93E‐09 no
rs1373004 10q21.1 54097831 MBL2 t g 0.12 Females ‐0.065 6.32E‐06 ‐0.089 8.87E‐09 no
rs7071206 10q22.3_1 79071322 KCNMA1 t c 0.76 Females ‐0.020 8.68E‐02 ‐0.087 8.34E‐13 no
rs2784767 10q22.3_2 81884474 PLAC9 t c 0.43 Females 0.052 4.80E‐06 0.036 5.09E‐03 no
rs7084921 10q24.2 101803792 CPN1 t c 0.40 Females 0.045 3.13E‐06 0.027 8.62E‐03 no
rs11602954 11p15.5 192856 BET1L a g 0.23 Both sexes 0.034 1.06E‐03 0.056 2.74E‐07 no
rs7108738 11p15.2 15666660 SOX6 t g 0.82 Both sexes ‐0.093 1.03E‐17 ‐0.047 4.51E‐05 yes
rs10835187 11p14.1_1 27462253 LIN7C t c 0.54 Females ‐0.028 3.70E‐03 ‐0.052 4.14E‐07 no
rs163879 11p14.1_2 30908250 DCDC5 t c 0.66 Both sexes ‐0.042 1.70E‐06 ‐0.049 8.81E‐08 yes
rs7932354 11p11.2 46678797 ARHGAP1 t c 0.33 Both sexes 0.050 2.29E‐08 0.041 1.23E‐05 yes
rs600231 11q13.1 65017222 SCYL1 a g 0.69 Females ‐0.051 9.03E‐07 ‐0.032 3.55E‐03 no
rs3736228 11q13.2 67957871 LRP5 t c 0.15 Both sexes ‐0.054 1.79E‐06 ‐0.081 1.62E‐11 yes
rs2887571 12p13.33 1508432 ERC1 a g 0.76 Both sexes ‐0.037 1.06E‐04 ‐0.052 2.20E‐07 no
rs11048046 12p12.1 25496076 IFLTD1 a g 0.08 Males ‐0.148 3.59E‐06 ‐0.055 8.30E‐02 no
rs7953528 12p11.22 27908426 KLHDC5 a t 0.18 Both sexes 0.058 5.75E‐08 0.001 9.44E‐01 no
rs12821008 12q13.12 47760872 DHH t c 0.40 Both sexes 0.032 1.89E‐04 0.047 1.53E‐07 no
rs2016266 12q13.13 52014222 SP7 a g 0.69 Both sexes ‐0.045 4.79E‐07 ‐0.063 1.53E‐11 yes
rs736825 12q13.13 52703843 HOXC6 c g 0.56 Secondary signal 0.036 7.65E‐06 0.054 2.40E‐10 yes/no
rs1053051 12q23.3 105891355 C12orf23 t c 0.51 Both sexes ‐0.036 1.35E‐05 ‐0.041 2.47E‐06 no
rs9533090 13q14.11 41849449 AKAP11 t c 0.48 Both sexes ‐0.054 9.84E‐11 ‐0.110 1.02E‐35 yes
rs7326472 13q14.11 41877951 AKAP11 a g 0.92 Secondary signal ‐0.055 2.55E‐03 ‐0.103 9.80E‐08 yes/no
rs1286083 14q32.12 90512532 RPS6KA5 t c 0.80 Both sexes ‐0.059 2.91E‐08 ‐0.074 1.69E‐11 no
rs11623869 14q32.32 102953386 MARK3 t g 0.34 Both sexes ‐0.041 1.26E‐06 ‐0.030 7.53E‐04 yes









rs9921222 16p13.3_1 315783 AXIN1 t c 0.46 Both sexes ‐0.043 2.46E‐07 ‐0.049 2.20E‐08 no
rs13336428 16p13.3_2 1472464 C16orf38 a g 0.44 Both sexes ‐0.043 2.87E‐07 ‐0.036 5.94E‐05 no
rs4985155 16p13.11 15036960 NTAN1 a g 0.65 Both sexes ‐0.031 3.53E‐04 ‐0.045 8.71E‐07 no
rs1564981 16q12.1 49543809 CYLD a g 0.50 Secondary signal ‐0.025 1.05E‐03 ‐0.045 6.24E‐08 no
rs1566045 16q12.1 49579304 SALL1 t c 0.80 Both sexes ‐0.074 4.95E‐12 ‐0.030 7.83E‐03 no
rs10048146 16q24.1 85268161 FOXL1 a g 0.80 Both sexes 0.056 1.28E‐07 0.061 2.95E‐08 yes
rs4790881 17p13.3 2015682 SMG6 a c 0.67 Both sexes 0.051 1.66E‐08 0.032 6.04E‐04 no
rs4792909 17q21.31_1 39154350 SOST t g 0.37 Secondary signal 0.035 1.85E‐05 0.044 5.14E‐07 yes/yes
rs227584 17q21.31_1 39581073 C17orf53 a c 0.67 Both sexes ‐0.060 3.44E‐11 ‐0.048 4.77E‐07 yes
rs1864325 17q21.31_2 41333623 MAPT t c 0.22 Both sexes ‐0.040 7.79E‐05 ‐0.057 1.11E‐07 yes
rs7226305 17q22 49464490 KIF2B a c 0.82 Both sexes ‐0.017 1.29E‐01 ‐0.058 1.33E‐06 no
rs7217932 17q24.3 67460611 SOX9 a g 0.46 Both sexes 0.045 3.65E‐08 0.009 3.12E‐01 no
rs4796995 18p11.21 13698574 C18orf19 a g 0.61 Both sexes 0.040 3.18E‐06 0.031 5.22E‐04 no
rs884205 18q21.33 58205837 TNFRSF11A a c 0.25 Both sexes ‐0.042 3.87E‐05 ‐0.065 4.85E‐09 yes
rs7257450 19p13.11 17349607 PLVAP a g 0.76 Females 0.014 2.78E‐01 0.065 4.79E‐06 no
rs10416218 19q13.11 38290967 GPATCH1 t c 0.72 Both sexes ‐0.042 5.73E‐06 ‐0.056 9.19E‐09 no
rs3790160 20p12.2 10587988 JAG1 t c 0.50 Both sexes 0.043 1.32E‐07 0.057 5.36E‐11 yes
rs4817775 21q22.12 36406932 CBR3 a c 0.58 Both sexes 0.023 6.24E‐03 0.042 1.49E‐06 no
rs4820539 22q11.23 21807970 RTDR1 a g 0.44 Both sexes 0.038 4.86E‐06 0.025 3.65E‐03 no
rs5934507 Xp22.31 8877206 FAM9B a g 0.73 ChrX ‐ men ‐0.031 1.19E‐02 ‐0.057 5.66E‐06 no
rs5926033 Xp22.11 22594282 DDX53 t c 0.71 ChrX ‐ both sexes 0.037 4.13E‐06 0.014 9.96E‐02 no
rs5952638 Xp11.3 44579849 DUSP21 a t 0.93 ChrX ‐ both sexes 0.056 3.03E‐04 0.069 2.29E‐05 no
rs4492531 Xq13.3 74948856 MAGEE2 a g 0.55 ChrX ‐ both sexes ‐0.066 1.98E‐03 ‐0.094 2.40E‐05 no




















r2 A1d Beta P Beta P Beta P Beta P
rs17482952 1p31.3 WLS 0.07 rs12407028 8,331     0.01 0.062 a 0.08 2.32E‐07 0.06 7.19E‐05 0.08 1.31E‐11 0.07 1.69E‐08
rs7521902 1p36.12 WNT4 0.19 rs6426749 220,749 0.42 0.003 a ‐0.05 8.78E‐08 ‐0.05 1.25E‐06 ‐0.04 2.85E‐09 ‐0.05 9.66E‐11
rs7751941 6q25.1 C6orf97/ESR1 0.23 rs4869742 38,910   0.11 0.008 a ‐0.05 5.34E‐07 ‐0.08 3.97E‐14 ‐0.04 1.59E‐09 ‐0.08 1.99E‐24
rs10226308 7p14.1 TXNDC3/SFRP4 0.19 rs6959212 189,904 0.25 0.004 a ‐0.03 3.81E‐03 ‐0.06 3.36E‐09 ‐0.02 1.53E‐02 ‐0.06 6.40E‐13
rs13245690 7q31.31 C7orf58 0.38 rs3801387 189,701 0.15 0.028 a 0.03 8.57E‐05 0.05 1.07E‐09 0.02 8.20E‐04 0.05 1.65E‐11
rs736825 12q13.13 HOXC6 0.35 rs2016266 689,621 NA NA c 0.04 7.65E‐06 0.05 2.40E‐10 0.04 1.06E‐09 0.05 7.68E‐16
rs7326472 13q14.11 AKAP11/TNFSF11 0.04 rs9533090 28,502   0.01 0.033 a ‐0.05 2.55E‐03 ‐0.10 9.80E‐08 ‐0.05 5.07E‐04 ‐0.07 2.61E‐07
rs1564981 16q12.1 CYLD 0.47 rs1566045 35,495   0.10 0.009 a ‐0.03 1.05E‐03 ‐0.04 6.24E‐08 ‐0.02 4.38E‐05 ‐0.04 1.95E‐10













TRAIT SNP1 GENE1 SNP2 GENE2 Beta_interaction se_interaction I2 P_interaction
FNBMD rs4869742 C6orf97 rs12821008 DHH 0.04 0.009 0 4.90E‐05
FNBMD rs11809524 COL11A1 rs9533090 AKAP11 0.04 0.011 20 2.18E‐04
LSBMD rs9466056 CDKAL1 rs2016266 SP7 0.02 0.007 8 2.23E‐04
LSBMD rs11675051 NAB1 rs2282930 GRB10 ‐0.03 0.009 0 5.98E‐04
LSBMD rs9921222 AXIN1 rs1864325 MAPT 0.03 0.009 37 7.58E‐04
FNBMD rs11675051 NAB1 rs3755955 IDUA 0.04 0.012 0 1.20E‐03
FNBMD rs2120461 RERE rs2282930 GRB10 0.03 0.010 24 1.25E‐03
LSBMD rs7953528 KLHDC5 rs7257450 PLVAP 0.02 0.007 16 1.34E‐03





SNP Locus Closest Gene A1a A2 Freq1 Beta P Beta P I2 Qhet P Beta P Beta P Beta P I2 Qhet P Beta P
rs479336 1q24.3 DNM3 t g 0.74 ‐0.05 1.06E‐07 ‐0.04 1.30E‐08 0 0.94 ‐0.04 8.51E‐15 ‐0.02 0.01 ‐0.03 4.97E‐04 0 0.84 ‐0.03 2.14E‐05
rs7584262 2p21 PKDCC t c 0.23 0.05 1.44E‐07 0.03 3.37E‐04 0 0.75 0.04 1.27E‐09 0.02 0.13 0.01 0.28 0 0.93 0.01 0.07
rs17040773 2q13 ANAPC1 a c 0.76 0.05 4.26E‐06 0.03 6.08E‐05 21 0.14 0.04 1.51E‐09 0.01 0.61 0.01 0.21 0 0.97 0.01 0.19
rs1878526 2q14.2 INSIG2 a g 0.22 0.00 0.70 0.00 0.97 12 0.27 0.00 0.79 0.05 7.31E‐06 0.04 3.38E‐06 0 0.48 0.04 1.22E‐10
rs1026364 3q13.2 KIAA2018 t g 0.37 0.04 2.01E‐06 0.03 2.51E‐05 0 0.66 0.03 4.08E‐10 0.02 0.04 0.02 7.26E‐03 33 0.04 0.02 7.57E‐04
rs344081 3q25.31 LEKR1 t c 0.87 0.05 1.09E‐04 0.03 2.50E‐03 21 0.14 0.04 2.22E‐06 0.06 2.76E‐05 0.06 3.54E‐08 0 0.77 0.06 4.46E‐12
rs3755955 4p16.3 IDUA a g 0.16 ‐0.06 3.90E‐07 ‐0.05 6.14E‐09 6 0.37 ‐0.06 1.46E‐14 ‐0.07 1.35E‐07 ‐0.05 5.52E‐09 20 0.16 ‐0.06 5.24E‐15
rs11755164 6p21.1 SUPT3H t c 0.40 ‐0.01 0.23 ‐0.01 0.12 0 0.91 ‐0.01 0.05 ‐0.05 3.52E‐07 ‐0.03 9.19E‐06 0 0.82 ‐0.04 5.60E‐11
rs9466056 6p22.3 CDKAL1 a g 0.38 ‐0.05 1.80E‐08 ‐0.03 1.55E‐06 0 0.74 ‐0.04 2.73E‐13 ‐0.04 6.53E‐05 ‐0.03 1.11E‐04 16 0.21 ‐0.03 3.56E‐08
rs3801387 7q31.31 WNT16 a g 0.74 ‐0.07 4.23E‐14 ‐0.08 2.00E‐27 12 0.27 ‐0.08 5.02E‐40 ‐0.08 1.35E‐16 ‐0.10 1.50E‐36 17 0.19 ‐0.09 3.17E‐51
rs13245690 7q31.31 C7orf58 a g 0.65 0.03 8.57E‐05 0.00 0.69 37 0.07 0.02 8.20E‐04 0.05 1.07E‐09 0.03 1.30E‐03 18 0.24 0.05 1.65E‐11
rs7812088 7q36.1 ABCF2 a g 0.13 0.06 1.22E‐06 0.04 4.41E‐04 27 0.08 0.05 7.28E‐09 0.06 2.93E‐05 0.04 1.10E‐03 50 0.002 0.04 2.24E‐07
rs7017914* 8q13.3 XKR9 a g 0.49 0.04 3.60E‐07 0.02 0.02 10 0.35 0.03 2.29E‐07 0.00 0.91 ‐0.01 0.11 5 0.78 ‐0.01 0.26
rs7851693 9q34.11 FUBP3 c g 0.64 0.05 3.08E‐08 0.05 1.43E‐15 0 0.51 0.05 3.37E‐22 0.02 0.06 0.04 6.71E‐08 1 0.45 0.03 6.08E‐08
rs3905706 10p11.23 MPP7 t c 0.22 0.00 0.63 ‐0.02 1.67E‐03 0 0.95 ‐0.01 0.03 0.06 2.93E‐09 0.05 6.68E‐09 0 0.49 0.05 2.41E‐16
rs1373004 10q21.1 MBL2 t g 0.13 ‐0.06 1.39E‐05 ‐0.04 1.45E‐04 19 0.18 ‐0.04 1.45E‐08 ‐0.07 5.40E‐08 ‐0.05 2.24E‐06 26 0.10 ‐0.06 1.56E‐12
rs7071206 10q22.3_1 KCNMA1 t c 0.78 ‐0.01 0.29 0.01 0.26 1 0.45 0.00 0.81 ‐0.07 1.54E‐12 ‐0.05 6.24E‐09 28 0.07 ‐0.06 5.02E‐19
rs7084921 10q24.2 CPN1 t c 0.39 0.03 1.42E‐04 0.03 1.55E‐06 0 0.51 0.03 9.03E‐10 0.02 0.01 0.03 1.92E‐05 15 0.23 0.03 9.15E‐07
rs10835187 11p14.1_1 LIN7C t c 0.55 ‐0.01 0.17 ‐0.01 0.08 0 0.91 ‐0.01 0.03 ‐0.04 3.04E‐05 ‐0.02 2.36E‐04 24 0.11 ‐0.03 4.90E‐08
rs7953528 12p11.22 KLHDC5 a t 0.18 0.06 5.75E‐08 0.04 2.43E‐06 0 0.54 0.05 1.87E‐12 0.00 0.94 ‐0.02 0.05 0 0.94 ‐0.01 0.13
rs2887571 12p13.33 ERC1 a g 0.76 ‐0.04 1.06E‐04 ‐0.03 1.60E‐05 25 0.10 ‐0.03 6.49E‐09 ‐0.05 2.20E‐07 ‐0.04 2.88E‐06 0 0.52 ‐0.04 5.59E‐12
rs12821008 12q13.12 DHH t c 0.39 0.03 1.89E‐04 0.03 5.20E‐04 0 0.72 0.03 3.34E‐07 0.05 1.53E‐07 0.05 1.89E‐09 7 0.36 0.05 1.17E‐15
rs1053051 12q23.3 C12orf23 t c 0.52 ‐0.04 1.35E‐05 ‐0.03 1.82E‐05 13 0.27 ‐0.03 9.60E‐10 ‐0.04 2.47E‐06 ‐0.02 2.38E‐03 0 0.86 ‐0.03 7.90E‐08
rs1286083 14q32.12 RPS6KA5 t c 0.81 ‐0.06 2.91E‐08 ‐0.05 9.32E‐09 0 0.50 ‐0.05 2.02E‐15 ‐0.07 1.69E‐11 ‐0.04 7.13E‐06 25 0.10 ‐0.05 1.75E‐14
rs4985155 16p13.11 NTAN1 a g 0.67 ‐0.03 3.53E‐04 ‐0.03 1.38E‐07 4 0.41 ‐0.03 1.74E‐10 ‐0.04 8.71E‐07 ‐0.03 1.83E‐04 0 0.66 ‐0.03 2.15E‐09
rs9921222 16p13.3_1 AXIN1 t c 0.48 ‐0.04 2.46E‐07 ‐0.03 2.37E‐06 43 0.01 ‐0.04 5.18E‐12 ‐0.05 2.20E‐08 ‐0.04 8.29E‐10 28 0.07 ‐0.04 1.00E‐16
rs13336428 16p13.3_2 C16orf38 a g 0.43 ‐0.04 2.87E‐07 ‐0.04 1.08E‐10 0 0.79 ‐0.04 1.49E‐16 ‐0.04 5.94E‐05 ‐0.04 5.75E‐10 0 0.65 ‐0.04 1.66E‐13
rs1566045 16q12.1 SALL1 t c 0.80 ‐0.07 4.95E‐12 ‐0.06 3.03E‐12 30 0.05 ‐0.06 1.94E‐22 ‐0.03 7.83E‐03 ‐0.01 0.55 25 0.11 ‐0.01 0.04
rs1564981 16q12.1 CYLD a g 0.50 ‐0.03 1.05E‐03 ‐0.02 0.01 23 0.18 ‐0.02 4.38E‐05 ‐0.04 6.24E‐08 ‐0.03 5.37E‐04 48 0.01 ‐0.04 1.95E‐10
rs4790881 17p13.3 SMG6 a c 0.69 0.05 1.66E‐08 0.05 1.18E‐11 12 0.28 0.05 9.75E‐19 0.03 6.04E‐04 0.04 1.65E‐06 27 0.09 0.03 3.38E‐09
rs7217932 17q24.3 SOX9 a g 0.46 0.05 3.65E‐08 0.03 2.69E‐05 5 0.39 0.03 1.92E‐11 0.01 0.31 0.01 0.15 0 0.69 0.01 0.08
rs4796995 18p11.21 C18orf19 a g 0.63 0.04 3.18E‐06 0.02 1.13E‐03 39 0.01 0.03 4.85E‐08 0.03 5.22E‐04 0.01 0.11 14 0.24 0.02 6.65E‐04
rs10416218 19q13.11 GPATCH1 t c 0.73 ‐0.04 5.73E‐06 ‐0.02 7.11E‐04 0 0.69 ‐0.03 5.52E‐08 ‐0.06 9.19E‐09 ‐0.03 1.22E‐04 0 0.96 ‐0.04 6.64E‐11
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rs17482952 1p31.3 WLS a g 0.93 0.08 2.32E‐07 0.08 1.23E‐05 17 0.25 0.08 1.31E‐11 0.06 7.19E‐05 0.07 5.66E‐05 8 0.36 0.07 1.69E‐08
rs12407028 1p31.3 WLS t c 0.60 0.05 1.47E‐08 0.05 4.62E‐16 0 0.75 0.05 3.44E‐23 0.08 6.86E‐20 0.07 1.12E‐26 27 0.09 0.08 3.11E‐45
rs7521902 1p36.12 WNT4 a c 0.31 ‐0.05 8.78E‐08 ‐0.03 3.92E‐03 0 0.45 ‐0.04 2.85E‐09 ‐0.05 1.25E‐06 ‐0.05 1.60E‐05 42 0.03 ‐0.05 9.66E‐11
rs6426749 1p36.12 ZBTB40 c g 0.17 0.11 1.35E‐23 0.11 3.49E‐35 0 0.86 0.11 7.39E‐57 0.11 2.35E‐20 0.10 3.66E‐26 0 0.80 0.10 1.86E‐44
rs4233949 2p16.2 SPTBN1 c g 0.38 0.03 1.49E‐04 0.02 6.40E‐03 0 0.56 0.02 5.91E‐06 0.06 5.01E‐12 0.04 2.35E‐08 41 0.01 0.05 2.25E‐18
rs1346004 2q24.3 GALNT3 a g 0.50 ‐0.05 1.79E‐10 ‐0.05 1.16E‐16 30 0.06 ‐0.05 1.08E‐25 ‐0.05 1.29E‐08 ‐0.07 1.50E‐23 6 0.37 ‐0.06 3.87E‐30
rs430727 3p22.1 CTNNB1 t c 0.48 ‐0.07 9.73E‐17 ‐0.05 3.43E‐11 12 0.28 ‐0.06 4.41E‐25 ‐0.06 2.87E‐09 ‐0.05 9.58E‐11 27 0.10 ‐0.05 1.54E‐18
rs6532023 4q22.1 MEPE t g 0.34 0.05 2.55E‐09 0.06 3.62E‐18 0 0.53 0.06 4.95E‐26 0.06 1.72E‐11 0.06 7.32E‐18 3 0.41 0.06 1.23E‐27
rs1366594 5q14.3 MEF2C a c 0.54 0.09 7.38E‐29 0.08 6.25E‐34 26 0.09 0.08 4.47E‐61 0.02 0.03 0.01 0.14 0 0.53 0.01 0.01
rs13204965 6q22.32 RSPO3 a c 0.76 0.05 1.49E‐06 0.04 7.24E‐07 0 0.82 0.04 8.12E‐12 0.04 2.68E‐04 0.04 3.90E‐07 0 0.75 0.04 3.61E‐10
rs7751941 6q25.1 C6orf97 a g 0.21 ‐0.05 5.34E‐07 ‐0.04 7.49E‐04 0 0.84 ‐0.04 1.59E‐09 ‐0.08 3.97E‐14 ‐0.08 8.27E‐12 32 0.10 ‐0.08 1.99E‐24
rs4869742 6q25.1 C6orf97 t c 0.31 ‐0.07 3.61E‐14 ‐0.04 5.38E‐07 16 0.21 ‐0.05 4.15E‐18 ‐0.09 3.27E‐20 ‐0.07 5.05E‐17 14 0.24 ‐0.08 3.95E‐35
rs10226308 7p14.1 TXNDC3 a g 0.84 ‐0.03 3.81E‐03 0.00 0.81 8 0.36 ‐0.02 0.02 ‐0.06 3.36E‐09 ‐0.05 3.17E‐05 28 0.13 ‐0.06 6.40E‐13
rs6959212 7p14.1 STARD3NL t c 0.32 ‐0.03 6.36E‐04 ‐0.05 1.85E‐11 0 0.97 ‐0.04 1.18E‐13 ‐0.08 6.86E‐17 ‐0.07 7.21E‐23 0 0.66 ‐0.07 3.76E‐38
rs4727338 7q21.3 SLC25A13 c g 0.67 0.08 2.99E‐20 0.08 2.61E‐29 26 0.09 0.08 8.10E‐48 0.07 1.11E‐15 0.07 5.24E‐21 4 0.40 0.07 2.13E‐35
rs2062377 8q24.12 TNFRSF11B a t 0.57 ‐0.06 2.50E‐14 ‐0.05 2.63E‐12 4 0.40 ‐0.06 9.06E‐25 ‐0.08 2.26E‐20 ‐0.07 2.18E‐20 0 0.59 ‐0.08 3.16E‐39
rs7932354 11p11.2 ARHGAP1 t c 0.31 0.05 2.29E‐08 0.05 3.46E‐11 0 0.97 0.05 5.12E‐18 0.04 1.23E‐05 0.04 1.10E‐07 0 0.60 0.04 5.45E‐12
rs163879 11p14.1_2 DCDC5 t c 0.68 ‐0.04 1.70E‐06 ‐0.02 6.66E‐04 34 0.03 ‐0.03 2.06E‐08 ‐0.05 8.81E‐08 ‐0.03 1.72E‐05 0 0.58 ‐0.04 2.19E‐11
rs7108738 11p15.2 SOX6 t g 0.83 ‐0.09 1.03E‐17 ‐0.07 1.82E‐17 6 0.37 ‐0.08 1.08E‐32 ‐0.05 4.51E‐05 ‐0.03 3.93E‐03 30 0.06 ‐0.03 2.14E‐06
rs3736228 11q13.2 LRP5 t c 0.16 ‐0.05 1.79E‐06 ‐0.05 5.29E‐06 0 0.80 ‐0.05 4.83E‐11 ‐0.08 1.62E‐11 ‐0.09 1.30E‐16 0 0.85 ‐0.08 2.08E‐26
rs736825 12q13.13 HOXC6 c g 0.56 0.04 7.65E‐06 0.04 2.76E‐05 44 0.03 0.04 1.06E‐09 0.05 2.40E‐10 0.05 5.59E‐07 41 0.04 0.05 7.68E‐16
rs2016266 12q13.13 SP7 a g 0.68 ‐0.04 4.79E‐07 ‐0.03 4.48E‐05 3 0.42 ‐0.03 3.67E‐10 ‐0.06 1.53E‐11 ‐0.05 1.59E‐10 0 0.76 ‐0.05 2.95E‐20
rs9533090b 13q14.11 AKAP11 t c 0.49 ‐0.05 9.84E‐11 ‐0.05 1.04E‐13 27 0.09 ‐0.05 4.94E‐23 ‐0.11 1.02E‐35 ‐0.09 1.92E‐34 66.1b 2.73E‐07 ‐0.10 4.82E‐68
rs11623869 14q32.32 MARK3 t g 0.35 ‐0.04 1.26E‐06 ‐0.04 7.02E‐11 26 0.09 ‐0.04 5.20E‐16 ‐0.03 7.53E‐04 ‐0.04 1.23E‐08 1 0.45 ‐0.04 5.12E‐11
rs10048146 16q24.1 FOXL1 a g 0.80 0.06 1.28E‐07 0.05 1.63E‐08 0 0.51 0.05 1.00E‐14 0.06 2.95E‐08 0.04 4.70E‐05 0 0.93 0.05 3.09E‐11
rs4792909 17q21.31_1 SOST t g 0.37 0.04 1.85E‐05 0.05 8.74E‐08 41 0.04 0.04 1.95E‐11 0.04 5.14E‐07 0.03 3.29E‐04 23 0.18 0.04 9.43E‐10
rs227584 17q21.31_1 C17orf53 a c 0.70 ‐0.06 3.44E‐11 ‐0.05 1.18E‐14 9 0.32 ‐0.06 2.56E‐24 ‐0.05 4.77E‐07 ‐0.03 1.23E‐04 13 0.27 ‐0.04 9.92E‐10
rs1864325 17q21.31_2 MAPT t c 0.22 ‐0.04 7.79E‐05 ‐0.02 0.06 10 0.31 ‐0.03 7.47E‐05 ‐0.06 1.11E‐07 ‐0.04 3.11E‐05 14 0.25 ‐0.04 4.89E‐11
rs884205 18q21.33 TNFRSF11A a c 0.27 ‐0.04 3.87E‐05 ‐0.03 1.68E‐06 0 0.70 ‐0.04 3.18E‐10 ‐0.06 4.85E‐09 ‐0.05 2.61E‐10 0 0.71 ‐0.05 1.58E‐17
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rs11809524 1p21.1 COL11A1 t c 0.85 0.06 1.37E‐06 0.02 0.06 13 0.26 0.03 9.32E‐06 0.05 1.06E‐04 0.02 0.10 0 0.69 0.03 2.23E‐04
rs12137389 1p34.1 TESK2 t c 0.03 ‐0.13 3.05E‐06 ‐0.01 0.69 31 0.05 ‐0.06 5.76E‐04 ‐0.05 0.07 0.02 0.45 24 0.12 ‐0.01 0.52
rs2120461 1p36.23 RERE t c 0.67 0.05 3.91E‐08 0.01 0.10 0 0.49 0.03 3.07E‐06 0.04 1.44E‐04 0.02 3.53E‐03 21 0.15 0.03 3.11E‐06
rs12120297 1q41 SUSD4 t c 0.86 0.04 7.95E‐04 ‐0.01 0.38 17 0.20 0.01 0.24 0.06 3.05E‐06 0.01 0.45 0 0.53 0.03 1.19E‐03
rs730402 2p16.1 BCL11A a g 0.45 0.03 9.01E‐05 0.00 0.44 0 0.76 0.02 2.49E‐03 0.02 0.04 0.001 0.88 0 0.57 0.01 0.16
rs13413210 2p23.2 ALK a c 0.91 ‐0.02 0.23 ‐0.01 0.58 0 0.69 ‐0.01 0.25 ‐0.05 3.86E‐03 0.001 0.92 7 0.36 ‐0.02 0.10
rs11675051 2q32.2 NAB1 a g 0.33 0.04 2.38E‐06 0.01 0.07 23 0.12 0.02 1.02E‐05 0.01 0.12 0.01 0.11 0 0.49 0.01 0.03
rs12995369 2q33.1 ALS2CR7 a g 0.52 0.05 1.94E‐07 0.01 0.24 6 0.37 0.02 8.40E‐05 0.03 4.71E‐03 0.001 0.84 14 0.24 0.01 0.09
rs6436440 2q36.1 AP1S3 a g 0.47 0.03 2.46E‐05 0.01 0.06 0 0.98 0.02 4.58E‐05 0.03 6.44E‐04 0.02 7.13E‐03 0 0.70 0.02 2.41E‐05
rs7427438 3p24.1 RBMS3 a c 0.33 ‐0.04 2.99E‐05 ‐0.01 0.13 34 0.04 ‐0.02 1.16E‐04 ‐0.01 0.15 0.004 0.65 0 0.59 0.00 0.55
rs2291296 3p24.2 RARB a g 0.17 ‐0.004 0.74 ‐0.01 0.11 0 0.82 ‐0.01 0.15 ‐0.04 1.20E‐04 ‐0.02 0.02 22 0.14 ‐0.03 3.01E‐05
rs4957742 5q21.3 EFNA5 a g 0.77 ‐0.04 4.74E‐06 ‐0.01 0.45 0 0.55 ‐0.02 5.21E‐04 ‐0.03 7.56E‐03 ‐0.005 0.59 14 0.25 ‐0.01 0.03
rs2282930 7p12.2 GRB10 a g 0.24 ‐0.04 8.09E‐06 ‐0.02 0.01 0 0.71 ‐0.03 3.43E‐06 ‐0.03 4.85E‐03 ‐0.02 4.10E‐03 0 0.84 ‐0.02 6.51E‐05
rs7788807 7p22.1_1 FOXK1 t c 0.94 0.02 0.17 0.00 0.96 0 0.89 0.01 0.41 0.06 1.74E‐03 0.01 0.54 29 0.07 0.03 0.01
rs2008425 7p22.1_2 RNF216 t g 0.02 ‐0.08 0.03 ‐0.05 0.06 20 0.15 ‐0.06 5.08E‐03 ‐0.11 2.01E‐03 ‐0.04 0.10 15 0.23 ‐0.06 1.86E‐03
rs1670346 7q36.3 PTPRN2 a g 0.29 ‐0.04 2.81E‐06 0.00 0.78 0 0.60 ‐0.02 2.27E‐03 ‐0.02 0.03 0.002 0.77 15 0.23 ‐0.01 0.28
rs13272568 8q21.12 PKIA a c 0.44 ‐0.04 2.13E‐06 ‐0.02 9.76E‐03 0 0.66 ‐0.03 6.08E‐07 ‐0.01 0.10 ‐0.004 0.53 27 0.09 ‐0.01 0.13
rs4240467 9q33.2 DAB2IP c g 0.32 ‐0.0004 0.96 0.01 0.51 34 0.04 0.003 0.64 ‐0.01 0.56 ‐0.004 0.58 2 0.43 0.00 0.42
rs2784767 10q22.3_2 PLAC9 t c 0.41 0.03 5.08E‐04 0.00 0.60 19 0.17 0.01 0.02 0.02 0.07 ‐0.01 0.23 0 0.89 0.00 0.96
rs11602954 11p15.5 BET1L a g 0.24 0.03 1.06E‐03 0.01 0.17 0 0.47 0.02 1.92E‐03 0.06 2.74E‐07 0.02 0.05 0 0.94 0.03 2.25E‐06
rs600231 11q13.1 SCYL1 a g 0.70 ‐0.04 1.19E‐05 ‐0.02 0.01 0 0.74 ‐0.02 4.03E‐06 ‐0.02 0.03 ‐0.005 0.53 0 0.94 ‐0.01 0.07
rs11048046 12p12.1 IFLTD1 a g 0.09 ‐0.03 0.09 0.00 0.99 0 0.97 ‐0.01 0.25 ‐0.01 0.50 ‐0.001 0.98 0 0.73 ‐0.01 0.63
rs7326472 13q14.11 AKAP11 a g 0.92 ‐0.05 2.55E‐03 ‐0.04 0.06 30 0.12 ‐0.05 5.07E‐04 ‐0.10 9.80E‐08 ‐0.04 0.05 2 0.43 ‐0.07 2.61E‐07
rs2118784 15q21.2 CYP19A1 a c 0.28 ‐0.04 5.20E‐05 0.00 0.55 17 0.20 ‐0.02 3.48E‐03 ‐0.03 5.02E‐03 ‐0.01 0.20 16 0.21 ‐0.02 6.72E‐03
rs7226305 17q22 KIF2B a c 0.84 ‐0.02 0.13 0.00 0.71 0 0.75 ‐0.004 0.54 ‐0.06 1.33E‐06 0.002 0.81 33 0.04 ‐0.02 6.66E‐03
rs7257450 19p13.11 PLVAP a g 0.79 0.01 0.55 0.00 0.92 0 0.84 0.003 0.68 0.05 4.01E‐05 ‐0.001 0.94 0 0.65 0.02 0.03
rs4817775 21q22.12 CBR3 a c 0.59 0.02 6.24E‐03 0.01 0.04 19 0.16 0.02 8.59E‐04 0.04 1.49E‐06 0.02 0.01 14 0.24 0.03 8.94E‐07
rs4820539 22q11.23 RTDR1 a g 0.42 0.04 4.86E‐06 0.02 2.10E‐03 1 0.45 0.03 1.65E‐07 0.03 3.65E‐03 0.02 1.63E‐03 0 0.93 0.02 1.96E‐05
rs5926033 Xp22.11 DDX53 t c 0.71 0.04 4.13E‐06 0.01 0.19 0 0.68 0.03 9.73E‐06 0.01 0.10 0.01 0.35 0 0.49 0.01 0.06
rs5952638 Xp11.3 DUSP21 a t 0.93 0.06 3.03E‐04 0.01 0.72 12 0.35 0.04 2.74E‐03 0.07 2.29E‐05 ‐0.001 0.94 0 0.72 0.04 1.74E‐03
rs4492531 Xq13.3 MAGEE2 a g 0.55 ‐0.07 1.98E‐03 0.01 0.59 0 0.92 ‐0.03 0.08 ‐0.09 2.40E‐05 ‐0.02 0.39 4 0.41 ‐0.05 4.52E‐04
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rs479336 1q24.3 DNM3 t g 0.74 ‐0.05 8.17E‐06 ‐0.03 2.73E‐05 ‐0.04 1.56E‐09 ‐0.06 9.51E‐04 ‐0.06 2.94E‐05 ‐0.06 1.02E‐07 0.11 ‐0.03 0.01 ‐0.02 4.98E‐03 ‐0.03 1.80E‐04 ‐0.02 0.37 ‐0.03 0.03 ‐0.03 0.03 0.96
rs7584262 2p21 PKDCC t c 0.23 0.05 6.82E‐05 0.03 3.42E‐03 0.03 2.17E‐06 0.07 1.06E‐04 0.04 0.03 0.05 2.64E‐05 0.21 0.01 0.25 0.02 0.11 0.01 0.05 0.02 0.20 ‐0.01 0.39 0.00 0.78 0.43
rs17040773 2q13 ANAPC1 a c 0.77 0.04 3.96E‐04 0.03 4.73E‐04 0.04 7.58E‐07 0.07 4.31E‐04 0.03 0.04 0.05 1.14E‐04 0.39 0.01 0.64 0.00 0.61 0.01 0.50 0.01 0.74 0.03 0.09 0.02 0.14 0.36
rs1878526 2q14.2 INSIG2 a g 0.22 0.01 0.28 ‐0.01 0.42 0.00 0.99 ‐0.02 0.34 0.02 0.14 0.01 0.61 0.66 0.06 6.41E‐07 0.04 6.13E‐05 0.05 5.44E‐10 0.02 0.28 0.04 0.02 0.03 0.01 0.27
rs1026364 3q13.2 KIAA2018 t g 0.36 0.04 1.34E‐04 0.03 1.10E‐03 0.03 8.86E‐07 0.04 8.57E‐03 0.03 0.01 0.04 2.68E‐04 0.55 0.02 0.12 0.02 0.05 0.02 0.01 0.02 0.17 0.02 0.08 0.02 0.03 0.59
rs344081 3q25.31 LEKR1 t c 0.87 0.03 0.07 0.03 8.87E‐03 0.03 1.52E‐03 0.11 6.83E‐07 0.03 0.11 0.07 6.62E‐06 0.02 0.05 2.97E‐03 0.06 1.24E‐06 0.05 1.49E‐08 0.08 2.87E‐04 0.06 6.63E‐03 0.07 8.69E‐06 0.45
rs3755955 4p16.3 IDUA a g 0.16 ‐0.06 3.62E‐05 ‐0.05 1.30E‐06 ‐0.05 2.22E‐10 ‐0.07 1.52E‐03 ‐0.06 1.07E‐03 ‐0.07 5.77E‐06 0.46 ‐0.06 2.65E‐05 ‐0.05 1.56E‐06 ‐0.06 2.22E‐10 ‐0.07 1.79E‐03 ‐0.06 9.86E‐04 ‐0.07 5.92E‐06 0.50
rs11755164 6p21.1 SUPT3H t c 0.40 ‐0.02 0.13 ‐0.02 0.04 ‐0.02 0.01 ‐0.01 0.73 0.01 0.59 0.00 0.85 0.15 ‐0.05 1.09E‐05 ‐0.04 2.47E‐06 ‐0.04 2.19E‐10 ‐0.06 5.21E‐04 ‐0.01 0.55 ‐0.03 6.28E‐03 0.28
rs9466056 6p22.3 CDKAL1 a g 0.38 ‐0.04 9.17E‐06 ‐0.04 3.86E‐06 ‐0.04 1.47E‐10 ‐0.06 2.48E‐04 ‐0.02 0.10 ‐0.04 2.24E‐04 0.91 ‐0.02 0.02 ‐0.03 7.87E‐04 ‐0.03 4.50E‐05 ‐0.06 2.55E‐05 ‐0.03 0.06 ‐0.05 1.74E‐05 0.12
rs3801387 7q31.31 WNT16 a g 0.74 ‐0.07 2.22E‐11 ‐0.08 1.30E‐23 ‐0.08 2.78E‐33 ‐0.06 1.33E‐04 ‐0.07 1.66E‐05 ‐0.06 8.50E‐09 0.27 ‐0.10 1.87E‐16 ‐0.11 3.44E‐36 ‐0.11 6.38E‐51 ‐0.05 2.12E‐03 ‐0.06 4.87E‐04 ‐0.05 3.41E‐06 1.27E‐04
rs7812088 7q36.1 ABCF2 a g 0.12 0.06 8.92E‐05 0.03 5.50E‐03 0.04 3.86E‐06 0.07 1.90E‐03 0.05 0.03 0.06 1.92E‐04 0.37 0.05 6.33E‐04 0.04 1.28E‐03 0.05 3.34E‐06 0.06 0.01 0.02 0.43 0.04 0.02 0.68
rs7017914 8q13.3 XKR9 a g 0.49 0.05 4.70E‐08 0.02 7.11E‐03 0.04 1.94E‐08 0.02 0.16 0.00 0.85 0.01 0.38 0.03 0.01 0.35 ‐0.01 0.41 0.00 0.98 ‐0.02 0.21 ‐0.03 0.05 ‐0.02 0.02 0.06
rs7851693 9q34.11 FUBP3 c g 0.63 0.05 1.02E‐06 0.06 8.04E‐13 0.05 5.26E‐18 0.04 6.84E‐03 0.05 3.27E‐04 0.05 7.39E‐06 0.58 0.02 0.02 0.04 2.11E‐06 0.03 2.59E‐07 0.00 0.88 0.04 9.42E‐03 0.02 0.06 0.25
rs3905706 10p11.23 MPP7 t c 0.23 0.01 0.58 ‐0.02 0.01 ‐0.01 0.11 0.00 0.96 ‐0.03 0.04 ‐0.02 0.13 0.63 0.07 1.19E‐08 0.05 1.27E‐06 0.05 2.43E‐13 0.05 0.01 0.05 1.37E‐03 0.05 4.91E‐05 0.71
rs1373004 10q21.1 MBL2 t g 0.12 ‐0.07 6.32E‐06 ‐0.04 4.62E‐04 ‐0.05 3.01E‐08 ‐0.02 0.37 ‐0.03 0.11 ‐0.03 0.07 0.22 ‐0.09 8.87E‐09 ‐0.06 3.58E‐06 ‐0.07 6.63E‐13 ‐0.03 0.18 ‐0.03 0.10 ‐0.03 0.03 0.06
rs7071206 10q22.3_1 KCNMA1 t c 0.76 ‐0.02 0.09 0.01 0.52 0.00 0.59 0.01 0.41 0.02 0.26 0.02 0.17 0.14 ‐0.09 8.34E‐13 ‐0.05 1.34E‐07 ‐0.06 1.64E‐17 ‐0.04 0.02 ‐0.04 0.01 ‐0.04 7.27E‐04 0.12
rs7084921 10q24.2 CPN1 t c 0.40 0.05 3.13E‐06 0.03 2.13E‐04 0.03 7.16E‐09 0.00 0.82 0.04 2.46E‐03 0.02 0.02 0.42 0.03 8.62E‐03 0.03 2.90E‐04 0.03 7.58E‐06 0.02 0.25 0.03 0.03 0.02 0.02 0.75
rs10835187 11p14.1_1 LIN7C t c 0.54 ‐0.03 3.70E‐03 ‐0.01 0.23 ‐0.02 6.41E‐03 0.03 0.03 ‐0.02 0.13 0.00 0.77 0.10 ‐0.05 4.14E‐07 ‐0.03 1.05E‐03 ‐0.04 1.23E‐08 0.01 0.74 ‐0.02 0.12 ‐0.01 0.35 0.03
rs7953528 12p11.22 KLHDC5 a t 0.18 0.05 3.65E‐05 0.03 4.54E‐04 0.04 1.02E‐07 0.08 8.17E‐05 0.05 1.06E‐03 0.06 4.29E‐07 0.11 0.00 0.73 ‐0.02 0.13 ‐0.01 0.16 0.01 0.57 ‐0.02 0.16 ‐0.01 0.49 0.87
rs2887571 12p13.33 ERC1 a g 0.76 ‐0.05 1.37E‐05 ‐0.02 3.84E‐03 ‐0.03 8.59E‐07 ‐0.01 0.50 ‐0.06 1.48E‐04 ‐0.04 9.81E‐04 0.73 ‐0.05 5.60E‐06 ‐0.04 6.13E‐06 ‐0.05 2.08E‐10 ‐0.05 1.96E‐03 ‐0.03 0.09 ‐0.04 8.44E‐04 0.64
rs12821008 12q13.12 DHH t c 0.40 0.03 1.87E‐03 0.03 3.22E‐03 0.03 1.94E‐05 0.04 0.02 0.01 0.29 0.02 0.02 0.81 0.05 3.46E‐06 0.04 2.47E‐06 0.04 4.53E‐11 0.04 8.86E‐03 0.06 3.06E‐05 0.05 1.36E‐06 0.59
rs1053051 12q23.3 C12orf23 t c 0.51 ‐0.04 3.11E‐05 ‐0.03 4.55E‐05 ‐0.04 6.19E‐09 ‐0.02 0.11 ‐0.02 0.14 ‐0.02 0.03 0.36 ‐0.04 6.70E‐05 ‐0.03 1.58E‐03 ‐0.03 7.14E‐07 ‐0.04 4.61E‐03 ‐0.01 0.77 ‐0.03 0.02 0.71
rs1286083 14q32.12 RPS6KA5 t c 0.80 ‐0.06 2.65E‐06 ‐0.05 5.93E‐08 ‐0.05 8.93E‐13 ‐0.06 3.43E‐03 ‐0.03 0.04 ‐0.04 4.85E‐04 0.50 ‐0.07 7.44E‐09 ‐0.05 9.43E‐07 ‐0.06 1.33E‐13 ‐0.07 1.44E‐04 ‐0.01 0.69 ‐0.04 5.25E‐03 0.13
rs4985155 16p13.11 NTAN1 a g 0.65 ‐0.01 0.16 ‐0.03 4.29E‐06 ‐0.03 5.56E‐06 ‐0.07 1.79E‐06 ‐0.04 9.32E‐03 ‐0.05 2.96E‐07 0.03 ‐0.03 1.16E‐03 ‐0.03 1.16E‐03 ‐0.03 5.35E‐06 ‐0.06 4.76E‐05 ‐0.03 0.08 ‐0.04 5.88E‐05 0.28
rs9921222 16p13.3_1 AXIN1 t c 0.46 ‐0.05 2.84E‐06 ‐0.03 4.73E‐05 ‐0.04 1.08E‐09 ‐0.04 0.01 ‐0.03 0.02 ‐0.04 4.68E‐04 1.00 ‐0.05 4.03E‐06 ‐0.05 7.94E‐09 ‐0.05 1.37E‐13 ‐0.06 2.66E‐04 ‐0.03 0.03 ‐0.04 3.62E‐05 0.78
rs13336428 16p13.3_2 C16orf38 a g 0.44 ‐0.05 2.56E‐06 ‐0.04 5.51E‐09 ‐0.04 7.17E‐14 ‐0.04 0.02 ‐0.04 4.22E‐03 ‐0.04 2.48E‐04 0.57 ‐0.04 2.38E‐05 ‐0.05 7.82E‐09 ‐0.04 1.03E‐12 ‐0.02 0.23 ‐0.03 0.02 ‐0.03 0.01 0.13
rs1566045 16q12.1 SALL1 t c 0.80 ‐0.07 2.01E‐09 ‐0.06 5.05E‐09 ‐0.06 8.89E‐17 ‐0.08 7.45E‐05 ‐0.06 1.42E‐04 ‐0.07 5.06E‐08 0.55 ‐0.03 9.68E‐03 ‐0.01 0.45 ‐0.02 0.03 ‐0.02 0.35 0.00 0.91 ‐0.01 0.61 0.49
rs4790881 17p13.3 SMG6 a c 0.67 0.05 3.03E‐06 0.05 1.86E‐11 0.05 2.54E‐16 0.05 1.27E‐03 0.03 0.05 0.04 3.51E‐04 0.32 0.04 8.79E‐04 0.05 2.72E‐09 0.05 1.32E‐11 0.01 0.48 ‐0.01 0.45 0.00 0.93 3.56E‐04
rs7217932 17q24.3 SOX9 a g 0.46 0.04 4.30E‐06 0.03 4.45E‐05 0.03 1.65E‐09 0.05 4.91E‐04 0.02 0.23 0.03 1.25E‐03 0.82 0.01 0.23 0.02 0.04 0.01 0.02 0.00 0.84 ‐0.01 0.57 0.00 0.78 0.14
rs4796995 18p11.21 C18orf19 a g 0.61 0.04 1.09E‐04 0.03 5.81E‐04 0.03 3.30E‐07 0.04 0.01 0.01 0.59 0.02 0.03 0.46 0.03 8.80E‐03 0.01 0.18 0.02 7.27E‐03 0.04 6.08E‐03 0.01 0.43 0.03 0.01 0.49
rs10416218 19q13.11 GPATCH1 t c 0.72 ‐0.05 1.23E‐05 ‐0.03 9.88E‐04 ‐0.03 1.55E‐07 ‐0.03 0.10 ‐0.02 0.29 ‐0.02 0.06 0.31 ‐0.06 1.08E‐06 ‐0.03 9.66E‐04 ‐0.04 2.68E‐08 ‐0.05 1.72E‐03 ‐0.03 0.05 ‐0.04 3.75E‐04 0.90











































Gene A1a A2 Freq1 Beta P Beta P Beta P Beta P Beta P Beta P P Beta P Beta P Beta P Beta P Beta P Beta P P
rs12407028 1p31.3 WLS t c 0.61 0.06 1.18E‐08 0.06 1.77E‐15 0.06 1.46E‐22 0.03 0.04 0.04 0.01 0.03 1.15E‐03 0.04 0.08 4.57E‐16 0.08 2.19E‐22 0.08 5.51E‐37 0.08 9.60E‐08 0.07 5.19E‐06 0.07 2.81E‐12 0.60
rs6426749 1p36.12 ZBTB40 c g 0.17 0.11 1.88E‐19 0.11 4.86E‐27 0.11 7.83E‐45 0.09 1.64E‐06 0.11 1.26E‐09 0.10 1.16E‐14 0.63 0.11 7.58E‐18 0.10 1.34E‐20 0.11 1.08E‐36 0.09 2.26E‐05 0.09 3.78E‐07 0.09 3.81E‐11 0.29
rs4233949 2p16.2 SPTBN1 c g 0.38 0.03 4.49E‐03 0.02 0.03 0.02 4.15E‐04 0.04 4.67E‐03 0.02 0.11 0.03 1.78E‐03 0.39 0.06 2.72E‐09 0.04 2.52E‐06 0.05 9.31E‐14 0.06 5.46E‐05 0.05 1.47E‐03 0.05 3.35E‐07 0.74
rs1346004 2q24.3 GALNT3 a g 0.49 ‐0.05 1.35E‐08 ‐0.05 3.89E‐14 ‐0.05 3.31E‐21 ‐0.05 1.34E‐03 ‐0.05 3.45E‐04 ‐0.05 1.56E‐06 0.54 ‐0.04 2.57E‐05 ‐0.06 2.84E‐16 ‐0.06 1.17E‐19 ‐0.07 4.79E‐06 ‐0.08 3.89E‐09 ‐0.07 1.04E‐13 0.10
rs430727 3p22.1 CTNNB1 t c 0.47 ‐0.07 7.29E‐13 ‐0.04 3.29E‐08 ‐0.05 1.39E‐18 ‐0.07 5.98E‐06 ‐0.05 2.46E‐04 ‐0.06 6.85E‐09 0.56 ‐0.06 1.28E‐07 ‐0.05 6.40E‐09 ‐0.05 4.53E‐15 ‐0.06 3.48E‐05 ‐0.04 4.74E‐03 ‐0.05 8.90E‐07 0.88
rs6532023 4q22.1 MEPE t g 0.34 0.06 2.04E‐09 0.06 1.42E‐13 0.06 1.22E‐21 0.03 0.07 0.06 4.78E‐06 0.05 4.42E‐06 0.40 0.07 2.25E‐11 0.06 1.48E‐12 0.06 2.71E‐22 0.04 0.01 0.07 5.93E‐07 0.06 9.85E‐08 0.62
rs1366594 5q14.3 MEF2C a c 0.53 0.10 6.48E‐25 0.08 2.58E‐26 0.09 7.85E‐49 0.08 4.18E‐08 0.08 1.78E‐09 0.08 4.24E‐16 0.64 0.02 0.02 0.01 0.52 0.01 0.05 0.02 0.32 0.03 0.06 0.02 0.04 0.46
rs13204965 6q22.32 RSPO3 a c 0.76 0.07 2.90E‐07 0.05 4.43E‐07 0.05 1.90E‐12 0.02 0.21 0.02 0.35 0.02 0.12 0.04 0.05 8.23E‐04 0.04 1.77E‐05 0.04 5.38E‐08 0.04 0.02 0.05 9.44E‐03 0.05 5.73E‐04 0.83
rs4869742 6q25.1 C6orf97 t c 0.32 ‐0.07 1.40E‐11 ‐0.03 9.59E‐05 ‐0.05 3.14E‐13 ‐0.06 1.48E‐04 ‐0.06 1.53E‐05 ‐0.06 8.84E‐09 0.24 ‐0.09 3.39E‐15 ‐0.06 6.67E‐11 ‐0.07 9.41E‐24 ‐0.09 8.95E‐08 ‐0.09 5.02E‐09 ‐0.09 2.56E‐15 0.19
rs6959212 7p14.1 STARD3NL t c 0.34 ‐0.03 9.26E‐03 ‐0.05 1.09E‐09 ‐0.04 1.30E‐10 ‐0.04 0.01 ‐0.04 3.31E‐03 ‐0.04 9.15E‐05 0.90 ‐0.08 3.68E‐13 ‐0.08 2.54E‐20 ‐0.08 4.10E‐32 ‐0.07 4.23E‐06 ‐0.05 2.20E‐04 ‐0.06 6.12E‐09 0.23
rs4727338 7q21.3 SLC25A13 c g 0.67 0.08 1.92E‐15 0.08 6.04E‐24 0.08 1.20E‐37 0.08 2.01E‐07 0.07 3.73E‐07 0.08 3.33E‐13 0.73 0.07 2.23E‐10 0.07 1.00E‐15 0.07 1.34E‐24 0.09 6.43E‐08 0.07 1.18E‐06 0.08 4.67E‐13 0.48
rs2062377 8q24.12 TNFRSF11B a t 0.59 ‐0.06 1.16E‐09 ‐0.05 1.68E‐09 ‐0.05 1.60E‐17 ‐0.07 8.34E‐07 ‐0.06 3.26E‐04 ‐0.06 1.50E‐09 0.33 ‐0.08 7.13E‐16 ‐0.07 3.35E‐15 ‐0.07 2.55E‐29 ‐0.07 9.83E‐07 ‐0.08 8.65E‐07 ‐0.08 3.94E‐12 0.91
rs7932354 11p11.2 ARHGAP1 t c 0.33 0.05 9.97E‐07 0.04 2.77E‐06 0.04 1.60E‐11 0.05 3.41E‐03 0.07 3.93E‐07 0.06 9.34E‐09 0.16 0.04 3.49E‐04 0.04 1.09E‐05 0.04 1.34E‐08 0.04 8.59E‐03 0.04 4.39E‐03 0.04 1.09E‐04 0.85
rs163879 11p14.1_2 DCDC5 t c 0.66 ‐0.04 1.19E‐04 ‐0.02 9.89E‐03 ‐0.03 1.15E‐05 ‐0.05 1.34E‐03 ‐0.04 9.74E‐03 ‐0.05 4.10E‐05 0.15 ‐0.05 5.13E‐07 ‐0.02 4.40E‐03 ‐0.03 1.01E‐07 ‐0.04 7.47E‐03 ‐0.06 1.03E‐04 ‐0.05 3.67E‐06 0.18
rs7108738 11p15.2 SOX6 t g 0.82 ‐0.09 6.42E‐14 ‐0.07 3.47E‐14 ‐0.08 3.52E‐26 ‐0.08 2.55E‐05 ‐0.07 9.09E‐05 ‐0.07 1.05E‐08 0.69 ‐0.05 1.20E‐04 ‐0.02 0.03 ‐0.03 5.76E‐05 ‐0.03 0.14 ‐0.03 0.05 ‐0.03 0.01 0.99
rs3736228 11q13.2 LRP5 t c 0.15 ‐0.05 5.08E‐04 ‐0.05 9.14E‐05 ‐0.05 1.82E‐07 ‐0.08 2.30E‐04 ‐0.05 0.02 ‐0.06 2.06E‐05 0.32 ‐0.08 1.91E‐08 ‐0.10 1.34E‐15 ‐0.09 2.80E‐22 ‐0.10 5.51E‐06 ‐0.06 0.01 ‐0.08 4.21E‐07 0.53
rs2016266 12q13.13 SP7 a g 0.69 ‐0.04 2.91E‐05 ‐0.02 1.43E‐03 ‐0.03 3.82E‐07 ‐0.04 0.01 ‐0.04 7.19E‐03 ‐0.04 2.39E‐04 0.54 ‐0.07 2.18E‐10 ‐0.05 6.68E‐09 ‐0.06 2.13E‐17 ‐0.04 5.72E‐03 ‐0.04 5.36E‐03 ‐0.04 9.14E‐05 0.29
rs9533090 13q14.11 AKAP11 t c 0.48 ‐0.06 1.80E‐10 ‐0.05 2.79E‐13 ‐0.06 3.36E‐22 ‐0.03 0.03 ‐0.03 0.06 ‐0.03 3.61E‐03 0.05 ‐0.12 6.31E‐31 ‐0.10 6.92E‐33 ‐0.11 1.51E‐61 ‐0.09 7.43E‐09 ‐0.08 7.96E‐07 ‐0.09 2.62E‐14 0.16
rs11623869 14q32.32 MARK3 t g 0.34 ‐0.04 1.41E‐05 ‐0.05 1.70E‐09 ‐0.05 1.27E‐13 ‐0.04 8.02E‐03 ‐0.04 9.64E‐03 ‐0.04 2.12E‐04 0.59 ‐0.03 9.24E‐03 ‐0.04 3.83E‐07 ‐0.04 2.30E‐08 ‐0.04 7.11E‐03 ‐0.04 6.65E‐03 ‐0.04 1.30E‐04 0.74
rs10048146 16q24.1 FOXL1 a g 0.80 0.05 5.29E‐06 0.04 3.40E‐05 0.05 1.14E‐09 0.06 9.58E‐04 0.07 4.50E‐05 0.07 1.66E‐07 0.15 0.07 1.55E‐07 0.04 1.27E‐04 0.05 4.37E‐10 0.06 3.52E‐03 0.03 0.13 0.04 2.10E‐03 0.59
rs227584 17q21.31_1 C17orf53 a c 0.67 ‐0.06 3.31E‐09 ‐0.05 1.35E‐10 ‐0.06 3.15E‐18 ‐0.05 2.11E‐03 ‐0.06 1.99E‐05 ‐0.06 1.87E‐07 0.86 ‐0.04 5.66E‐05 ‐0.03 2.98E‐03 ‐0.03 1.64E‐06 ‐0.06 2.96E‐04 ‐0.04 0.01 ‐0.05 1.63E‐05 0.23
rs1864325 17q21.31_2 MAPT t c 0.22 ‐0.04 1.68E‐03 ‐0.01 0.25 ‐0.02 4.60E‐03 ‐0.05 4.55E‐03 ‐0.03 0.06 ‐0.04 8.44E‐04 0.14 ‐0.06 8.01E‐06 ‐0.03 4.83E‐04 ‐0.04 3.96E‐08 ‐0.06 1.40E‐03 ‐0.04 0.02 ‐0.05 9.06E‐05 0.63
rs884205 18q21.33 TNFRSF11A a c 0.25 ‐0.05 2.57E‐05 ‐0.04 9.47E‐07 ‐0.04 1.43E‐10 ‐0.03 0.13 ‐0.01 0.38 ‐0.02 0.10 0.06 ‐0.07 2.67E‐07 ‐0.06 9.12E‐10 ‐0.06 1.66E‐15 ‐0.06 8.99E‐04 ‐0.03 0.04 ‐0.04 1.63E‐04 0.28
rs3790160 20p12.2 JAG1 t c 0.50 0.04 2.58E‐05 0.02 6.36E‐04 0.03 1.31E‐07 0.05 6.06E‐04 0.05 2.90E‐04 0.05 6.14E‐07 0.09 0.06 1.81E‐08 0.04 9.42E‐07 0.05 2.49E‐13 0.05 6.94E‐04 0.06 3.49E‐05 0.05 9.21E‐08 0.45
Gender‐stratified meta‐analysis results across stages for known loci associated with BMD at GWS level. 
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Gene A1a A2 Freq1 Beta P Beta P Beta P Beta P Beta P Beta P P Beta P Beta P Beta P Beta P Beta P Beta P P
rs11809524 1p21.1 COL11A1 t c 0.85 0.05 1.07E‐04 0.02 0.06 0.03 1.20E‐04 0.06 2.20E‐03 0.01 0.67 0.03 0.02 0.90 0.05 1.25E‐03 0.02 0.14 0.03 1.79E‐03 0.06 3.98E‐03 0.01 0.43 0.04 0.01 0.60
rs12137389 1p34.1 TESK2 t c 0.02 ‐0.12 1.19E‐04 ‐0.01 0.60 ‐0.06 3.36E‐03 ‐0.13 5.67E‐03 0.00 1.00 ‐0.07 0.04 0.75 ‐0.04 0.28 0.02 0.58 ‐0.01 0.77 ‐0.07 0.15 0.03 0.58 ‐0.03 0.48 0.65
rs2120461 1p36.23 RERE t c 0.68 0.04 9.40E‐06 0.01 0.15 0.02 1.06E‐04 0.06 1.21E‐04 0.01 0.44 0.03 1.32E‐03 0.39 0.04 1.61E‐04 0.02 0.01 0.03 1.50E‐05 0.03 0.06 0.02 0.14 0.03 0.02 0.84
rs12120297 1q41 SUSD4 t c 0.85 0.05 2.59E‐04 0.01 0.58 0.02 0.01 0.02 0.38 ‐0.05 4.64E‐03 ‐0.03 0.08 5.06E‐03 0.06 1.72E‐04 0.01 0.19 0.03 1.38E‐03 0.08 1.38E‐03 ‐0.02 0.41 0.02 0.22 0.54
rs730402 2p16.1 BCL11A a g 0.45 0.02 0.07 ‐0.002 0.80 0.01 0.36 0.07 2.62E‐06 0.03 0.05 0.05 4.29E‐06 4.18E‐04 0.01 0.25 ‐0.001 0.91 0.004 0.53 0.04 0.01 0.01 0.59 0.02 0.04 0.16
rs13413210 2p23.2 ALK a c 0.91 0.00 0.83 ‐0.01 0.44 ‐0.01 0.46 ‐0.06 0.03 0.01 0.74 ‐0.02 0.24 0.53 ‐0.01 0.59 ‐0.005 0.73 ‐0.01 0.55 ‐0.13 2.65E‐06 0.02 0.43 ‐0.05 0.01 0.07
rs11675051 2q32.2 NAB1 a g 0.32 0.05 1.47E‐06 0.01 0.24 0.02 9.46E‐05 0.02 0.28 0.02 0.11 0.02 0.06 0.74 0.02 0.08 0.01 0.26 0.01 0.05 0.001 0.95 0.02 0.25 0.01 0.39 0.78
rs12995369 2q33.1 ALS2CR7 a g 0.55 0.05 4.56E‐06 0.01 0.37 0.02 8.80E‐04 0.06 1.26E‐03 0.01 0.45 0.03 8.95E‐03 0.55 0.02 0.05 ‐0.003 0.71 0.005 0.47 0.05 8.13E‐03 0.02 0.23 0.03 9.05E‐03 0.06
rs6436440 2q36.1 AP1S3 a g 0.47 0.05 1.17E‐06 0.02 0.01 0.03 5.58E‐07 0.01 0.71 ‐0.01 0.47 ‐0.003 0.77 5.58E‐03 0.03 1.10E‐03 0.02 0.02 0.02 1.24E‐04 0.02 0.11 0.02 0.27 0.02 0.06 0.69
rs7427438 3p24.1 RBMS3 a c 0.33 ‐0.05 2.29E‐06 ‐0.004 0.66 ‐0.02 6.70E‐04 ‐0.01 0.67 ‐0.03 0.04 ‐0.02 0.07 0.82 ‐0.02 0.12 0.01 0.17 ‐0.0001 0.98 ‐0.01 0.73 ‐0.02 0.16 ‐0.01 0.21 0.30
rs2291296 3p24.2 RARB a g 0.17 ‐0.01 0.59 ‐0.01 0.13 ‐0.01 0.12 0.00 0.85 ‐0.01 0.63 ‐0.003 0.84 0.58 ‐0.06 3.76E‐06 ‐0.02 0.03 ‐0.04 5.22E‐06 ‐0.01 0.78 ‐0.02 0.40 ‐0.01 0.44 0.12
rs4957742 5q21.3 EFNA5 a g 0.77 ‐0.05 1.27E‐05 ‐0.01 0.21 ‐0.03 2.38E‐04 ‐0.03 0.05 0.02 0.31 ‐0.01 0.51 0.23 ‐0.03 0.01 ‐0.01 0.51 ‐0.02 0.04 ‐0.03 0.15 0.000 0.99 ‐0.01 0.30 0.91
rs2282930 7p12.2 GRB10 a g 0.26 ‐0.06 5.03E‐07 ‐0.02 0.02 ‐0.03 1.08E‐06 ‐0.01 0.45 ‐0.01 0.38 ‐0.01 0.25 0.14 ‐0.04 2.26E‐03 ‐0.03 3.51E‐03 ‐0.03 3.02E‐05 ‐0.01 0.42 ‐0.01 0.48 ‐0.01 0.29 0.21
rs7788807 7p22.1_1 FOXK1 t c 0.94 0.04 0.03 0.002 0.90 0.02 0.16 ‐0.03 0.28 ‐0.01 0.66 ‐0.02 0.29 0.10 0.10 4.11E‐06 0.02 0.29 0.05 2.08E‐04 ‐0.04 0.24 ‐0.02 0.44 ‐0.03 0.17 1.99E‐03
rs2008425 7p22.1_2 RNF216 t g 0.02 ‐0.13 2.00E‐03 ‐0.06 0.02 ‐0.08 2.86E‐04 0.01 0.80 0.01 0.82 0.01 0.74 0.03 ‐0.19 2.97E‐06 ‐0.06 0.06 ‐0.10 2.14E‐05 ‐0.05 0.38 0.01 0.86 ‐0.02 0.67 0.06
rs1670346 7q36.3 PTPRN2 a g 0.30 ‐0.04 1.58E‐05 0.00 0.53 ‐0.02 1.74E‐03 ‐0.03 0.05 0.01 0.61 ‐0.01 0.37 0.43 ‐0.02 0.03 0.003 0.73 ‐0.01 0.27 ‐0.01 0.59 0.00 0.96 ‐0.004 0.69 0.81
rs13272568 8q21.12 PKIA a c 0.44 ‐0.04 4.34E‐05 ‐0.02 0.03 ‐0.03 1.90E‐05 ‐0.04 0.01 ‐0.02 0.21 ‐0.03 7.74E‐03 0.88 ‐0.01 0.24 ‐0.01 0.31 ‐0.01 0.13 ‐0.01 0.34 0.01 0.54 ‐0.002 0.83 0.55
rs4240467 9q33.2 DAB2IP c g 0.32 0.02 0.14 0.01 0.56 0.01 0.16 ‐0.04 6.75E‐03 0.004 0.77 ‐0.02 0.10 0.03 0.03 0.02 0.003 0.76 0.01 0.08 ‐0.08 9.65E‐07 ‐0.03 0.10 ‐0.05 4.75E‐06 1.36E‐06
rs2784767 10q22.3_2 PLAC9 t c 0.43 0.05 4.80E‐06 0.003 0.67 0.02 4.34E‐03 ‐0.01 0.42 0.002 0.86 ‐0.004 0.74 0.09 0.04 5.09E‐03 ‐0.004 0.65 0.01 0.28 ‐0.01 0.67 ‐0.02 0.08 ‐0.02 0.10 0.05
rs11602954 11p15.5 BET1L a g 0.23 0.03 0.03 0.01 0.15 0.02 0.01 0.05 5.10E‐03 0.003 0.85 0.03 0.04 0.59 0.05 6.74E‐05 0.03 5.71E‐03 0.04 4.24E‐06 0.07 3.24E‐04 ‐0.02 0.33 0.02 0.07 0.37
rs600231 11q13.1 SCYL1 a g 0.69 ‐0.05 9.03E‐07 ‐0.02 0.03 ‐0.03 1.98E‐06 ‐0.01 0.49 ‐0.01 0.31 ‐0.01 0.22 0.18 ‐0.03 3.55E‐03 ‐0.004 0.63 ‐0.01 0.03 0.001 0.97 ‐0.01 0.67 ‐0.003 0.77 0.38
rs11048046 12p12.1 IFLTD1 a g 0.08 0.01 0.73 0.00 0.91 0.004 0.75 ‐0.15 3.59E‐06 ‐0.01 0.85 ‐0.07 9.49E‐04 2.21E‐03 0.01 0.78 0.000 1.00 0.003 0.85 ‐0.05 0.08 ‐0.003 0.92 ‐0.03 0.20 0.23
rs2118784 15q21.2 CYP19A1 a c 0.29 ‐0.05 1.41E‐06 0.002 0.81 ‐0.02 6.15E‐03 0.00 0.78 ‐0.02 0.10 ‐0.02 0.15 0.89 ‐0.04 5.26E‐04 ‐0.01 0.35 ‐0.02 4.06E‐03 ‐0.01 0.68 ‐0.01 0.34 ‐0.01 0.32 0.51
rs7226305 17q22 KIF2B a c 0.82 ‐0.02 0.16 0.01 0.59 ‐0.003 0.69 ‐0.02 0.39 ‐0.004 0.82 ‐0.01 0.47 0.67 ‐0.06 1.97E‐05 0.01 0.56 ‐0.02 0.04 ‐0.05 0.01 ‐0.01 0.64 ‐0.03 0.05 0.54
rs7257450 19p13.11 PLVAP a g 0.76 0.01 0.28 0.00 0.63 0.01 0.32 ‐0.01 0.56 ‐0.01 0.59 ‐0.01 0.43 0.24 0.07 4.79E‐06 0.00 0.89 0.02 0.02 0.02 0.37 0.004 0.79 0.01 0.45 0.55
rs4817775 21q22.12 CBR3 a c 0.58 0.02 0.07 0.01 0.04 0.02 6.48E‐03 0.04 0.02 0.01 0.51 0.02 0.04 0.68 0.04 1.45E‐04 0.01 0.07 0.02 1.62E‐04 0.05 9.98E‐04 0.03 0.06 0.04 3.25E‐04 0.26
rs4820539 22q11.23 RTDR1 a g 0.44 0.04 1.18E‐04 0.02 0.01 0.02 1.49E‐05 0.04 8.38E‐03 0.02 0.09 0.03 2.68E‐03 0.68 0.02 0.06 0.02 8.80E‐03 0.02 1.29E‐03 0.04 0.02 0.02 0.08 0.03 4.78E‐03 0.46
rs5926033 Xp22.11 DDX53 t c 0.71 0.03 5.79E‐03 0.02 0.17 0.02 3.21E‐03 0.05 1.08E‐04 0.005 0.85 0.04 4.20E‐04 0.23 0.01 0.19 0.005 0.69 0.01 0.23 0.02 0.21 0.04 0.13 0.02 0.07 0.42
rs5952638 Xp11.3 DUSP21 a t 0.93 0.05 0.01 0.01 0.77 0.03 0.05 0.06 9.82E‐03 0.01 0.82 0.05 0.02 0.36 0.05 0.03 0.004 0.86 0.02 0.10 0.08 6.07E‐04 ‐0.02 0.62 0.06 5.79E‐03 0.16
rs4492531 Xq13.3 MAGEE2 a g 0.55 ‐0.05 0.04 0.001 0.96 ‐0.02 0.19 ‐0.09 0.02 0.05 0.24 ‐0.03 0.25 0.76 ‐0.09 7.42E‐04 ‐0.02 0.35 ‐0.05 4.09E‐03 ‐0.11 3.35E‐03 0.002 0.96 ‐0.06 0.02 0.71
rs964181 Xq28 MAGEA4 t c 0.41 0.04 3.44E‐04 ‐0.01 0.35 0.01 0.06 0.03 0.02 ‐0.02 0.37 0.02 0.13 0.83 0.02 0.03 0.00 0.71 0.01 0.08 0.03 0.01 0.02 0.35 0.03 9.21E‐03 0.90
Gender‐stratified meta‐analysis results across stages for BMD loci not reaching GWS level. 
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SNP Risk Allele Locus Closest Gene Freq1 OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P I
2
Qhet P
rs6426749 G 1p36.12 ZBTB40 0.83 1.1 (1.03‐1.16) 0.003 1.11 (1.06‐1.17) 4.20E‐05 1.03 (0.99‐1.07) 0.141 1.06 (1.03‐1.09) 2.36E‐04 1.07 (1.04‐1.1) 3.60E‐06 24 0.07
rs7521902 A 1p36.12* WNT4 0.27 1.08 (1.02‐1.15) 0.012 1.12 (1.06‐1.18) 1.50E‐05 1.07 (1‐1.13) 0.038 1.10 (1.06‐1.14) 3.51E‐06 1.09 (1.06‐1.13) 1.40E‐07 0 0.87
rs4233949 G 2p16.2 SPTBN1 0.63 1.05 (1‐1.1) 0.052 1.08 (1.04‐1.13) 3.00E‐05 1.05 (1.02‐1.09) 6.50E‐04 1.07 (1.04‐1.09) 1.39E‐07 1.06 (1.04‐1.08) 2.60E‐08 6 0.36
rs430727 T 3p22.1 CTNNB1 0.47 1.07 (1.02‐1.12) 0.003 1.04 (1.01‐1.08) 0.026 1.06 (1.03‐1.09) 2.90E‐04 1.05 (1.03‐1.08) 2.44E‐05 1.06 (1.03‐1.08) 2.90E‐07 0 0.93
rs6532023 G 4q22.1 MEPE 0.67 1.07 (1.02‐1.12) 0.006 1.03 (0.99‐1.07) 0.12 1.08 (1.05‐1.12) 5.20E‐07 1.06 (1.04‐1.09) 8.84E‐07 1.06 (1.04‐1.09) 1.70E‐08 0 1.00
rs6959212 T 7p14.1 STARD3NL 0.33 1.06 (1.01‐1.11) 0.021 1.02 (0.98‐1.06) 0.276 1.05 (1.02‐1.09) 0.001 1.04 (1.02‐1.07) 1.02E‐03 1.05 (1.02‐1.07) 7.20E‐05 2 0.43
rs4727338 G 7q21.3 SLC25A13 0.32 1.08 (1.03‐1.13) 0.002 1.09 (1.05‐1.14) 1.30E‐05 1.06 (1.03‐1.1) 1.10E‐04 1.08 (1.05‐1.1) 1.04E‐08 1.08 (1.05‐1.1) 5.90E‐11 31 0.03
rs3801387 A 7q31.31 WNT16 0.74 1.01 (0.97‐1.05) 0.666 1.07 (1.02‐1.11) 0.004 1.09 (1.06‐1.13) 2.30E‐07 1.08 (1.05‐1.11) 4.98E‐09 1.06 (1.04‐1.08) 2.70E‐07 0 0.69
rs7851693 G 9q34.11 FUBP3 0.37 1.07 (1.03‐1.12) 0.003 1.06 (1.02‐1.1) 0.003 1.03 (1‐1.06) 0.094 1.04 (1.01‐1.06) 1.88E‐03 1.05 (1.02‐1.07) 3.50E‐05 0 0.65
rs1373004 T 10q21.1 MBL2/DKK1 0.13 1.11 (1.04‐1.19) 0.003 1.05 (1‐1.12) 0.065 1.12 (1.07‐1.17) 1.10E‐06 1.09 (1.06‐1.13) 7.19E‐07 1.1 (1.06‐1.13) 9.00E‐09 0 0.64
rs163879 T 11p14.1 DCDC5 0.66 1.01 (0.96‐1.06) 0.775 1.05 (1.01‐1.1) 0.011 1.06 (1.03‐1.1) 1.70E‐04 1.06 (1.03‐1.09) 6.40E‐06 1.05 (1.03‐1.07) 3.30E‐05 28 0.05
rs3736228 T 11q13.2 LRP5 0.15 1.11 (1.04‐1.19) 0.002 1.14 (1.08‐1.2) 6.60E‐07 1.05 (1‐1.1) 0.051 1.09 (1.05‐1.12) 2.06E‐06 1.09 (1.06‐1.13) 1.40E‐08 0 0.78
rs1286083 T 14q32.12 RPS6KA5 0.81 1.07 (1.01‐1.13) 0.024 1.08 (1.02‐1.13) 0.004 1.04 (1‐1.08) 0.05 1.05 (1.02‐1.08) 9.76E‐04 1.05 (1.03‐1.08) 7.20E‐05 34 0.01
rs4792909 G 17q21.31* SOST 0.62 1.05 (1‐1.11) 0.053 1.07 (1.03‐1.12) 0.001 1.07 (1.02‐1.13) 0.009 1.07 (1.04‐1.11) 3.99E‐05 1.07 (1.04‐1.1) 6.90E‐06 10 0.31
rs227584 A 17q21.31 C17orf53 0.67 1.05 (1‐1.1) 0.076 1.06 (1.02‐1.1) 0.007 1.04 (1.01‐1.08) 0.01 1.05 (1.02‐1.08) 2.17E‐04 1.05 (1.03‐1.07) 4.10E‐05 0 0.49






STAGE 1 (In‐silico 1) STAGE 2 (In‐silico 2) STAGE 2 (De‐novo genotyping) STAGE 2 (Insilico 2 + De‐novo)
5411 cases,  21909 controls 9187 cases,  45057 controls 16418 cases, 35478 controls 25605 cases, 80535 controls
16
Supplementary Table 7 Proportion of Fracture Risk explained by BMD.  
SNP Risk Allele Locus Closest Gene Effect StdErr P Effect StdErr P
rs4796995 G 18p11.21 C18orf19 0.08 0.02 8.77E‐05 0.07 0.02 1.12E‐03 0.15
rs4727338 G 7q21.3 SLC25A13 0.08 0.02 2.78E‐04 0.05 0.02 1.46E‐02 0.32
rs3801387 A 7q31.31 WNT16 0.08 0.02 3.17E‐04 0.05 0.02 2.15E‐02 0.35
rs227584 A 17q21.31_1 C17orf53 0.08 0.02 4.84E‐04 0.06 0.02 9.78E‐03 0.25
rs1373004 T 10q21.1 MBL2 0.11 0.03 5.09E‐04 0.09 0.03 3.27E‐03 0.14
rs163879 T 11p14.1_2 DCDC5 0.06 0.02 1.85E‐03 0.06 0.02 5.29E‐03 0.09
rs430727 T 3p22.1 CTNNB1 0.06 0.02 4.13E‐03 0.05 0.02 2.63E‐02 0.21
rs6532023 G 4q22.1 MEPE 0.05 0.02 1.27E‐02 0.03 0.02 1.40E‐01 0.40
rs4233949 G 2p16.2 SPTBN1 0.05 0.02 3.07E‐02 0.04 0.02 5.60E‐02 0.10
rs6959212 T 7p14.1 STARD3NL 0.04 0.02 4.68E‐02 0.03 0.02 1.73E‐01 0.30
rs3736228 T 11q13.2 LRP5 0.05 0.03 0.13 0.04 0.03 0.29 NS
rs7851693 G 9q34.11 FUBP3 0.03 0.02 0.17 0.01 0.02 0.56 NS
rs1286083 T 14q32.12 RPS6KA5 0.03 0.03 0.17 0.02 0.03 0.35 NS








SNP Locus Closest Gene Risk Allele Freq OR (95% CI) P OR (95% CI) P OR (95% CI) P
rs6426749 1p36.12 ZBTB40 G 0.83 1.07 (1.04‐1.1) 3.6E‐06 1.09 (1.04‐1.13) 1.8E‐04 1.04 (0.97‐1.12) 0.28
rs4233949 2p16.2 SPTBN1 G 0.63 1.06 (1.04‐1.08) 2.6E‐08 1.06 (1.02‐1.09) 8.7E‐04 1.02 (0.96‐1.08) 0.50
rs430727 3p22.1 CTNNB1 T 0.47 1.06 (1.03‐1.08) 2.9E‐07 1.03 (1‐1.07) 4.6E‐02 1.07 (1.01‐1.14) 0.02
rs6532023 4q22.1 MEPE G 0.67 1.06 (1.04‐1.09) 1.7E‐08 1.07 (1.03‐1.11) 2.4E‐04 1.11 (1.04‐1.18) 9.3E‐04
rs6959212 7p14.1 STARD3NL T 0.33 1.05 (1.03‐1.08) 7.2E‐05 1.07 (1.03‐1.1) 3.4E‐04 1.04 (0.98‐1.1) 0.24
rs4727338 7q21.3 SLC25A13 G 0.32 1.08 (1.05‐1.1) 5.9E‐11 1.07 (1.04‐1.11) 5.2E‐05 1.08 (1.02‐1.15) 0.01
rs3801387 7q31.31 WNT16 A 0.74 1.06 (1.04‐1.08) 2.7E‐07 1.1 (1.06‐1.14) 2.4E‐07 0.98 (0.93‐1.05) 0.62
rs7851693 9q34.11 FUBP3 G 0.37 1.05 (1.02‐1.07) 3.5E‐05 1.05 (1.01‐1.09) 4.8E‐03 0.96 (0.91‐1.02) 0.18
rs1373004 10q21.1 MBL2 T 0.13 1.1 (1.06‐1.13) 9.0E‐09 1.11 (1.05‐1.17) 1.2E‐04 1.05 (0.96‐1.15) 0.29
rs163879 11p14.1 DCDC5 T 0.66 1.05 (1.03‐1.07) 3.3E‐05 1.05 (1.01‐1.09) 6.3E‐03 1.04 (0.98‐1.11) 0.20
rs3736228 11q13.2 LRP5 T 0.15 1.09 (1.06‐1.13) 1.4E‐08 1.07 (1.02‐1.13) 4.7E‐03 1.02 (0.94‐1.11) 0.61
rs1286083 14q32.12 RPS6KA5 T 0.81 1.05 (1.02‐1.07) 7.2E‐05 1.07 (1.03‐1.12) 1.7E‐03 0.99 (0.92‐1.06) 0.74
rs227584 17q21.31 C17orf53 A 0.67 1.05 (1.03‐1.07) 4.1E‐05 1.04 (1.01‐1.08) 2.1E‐02 1.05 (0.99‐1.12) 0.11









































































SNP rs# Chr. Position Freq Effect SE P‐value SNP rs# Position Freq Effect SE P‐value log10(Plead/P1000G)
rs1346004 2 166309292 0.51 ‐0.049 0.009 8.98E‐08 rs28549203 166282329 0.31 ‐0.063 0.010 1.00E‐09 ‐2.0
rs4727338 7 95958611 0.67 0.073 0.009 6.89E‐15 rs4729260 95955854 0.68 0.079 0.010 1.40E‐16 ‐1.7
rs7017914* 8 71753757 0.51 0.040 0.009 1.76E‐05 rs3110251 72099528 0.52 ‐0.046 0.009 3.12E‐07 ‐1.8
rs7932354 11 46678797 0.32 0.043 0.010 1.10E‐05 rs12274785 46670855 0.70 ‐0.050 0.010 5.80E‐07 ‐1.3







SNP rs# Chr. Position Freq Effect SE P‐value SNP rs# Position Freq Effect SE P‐value log10(Plead/P1000G)
rs1878526* 2 118755068 0.23 0.038 0.011 9.02E‐04 chr2:118804639 118804639 0.08 0.100 0.022 3.41E‐06 ‐2.4
rs3801387 7 120762001 0.74 ‐0.075 0.011 4.26E‐12 rs3779381 120754026 0.76 ‐0.082 0.011 2.03E‐13 ‐1.3
rs1373004* 10 54097831 0.12 ‐0.075 0.015 5.92E‐07 rs7902708 54109734 0.12 ‐0.082 0.015 5.68E‐08 ‐1.0
rs10835187* 11 27462253 0.55 ‐0.039 0.009 2.53E‐05 rs12270727 26672194 0.06 0.214 0.036 2.80E‐09 ‐4.0
rs3736228 11 67957871 0.15 ‐0.073 0.013 1.89E‐08 rs2291467 67973332 0.25 ‐0.069 0.011 5.14E‐10 ‐1.6
rs12821008 12 47760872 0.39 0.049 0.010 1.02E‐06 rs3741619 47675743 0.36 0.058 0.011 5.38E‐08 ‐1.3
rs2016266 12 52014222 0.69 ‐0.058 0.010 1.13E‐08 rs894736 52704433 0.60 0.061 0.010 2.49E‐10 ‐1.7







Targeted  FNBMD LSBMD Distance
SNPs Locus Gene_Symbol Functional SNP  (Kb) r2 D' Allele Freq Effect P‐value Effect P‐value Type Possible Functional Effects
rs12407028 7.89E‐06 5.15E‐12 1p31.3 hsa‐mir‐1262 rs2772297 4.37 1.00 1.00 t 0.40 ‐0.041 7.43E‐06 ‐0.067 5.46E‐12 INTRONIC Promoter/regulatory region
rs4233949 1.96E‐05 1.88E‐12 2p16.2 SPTBN1 rs4305309 24.00 0.83 0.93 t 0.35 0.031 1.06E‐03 0.069 1.64E‐11 INTRONIC Promoter/regulatory region
rs1026364 5.46E‐05 1.22E‐01 3q13.2 KIAA2018 rs9813630 7.4 0.91 1.00 a 0.66 ‐0.032 3.19E‐04 ‐0.012 2.08E‐01 SYNONYMOUS Sense/synonymous; Splicing regulation
rs1026364 5.46E‐05 1.22E‐01 3q13.2 KIAA2018 rs9866806 9.9 0.91 1.00 c 0.35 0.035 1.69E‐04 0.013 1.94E‐01 NON_SYNONYMOUS Missense (conservative); Splicing regulation
rs3755955 3.53E‐07 9.29E‐08 4p16.3 IDUA rs3755955 0.00 1.00 1.00 a 0.16 ‐0.067 3.53E‐07 ‐0.076 9.29E‐08 NON_SYNONYMOUS Missense (conservative)
rs3755955 3.53E‐07 9.29E‐08 4p16.3 IDUA rs6815946 0.89 1.00 1.00 t 0.84 0.068 1.57E‐07 0.079 1.74E‐08 SYNONYMOUS_CODING Sense/synonymous; Splicing regulation
rs3755955 3.53E‐07 9.29E‐08 4p16.3 IDUA rs6848974 1.05 1.00 1.00 t 0.15 ‐0.061 1.25E‐06 ‐0.063 3.77E‐06 SPLICE_SITE splicing site
rs3755955 3.53E‐07 9.29E‐08 4p16.3 IDUA rs6831280 1.75 1.00 1.00 a 0.16 ‐0.069 1.18E‐07 ‐0.079 1.88E‐08 NON_SYNONYMOUS Missense (conservative); Splicing regulation
rs4727338 6.89E‐15 1.84E‐12 7q21.3 FLJ42280 rs4729260 2.76 0.92 1.00 c 0.68 0.079 1.40E‐16 0.079 3.48E‐14 INTRONIC Promoter/regulatory region
rs3801387 8.98E‐11 4.26E‐12 7q31.31 WNT16 rs3779381 7.98 0.87 1.00 a 0.76 ‐0.074 2.77E‐12 ‐0.082 2.03E‐13 INTRONIC Promoter/regulatory region
rs7017914 1.76E‐05 9.44E‐01 8q13.3 LACTB2 rs13271442 6.0 0.97 1.00 t 0.49 0.043 1.37E‐06 0.000 9.63E‐01 WITHIN_NON_CODING_GENE Promoter/regulatory region
rs7932354 1.10E‐05 4.72E‐05 11p11.2 F2 rs2070852 22.7 0.96 1.00 c 0.68 ‐0.044 6.23E‐06 ‐0.044 1.89E‐05 SPLICE_SITE splicing site
rs3736228 2.38E‐05 1.89E‐08 11q13.2 LRP5 rs3736228 0.00 1.00 1.00 t 0.16 ‐0.052 2.38E‐05 ‐0.073 1.89E‐08 NON_SYNONYMOUS Missense (conservative); Splicing regulation
rs2016266 1.26E‐04 1.13E‐08 12q13.13 ESPL1 rs1318648 57.41 0.93 1.00 a 0.65 ‐0.030 1.24E‐03 ‐0.048 1.02E‐06 NON_SYNONYMOUS Missense (non‐conservative); Splicing regulation
rs2016266 1.26E‐04 1.13E‐08 12q13.13 ESPL1 rs1110720 45.63 0.96 1.00 a 0.65 ‐0.031 6.76E‐04 ‐0.050 3.26E‐07 SYNONYMOUS_CODING Sense/synonymous; Splicing regulation
rs11623869 4.58E‐08 7.13E‐05 14q32.32 MARK3 rs2273699 39.84 0.96 1.00 a 0.64 0.049 2.08E‐07 0.038 1.39E‐04 SPLICE_SITE splicing site
rs11623869 4.58E‐08 7.13E‐05 14q32.32 CKB rs1803283 102.6 1.00 1.00 t 0.65 0.047 3.44E‐07 0.034 4.91E‐04 SYNONYMOUS Sense/synonymous; Splicing regulation
rs4985155 1.60E‐03 7.08E‐06 16p13.11 PDXDC1 rs7200543 0.5 0.89 1.00 a 0.70 ‐0.029 2.43E‐03 ‐0.046 6.37E‐06 SYNONYMOUS Sense/synonymous; Splicing regulation
rs4985155 1.60E‐03 7.08E‐06 16p13.11 NTAN1 rs1136001 2.52 0.89 1.00 t 0.29 0.029 2.42E‐03 0.046 6.83E‐06 3PRIME_UTR Missense (conservative); Splicing regulation
rs227584 1.17E‐09 5.88E‐08 17q21.31_1 C17orf53 rs227584 0.00 1.00 1.00 a 0.69 ‐0.061 1.17E‐09 ‐0.057 5.88E‐08 NON_SYNONYMOUS Missense (conservative); Splicing regulation
rs227584 1.17E‐09 5.88E‐08 17q21.31_1 C17orf65/ASB16 rs7212573 28.73 1.00 1.00 a 0.69 ‐0.060 2.20E‐09 ‐0.056 1.08E‐07 NON_SYNONYMOUS Missense (non‐conservative); Splicing regulation
rs227584 1.17E‐09 5.88E‐08 17q21.31_1 C17orf65/ASB16 rs7212854 28.9 0.83 1.00 a 0.72 ‐0.056 4.84E‐08 ‐0.052 1.86E‐06 NON_SYNONYMOUS Missense (non‐conservative); Splicing regulation
rs227584 1.17E‐09 5.88E‐08 17q21.31_1 C17orf65/ASB16 rs7217858 29.0 0.93 1.00 t 0.70 ‐0.057 1.45E‐08 ‐0.054 4.67E‐07 NON_SYNONYMOUS Missense (conservative)
rs227584 1.17E‐09 5.88E‐08 17q21.31_1 C17orf65/ASB16 rs3826412 29.6 1.00 1.00 t 0.69 ‐0.059 3.18E‐09 ‐0.056 1.05E‐07 SPLICE_SITE splicing site
rs1864325 3.26E‐03 1.09E‐04 17q21.31_2 AC217771.1 rs12373123 53.77 1.00 1.00 t 0.79 0.032 3.58E‐03 0.044 1.68E‐04 NON_SYNONYMOUS Missense (non‐conservative); Splicing regulation
rs1864325 3.26E‐03 1.09E‐04 17q21.31_2 AC217771.1 rs12373139 53.71 1.00 1.00 a 0.21 ‐0.032 4.00E‐03 ‐0.044 1.89E‐04 NON_SYNONYMOUS Missense (non‐conservative); Splicing regulation
rs1864325 3.26E‐03 1.09E‐04 17q21.31_2 AC217771.1 rs12373142 53.64 1.00 1.00 c 0.79 0.032 3.48E‐03 0.044 1.62E‐04 NON_SYNONYMOUS Missense (non‐conservative); Splicing regulation
rs1864325 3.26E‐03 1.09E‐04 17q21.31_2 MAPT rs10445337 89.61 1.00 1.00 t 0.79 0.031 4.24E‐03 0.045 1.23E‐04 NON_SYNONYMOUS Missense (conservative)
rs10416218 6.10E‐05 9.61E‐06 19q13.11 GPATCH1 rs2287679 1.6 1.00 1.00 t 0.73 ‐0.041 4.56E‐05 ‐0.048 5.99E‐06 NON_SYNONYMOUS Missense (conservative); Splicing regulation









FN r‐FN P value LS r‐LS
2p16.2 PSME4 212222_at 0.019 ‐0.255 6.30E‐04 ‐0.365
10q21.1 DKK1 204602_at 1.30E‐05 0.456 3.20E‐04 0.383
17p13.3 C17orf91 214696_at 6.30E‐04 ‐0.365 8.80E‐04 ‐0.356
17q21.31_1 SOST 223869_at 4.80E‐04 0.373 0.0069 0.292





Locus SNP Allelea Tissue (treatment)b Gender Gene Probe Effectc P value P adjd Best SNPe r2f
Best SNP  
Pvalue P adj.g
1p36.12 rs6426749 G Fibroblasts AE WNT4  NM_030761 ‐ 9.00E‐09 na rs7524102  1 2.70E‐11 na
rs6426749 G Osteoblasts (pge2) WNT4  NM_030761.3 ‐ 2.60E‐05 na rs12742784  0.81 1.50E‐05 na
rs6426749 G Osteoblasts (dex) WNT4  NM_030761.3 ‐ 5.30E‐05 na rs7524102  1 2.40E‐05 na
rs7521902 A Adipose females WNT4  Contig30409_RC ‐ 1.20E‐05 0.21 rs12042083  0.56 7.50E‐06 0.12
2q13 rs17040773 C Monocytes mixed ANAPC1 ILMN_1804812 + 3.60E‐10 na rs17040773 same SNP na
rs17040773 C Adipose mixed* ANAPC1  NM_022662 + 1.90E‐11 0.96 rs1548189  0.96 2.20E‐13 0.0046
rs17040773 C Fibroblasts AE ANAPC1  NM_022662 + 7.00E‐06 na rs1548189  0.96 2.40E‐08 na
rs17040773 C Lymphoblasts AE mixed ANAPC1  NM_022662 + 1.50E‐02 na rs11689168  0.95 3.20E‐07 na
2q32.2 rs11675051 G Osteoblasts (bmp2) MFSD6  NM_017694.2 ‐ 5.40E‐11 na rs4638823  0.88 2.10E‐11 na
rs11675051 G Osteoblasts (pge2) MFSD6  NM_017694.2 ‐ 7.70E‐11 na rs4597559  0.88 5.00E‐11 na
rs11675051 G Osteoblasts (dex) MFSD6  NM_017694.2 ‐ 8.90E‐11 na rs4638823  0.88 2.90E‐11 na
rs11675051 G Osteoblasts (pbs) MFSD6  NM_017694.2 ‐ 9.50E‐10 na rs17801596  0.78 8.60E‐11 na
rs11675051 G Fibroblasts (eth) MFSD6  NM_017694.3 ‐ 9.20E‐06 na rs6756354  0.86 1.20E‐06 na
rs11675051 G Fibroblasts (res) MFSD6  NM_017694.3 ‐ 3.30E‐05 na rs4343493  0.88 8.50E‐07 na
rs11675051 G Fibroblasts (cho) MFSD6 NM_017694.3 ‐ 6.00E‐05 na rs4597559  0.88 1.40E‐05 na
4q22.1 rs6532023 G Adipose mixed SPP1  NM_000582 ‐ 1.50E‐05 0.48 rs1477603  0.66 2.80E‐06 0.06
6q25.1 rs4869742 T Monocytes mixed C6orf97 ILMN_1772588 + 8.00E‐27 na rs6900089 0.19 6.20E‐29 na
8q13.3 rs7017914 G Whole blood mixed* LACTB2  NM_016027 + 1.40E‐20 0.31 rs13253842  0.87 9.60E‐21 0.19
rs7017914 G Adipose mixed LACTB2  NM_016027 + 3.10E‐05 0.36 rs6994814  0.77 4.00E‐06 0.033
rs7017914 G Lymphoblasts mixed LOC340435  XM_291285.1 + 3.50E‐15 na rs2732090  0.97 1.50E‐15 na
rs7017914 G Lymphoblasts AE mixed XKR9  NM_001011720 + 1.20E‐21 na rs7013657  1 1.10E‐22 na
rs7017914 G Fibroblasts AE XKR9  NM_001011720 + 6.90E‐18 na rs13252719  1 5.30E‐18 na
11p11.2 rs7932354 C Adipose mixed* ARHGAP1  NM_004308 + 1.70E‐11 0.81 rs2070852  1 1.30E‐11 0.45
rs7932354 C Adipose females C11orf49  Contig32649_RC + 4.90E‐05 0.5 rs6485690  0.81 1.30E‐05 0.091
rs7932354 C Adipose mixed LRP4  AB011540 + 1.20E‐06 0.42 rs1060573  0.5 9.60E‐09 0.0019
11p14.1_1 rs10835187 T Adipose mixed* LIN7C  NM_018362 ‐ 2.80E‐39 0.94 rs3763965  0.97 9.00E‐43 5.10E‐04
rs10835187 T Whole blood mixed* LIN7C  NM_018362 ‐ 8.90E‐16 0.78 rs3763965  0.97 2.60E‐16 0.091
12q23.3 rs1053051 T Adipose mixed* C12orf23  NM_152261 + 4.10E‐13 na rs1053051 same SNP na
rs1053051 T Whole blood mixed* C12orf23  NM_152261 + 1.40E‐08 0.79 rs7974499  0.79 7.40E‐10 0.02
rs1053051 T Adipose mixed MTERFD3  NM_025198 + 1.00E‐06 na rs1053051 same SNP na
14q32.32 rs11623869 T Adipose mixed* C14orf172  NM_152307 + 1.30E‐13 0.96 rs2273700  0.96 1.90E‐14 0.064
rs11623869 T Whole blood mixed* MARK3  NM_002376 ‐ 1.40E‐26 0.62 rs3783402  0.96 4.00E‐27 0.13
rs11623869 T Osteoblasts (bmp2) MARK3  NM_002376.4 ‐ 3.90E‐04 na rs879552  0.9 4.10E‐05 na
16p13.11 rs4985155 A Adipose females KIAA2013 NM_138346 + 6.90E‐07 na rs4985155 same SNP na
rs4985155 A Adipose mixed* NTAN1  NM_173474 + 1.30E‐10 0.92 rs4985148  0.82 9.50E‐12 0.029
17q21.31_1 rs227584** A Monocytes mixed C17orf53 ILMN_1776490 + 5.30E‐11 na rs11079983 0.83 5.80E‐14 na
rs227584** A Monocytes mixed C17orf65 ILMN_1676731 + 5.00E‐19 na rs3826412 same SNP na
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Supplementary Table 14 Probable BMD‐SNP cis eQTLs; Significant correlation between BMD associated SNP genotypes and gene expressions 
Locus SNP Allelea Tissue (treatment)b Gender Gene Probe Effectc P value P adjd Best SNPe r2f
Best SNP  
Pvalue P adj.g
rs227584 A Adipose mixed* C17orf65  NM_178542 + 4.90E‐18 0.29 rs721769  1 1.70E‐18 0.089
rs227584 A Whole blood mixed C17orf65  NM_178542 + 4.70E‐05 0.029 rs7089  0.93 3.90E‐06 0.0021
rs227584 A Lymphoblasts mixed C17orf65 NM_178542.2 + 1.10E‐04 na rs7089  0.92 2.00E‐05 na
rs227584 A Fibroblasts (eth) TMUB2  NM_024107.2 + 4.00E‐05 na rs9910055  0.7 1.70E‐06 na
rs227584 A Adipose mixed TMUB2  NM_177441 + 4.90E‐05 na rs227584 same SNP na
rs227584 A Adipose mixed* UBTF  AF289595 + 9.00E‐09 0.51 rs2071167  0.72 1.00E‐10 0.0031
18q21.33 rs884205 A Whole blood females TNFRSF11A  NM_003839 ‐ 1.60E‐06 na rs884205 same SNP na
rs884205 A Adipose mixed TNFRSF11A  NM_003839 ‐ 1.70E‐04 0.63 rs2957137  0.8 3.70E‐05 0.082











Locus SNP Allelea Tissue (treatment)b Gender Gene Probe Effectc P value P adjd Best SNPe r2f
Best SNP  
Pvalue P adj.g
1p31.3 rs12407028 C Whole Blood mixed* WLS  NM_024911 ‐ 1.60E‐07 1.60E‐04 rs12065581  0.07 8.50E‐51 4.90E‐47
1p36.12 rs6426749 G Osteoblasts (bmp2) WNT4 NM_030761.3 ‐ 1.50E‐04 na rs17837965  0 3.10E‐05 na
rs7521902 A Osteoblasts (dex) ELA3B  NM_007352.2 ‐ 5.00E‐05 na rs16826658  0.51 3.50E‐06 na
rs7521902 A Adipose mixed* HSPC157  NM_014179 ‐ 1.70E‐21 4.40E‐04 rs3765351  0.22 1.70E‐133 9.10E‐104
rs7521902 A Whole Blood mixed* HSPC157  NM_014179 ‐ 2.60E‐15 0.01 rs3765351  0.22 9.10E‐94 1.70E‐75
2q24.3 rs1346004 A Adipose mixed* GALNT3  NM_004482 ‐ 1.40E‐11 0.0016 rs11694833  0.03 1.10E‐38 4.10E‐29
rs1346004 A Adipose mixed* TTC21B NM_024753 + 1.60E‐05 0.84 rs9677856  0.19 2.40E‐34 3.20E‐29
2q32.2 rs11675051 G Lymphoblasts AE mixed TMEM194B  NM_001142645 + 3.00E‐10 na rs10165399  0.43 5.70E‐12 na
6p21.1 rs11755164 T Adipose mixed* SUPT3H  NM_003599 + 4.60E‐14 0.0082 rs2396373  0.27 1.20E‐19 4.00E‐08
rs11755164 T Whole Blood mixed* SUPT3H  NM_003599 + 2.50E‐06 0.53 rs9349303  0.3 9.10E‐17 1.40E‐11
rs4869742 T Whole Blood mixed* C6orf97  NM_025059 + 2.80E‐08 6.20E‐05 rs852003  0.04 2.60E‐15 6.20E‐12
rs7751941 A Adipose mixed* C6orf97  NM_025059 + 1.00E‐05 0.51 rs7776340  0.33 4.40E‐13 1.40E‐08
rs7751941 A Whole Blood mixed* C6orf97  NM_025059 + 1.50E‐05 0.48 rs852003  0.24 2.60E‐15 4.60E‐11
7q31.31 rs3801387 A Adipose females WNT16  NM_016087 ‐ 9.00E‐06 0.35 rs10231005  0.27 1.60E‐10 5.20E‐06
rs13245690 G Adipose mixed* C7orf58 NM_024913 ‐ 4.00E‐10 0.53 rs2222543  0.37 1.80E‐27 9.50E‐18
8q13.3 rs7017914** G Monocytes mixed LACTB2 ILMN_1660635 ‐ 9.40E‐28 na rs13271014 0.1 3.80E‐104 na
10q24.2 rs7084921** T Monocytes mixed CWF19L1 ILMN_1651886 ‐ 8.80E‐14 na rs11597086 0.39 8.20E‐50 na
rs7084921 C Adipose mixed* CWF19L1  NM_018294 ‐ 1.90E‐22 0.64 rs11597086  0.38 2.50E‐68 1.40E‐40
rs7084921 C Whole Blood mixed CWF19L1  NM_018294 ‐ 2.90E‐07 0.4 rs11597086  0.38 3.00E‐22 5.10E‐16
rs7084921 C Fibroblasts (cho) CWF19L1  NM_018294.3 ‐ 1.50E‐05 na rs4462272  0.65 3.30E‐09 na
11p14.1_2 rs163879 T Whole Blood mixed DCDC5  AB040926 + 1.80E‐05 0.55 rs2122681  0.13 9.80E‐19 2.10E‐14
11q13.2 rs3736228 T Adipose mixed* SAPS3  Contig52814_RC + 7.30E‐11 0.54 rs10896337  0.43 1.90E‐32 1.40E‐21
rs3736228 T Whole Blood mixed SAPS3  Contig52814_RC + 2.40E‐08 0.4 rs10896339  0.42 3.70E‐25 9.80E‐18
rs3736228 T Adipose mixed SAPS3  NM_018312 + 8.00E‐07 0.12 rs10896347  0.47 1.90E‐08 0.0022
12q13.12 rs12821008 C Whole Blood mixed* CCDC65  NM_033124 ‐ 3.10E‐08 0.29 rs1054376  0.05 3.30E‐91 4.60E‐81
12q23.3 rs1053051 T Whole Blood mixed* AK055712  Contig10844_RC + 9.00E‐06 0.045 rs10746071  0.78 1.30E‐10 5.80E‐07
rs1053051 T Adipose mixed* AK055712  Contig10844_RC + 2.70E‐13 0.2 rs10778515  0.6 3.20E‐16 2.20E‐04
13q14.11 rs9533090 T Whole Blood mixed* AKAP11  NM_144490 + 7.30E‐06 0.15 rs3783192  0.22 1.70E‐19 4.20E‐15
rs9533090 T Adipose mixed AKAP11  NM_144490 + 6.60E‐07 0.15 rs7318683  0.18 1.40E‐31 1.50E‐25
rs7326472 A Adipose mixed AKAP11  NM_144490 + 1.50E‐06 0.0075 rs7318683  0.06 1.40E‐31 2.70E‐27
14q32.32 rs11623869** G Monocytes mixed BAG5 ILMN_2361695 ‐ 2.70E‐12 na rs7148456 0.18 9.60E‐24 na
rs11623869** G Monocytes mixed MARK3 ILMN_1704795 ‐ 2.10E‐08 na rs975892 0.15 2.10E‐38 na
rs11623869 T Whole Blood mixed BAG5  NM_004873 + 6.00E‐06 0.23 rs752624  0.14 3.50E‐17 1.20E‐12
rs11623869 T Adipose mixed* C14orf153  NM_032374 + 2.10E‐07 1.40E‐02 rs2403197  0.19 3.50E‐14 2.80E‐09
rs11623869 T Whole Blood mixed* KLC1  NM_005552 ‐ 3.90E‐05 0.32 rs3212090  0.22 3.90E‐22 3.20E‐18
rs11623869 T Adipose mixed* MARK3  Contig43834_RC ‐ 2.10E‐47 2.30E‐07 rs4906319  0.15 1.90E‐147 6.60E‐89
rs11623869 T Whole Blood mixed* MARK3  Contig43834_RC ‐ 1.10E‐68 2.60E‐15 rs6575982  0.15 1.30E‐147 7.60E‐80
rs11623869 T Lymphoblasts AE mixed BAG5  NM_001015049 ‐ 3.30E‐06 na rs942863  0.56 1.20E‐08 na
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Supplementary Table 15 Non‐BMD SNP cis eQTLs; Significant correlation between non‐associated SNP genotypes and gene expressions 
Locus SNP Allelea Tissue (treatment)b Gender Gene Probe Effectc P value P adjd Best SNPe r2f
Best SNP  
Pvalue P adj.g
16p13.11 rs4985155 A Adipose females PDXDC1  D87438 ‐ 2.20E‐05 0.48 rs1136001  0.78 5.20E‐07 0.0072
16p13.3_1 rs9921222 T Monocytes mixed AXIN1 ILMN_1766185 ‐ 1.10E‐14 na rs1204042 0.07 5.40E‐114 na
rs9921222 T Monocytes mixed NME4 ILMN_1800634 + 3.90E‐23 na rs763151 0.14 3.20E‐204 na
rs9921222 T Monocytes mixed TMEM8 ILMN_1741371 ‐ 7.90E‐08 na rs3830160 0.18 2.80E‐80 na
rs9921222 T Adipose mixed* AXIN1  NM_181050 ‐ 1.80E‐06 0.12 rs214252  0.11 2.90E‐22 3.80E‐17
rs9921222 T Osteoblasts (dex) DECR2  NM_020664.3 + 5.80E‐06 na rs1698231  0.1 1.60E‐10 na
17p13.3 rs4790881 C Whole Blood mixed* SRR   NM_021947 + 8.40E‐09 0.37 rs17834563  0.06 4.60E‐71 5.50E‐61
17q21.31_1  rs4792909 G Adipose mixed* MPP3  NM_001932 + 6.30E‐15 0.92 rs17674998  0.14 4.20E‐60 4.60E‐42
19q13.11 rs10416218 T Adipose mixed* GPATCH1  NM_018025 ‐ 4.20E‐19 0.16 rs7256470  0.66 1.60E‐22 8.50E‐05
rs10416218 T Adipose mixed* WDR88  NM_173479 ‐ 1.40E‐06 0.12 rs10423969  0.52 6.70E‐16 6.80E‐11
















































































1p31.3 rs12407028 0.39 WLS YES MGI:1915401 Wnt 3
1p36.12 rs6426749 0.17 ZBTB40 YES 1
1p36.12 rs7521902 0.31 WNT4 YES NM_030761 YES Wnt 4
1q24.3 rs479336 0.26 DNM3 YES 1
2p16.2 rs4233949 0.38 SPTBN1 YES rs4305309 2
2p21 rs7584262 0.23 PKDCC YES MGI:2147077 2
2q13 rs17040773 0.23 ANAPC1 YES ILMN_1804812 2
2q14.2 rs1878526 0.22 INSIG2 YES 1
2q24.3 rs1346004 0.49 GALNT3 YES MGI:894695 MIM:211900 3
3p22.1 rs430727 0.47 CTNNB1 YES MGI:88276 YES Wnt 4
3q13.2 rs1026364 0.36 KIAA2018 YES rs9813630 2
3q25.31 rs344081 0.13 LEKR1 YES 1
4p16.3 rs3755955 0.16 IDUA YES MGI:96418 rs6848974 3
4q22.1 rs6532023 0.34 MEPE YES MGI:2137384 2
4q22.1 rs6532023 0.34 SPP1 NM_000582 MGI:98389 YES Endochondral Ossification 4
4q22.1 rs6532023 0.34 IBSP MGI:96389 1
5q14.3 rs1366594 0.47 MEF2C YES Endochondral Ossification 2
6p21.1 rs11755164 0.40 RUNX2 MGI:99829 YES Endochondral Ossification 3
6p22.3 rs9466056 0.38 SOX4 0
6q22.32 rs13204965 0.24 RSPO3 YES MGI:1920030 Wnt 3
6q25.1 rs4869742 0.32 ESR1 MGI:1352467 1
7p14.1 rs10226308 0.16 SFRP4 YES Wnt 2
7p14.1 rs6959212 0.34 STARD3NL YES 1
7q21.3 rs4727338 0.33 SLC25A13 YES 1
7q31.31 rs3801387 0.26 WNT16 YES rs3779381 YES Wnt 4
7q36.1 rs7812088 0.12 ABCF2 YES 1
8q13.3 rs7017914 0.49 LACTB2 NM_016027 rs13271442 2
8q24.12 rs2062377 0.41 TNFRSF11B YES MGI:109587 MIM:602080 YES OPG/RANK/RANKL 5
9q34.11 rs7851693 0.37 FUBP3 YES 1
10p11.23 rs3905706 0.23 MPP7 YES 1
10q21.1 rs1373004 0.12 DKK1 MGI:1329040 Wnt 2
10q22.3_1 rs7071206 0.24 KCNMA1 YES 1
10q24.2 rs7084921 0.40 CPN1 YES 1
11p11.2 rs7932354 0.33 LRP4 AB011540 MGI:2442252 MIM:604270 3
11p14.1_1 rs10835187 0.46 LIN7C YES NM_018362 2
11p14.1_2 rs163879 0.34 DCDC5 YES 1
11p15.2 rs7108738 0.18 SOX6 YES MGI:98368 YES Endochondral Ossification 4
11q13.2 rs3736228 0.15 LRP5 YES MGI:1278315 MIM:259770,MIM:607634 rs3736228 YES Wnt 6
12p11.22 rs7953528 0.18 PTHLH MGI:97800 MIM:613382  YES Endochondral Ossification 4
12p13.33 rs2887571 0.24 WNT5B YES Wnt 2
12q13.12 rs12821008 0.40 DHH YES Hedgehog  2
12q13.13 rs2016266 0.31 SP7 YES MGI:2153568 MIM:613849 YES MSC differentiation 5
12q13.13 rs736825 0.44 HOXC6 YES MGI:96197 Wnt 3
12q23.3 rs1053051 0.49 C12orf23 YES NM_152261 2
13q14.11 rs9533090 0.48 TNFSF11 MGI:1100089  MIM:259710 YES OPG/RANK/RANKL 4
14q32.12 rs1286083 0.20 RPS6KA5 YES 1
14q32.32 rs11623869 0.34 MARK3 YES NM_002376 rs2273699 3
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Supplementary Table 17 Functional and biological evidence for genes underlying  the GWAS loci











16p13.11 rs4985155 0.35 NTAN1 YES NM_173474 rs1136001 3
16p13.3_1 rs9921222 0.46 AXIN1 YES MGI:1096327 YES Wnt 4
16p13.3_2 rs13336428 0.44 CLCN7 MGI:1347048 MIM:611490 2
16q12.1 rs1566045 0.20 CYLD MGI:1921506 1
16q24.1 rs10048146 0.20 FOXL1 YES MGI:1347481 YES TGF‐beta 4
17p13.3 rs4790881 0.33 SMG6 YES 1
17q21.31_1 rs227584 0.33 C17orf53 ILMN_1776490 rs227584 2
17q21.31_1 rs4792909 0.37 SOST YES MGI:1921749 MIM:269500 Wnt 4
17q21.31_2 rs1864325 0.22 WNT3 MIM:273395 YES Wnt 3
17q24.3 rs7217932 0.46 SOX9 YES MGI:98371 MIM:608160 YES Endochondral Ossification 5
18p11.21 rs4796995 0.39 C18orf19 YES 1
18q21.33 rs884205 0.25 TNFRSF11A YES NM_003839 MGI:1314891 MIM:602080 YES OPG/RANK/RANKL 6
19q13.11 rs10416218 0.28 GPATCH1 YES rs2287679 2
20p12.2 rs3790160 0.50 JAG1 YES 1

























































































































































































7 FHS Framingham Heart Study Cohort Population‐based, 
family‐based
































































































11 Indiana Indiana Genetics of Bone Fragility Study Cross‐sectional Population‐based, 
family‐based, clinical‐
based



































































14 RS‐II Rotterdam Study‐III Cohort Population‐based The Netherlands Rotterdam North‐western 
European
≥ 97.5% 2,157
15 RS‐III Rotterdam Study‐III Cohort Population‐based The Netherlands Rotterdam North‐western 
European
≥ 97.5% 1,212






































Study Trait Assessment method N mean sd median min max N mean sd median min max
1 AFOS Age (yrs) Questionnaire 443 51.3 15.5 51.5 20.2 95.1 475 52.2 14.6 53.7 18.6 92.7
BMI (kg/m²) Calculated 443 26.4 3.7 26.1 18.3 43.6 475 28.4 5.6 27.8 16.7 49.3
Weight (kg) Measured 443 77.9 12.2 76.8 50.9 125.4 475 72.2 14.5 71.1 37.8 120.4
Height (cm) Measured 443 171.5 6.4 172.1 154.2 193.5 475 159.5 5.9 160.0 137.6 175.5
LS‐BMD (g/cm2) Hologic 4500 443 1.0 0.1 1.0 0.6 1.4 475 0.9 0.2 0.9 0.4 1.4
FN‐BMD (g/cm2) Hologic 4500 443 0.9 0.1 0.8 0.5 1.3 475 0.8 0.1 0.8 0.4 1.4
2 AOGC  Age (yrs) Questionnaire 0 NA NA NA NA NA 1,051 70.4 8.3 71.0 48.0 86.0
high BMD group BMI (kg/m²) Measured 0 NA NA NA NA NA 1,044 30.1 5.5 29.4 16.2 48.3
Weight (kg) Measured 0 NA NA NA NA NA 1,047 77.5 14.7 76.0 44.0 134.7
Height (cm) Measured 0 NA NA NA NA NA 1,044 160.5 6.2 160.2 139.1 180.0
LS‐BMD (g/cm2) Both Lunar and Hologic 0 NA NA NA NA NA 618 1.3 0.2 1.2 0.8 2.1
FN‐BMD (g/cm2) Both Lunar and Hologic 0 NA NA NA NA NA 1,021 0.9 0.1 0.9 0.6 1.8
AOGC   Age (yrs) Questionnaire 0 NA NA NA NA NA 900 68.7 8.8 68.0 50.0 86.0
low BMD group BMI (kg/m²) Measured 0 NA NA NA NA NA 893 24.3 4.8 23.4 14.8 48.5
Weight (kg) Measured 0 NA NA NA NA NA 894 61.5 13.7 59.3 34.5 136.0
Height (cm) Measured 0 NA NA NA NA NA 893 158.8 7.3 159.0 127.5 188.0
LS‐BMD (g/cm2) Both Lunar and Hologic 0 NA NA NA NA NA 552 0.9 0.2 0.9 0.5 1.5
FN‐BMD (g/cm2) Both Lunar and Hologic 0 NA NA NA NA NA 865 0.6 0.1 0.6 0.3 1.0
3 CHS Age (yrs) Questionnaire 340 77.0 4.8 76.0 70.0 93.0 568 76.3 4.2 75.0 69.0 93.0
BMI (kg/m²) Measured 340 26.3 3.8 26.1 11.1 41.4 568 26.0 5.1 25.8 7.5 44.6
Weight (kg) Measured 340 78.5 12.2 78.1 34.1 116.8 568 65.8 13.7 64.9 22.3 116.4
Height (cm) Measured 340 173 6.4 172 152 193 568 159 6.0 159 142 183
LS‐BMD (g/cm2) Whole Body Scan 340 1.1 0.2 1.1 0.6 2.6 568 0.9 0.2 0.9 0.4 3.3
FN‐BMD (g/cm2) Measured 340 0.8 0.1 0.8 0.4 1.4 568 0.6 0.1 0.6 0.3 1.1
4 DeCODE Age (yrs) NationalRegistry 1,136 66.1 14.2 69.2 20.1 96.1 6,469 59.7 13.8 59.9 20.0 97.8
BMI (kg/m²) Calculated 1,136 26.7 4.1 26.5 13.9 42.5 6,461 26.3 4.8 25.6 13.5 59.7
Weight (kg) Measured 1,136 83.4 14.4 83.0 38.4 129.5 6,461 71.1 13.4 69.7 30.0 129.3
Height (cm) Measured 1,136 176.5 6.7 176.0 148.5 196.0 6,469 164.4 6.2 164.5 116.5 188.0
LS‐BMD (g/cm2) Hologic 1,135 1.0 0.2 1.0 0.5 1.7 6,461 0.9 0.2 0.9 0.4 1.8
FN‐BMD (g/cm2) Hologic 1,115 0.8 0.1 0.9 0.4 1.3 6,279 0.7 0.1 0.6 0.2 1.4
5 ERF Age (yrs) Questionnaire 1,419 50.6 14.9 50.9 17.6 88.6 1,815 50.6 15.9 50.7 16.7 95.7
BMI (kg/m²) Measured 1,223 27.1 3.9 26.8 15.9 42.4 1,517 26.4 4.7 25.7 15.5 45.6
Weight (kg) Measured 1,232 83.3 14.0 81.8 41.9 154.7 1,532 69.4 13.6 67.4 42.1 161.0
Height (cm) Measured 1,232 174.8 7.2 174.7 152.2 196.5 1,533 161.8 6.5 161.6 141.0 182.8
LS‐BMD (g/cm2) GE‐lunar DPX‐L 1,215 1.2 0.2 1.2 0.6 1.8 1,504 1.1 0.2 1.1 0.6 1.8
FN‐BMD (g/cm2) GE‐lunar DPX‐L 1,207 1.0 0.1 1.0 0.5 1.7 1,512 0.9 0.1 0.9 0.5 1.3
6 EPIC Norfolk Age (yrs) Questionnaire 109 72.3 3.2 71.8 67.4 78.4 111 72.4 3.0 72.8 67.5 78.7
BMI (kg/m²) Measured 109 28.1 4.0 28.1 19.0 39.3 111 29.6 4.5 29.5 18.4 41.0
Weight (kg) Measured 109 82.7 12.9 82.8 56.4 128.5 111 74.9 12.5 74.4 46.8 104.0
Height (cm) Measured 109 171.5 5.3 171.7 154.9 188.9 111 159.0 5.7 159.1 144.9 177.2
LS‐BMD (g/cm2) NA NA NA NA NA NA NA NA NA NA NA NA NA
FN‐BMD (g/cm2) Hologic QDR 1000W 109 0.8 0.1 0.8 0.5 1.3 111 0.7 0.1 0.7 0.5 1.0
7 FHS Age (yrs) Questionnaire 1,548 64.5 10.9 64.0 35.0 92.0 2,081 64.9 11.5 65.0 29.0 96.0
BMI (kg/m²) Measured 1,540 28.4 4.4 27.9 17.1 53.4 2,060 27.3 5.5 26.4 15.4 58.2
Weight (kg) Measured 1,544 86.0 14.9 84.4 46.3 170.1 2,066 69.8 15.0 67.6 36.3 158.8





Study Trait Assessment method N mean sd median min max N mean sd median min max
Men Women
LS‐BMD (g/cm2) GE‐lunar DPX‐L 1,492 1.3 0.2 1.3 0.7 2.4 2,008 1.1 0.2 1.1 0.5 2.0
FN‐BMD (g/cm2) GE‐lunar DPX‐L 1,531 1.0 0.1 1.0 0.5 1.7 2,043 0.8 0.2 0.8 0.1 1.4
8 GOOD Age (yrs) Questionnaire 938 18.9 0.6 18.8 18.0 20.1 0 NA NA NA NA NA
BMI (kg/m²) Measured 938 22.4 3.2 21.9 16.1 41.6 0 NA NA NA NA NA
Weight (kg) Measured 938 73.9 11.6 72.0 51.3 127.0 0 NA NA NA NA NA
Height (cm) Measured 938 182 7.0 182 161 203 0 NA NA NA NA NA
LS‐BMD (g/cm2) GE_Lunar_Prodigy 938 1.2 0.2 1.2 0.8 1.7 0 NA NA NA NA NA
FN‐BMD (g/cm2) GE_Lunar_Prodigy 938 1.2 0.2 1.2 0.8 1.8 0 NA NA NA NA NA
9 HABC Age (yrs) Questionnaire 879 73.9 2.9 74.0 69.0 80.0 784 73.6 2.8 73.0 69.0 80.0
BMI (kg/m²) Measured 879 27.1 3.7 26.7 17.6 44.2 784 26.1 4.5 25.6 15.6 44.7
Weight (kg) Measured 879 81.6 12.4 80.0 52.2 134.5 784 66.4 12.1 65.1 40.8 123.0
Height (cm) Measured 879 173.6 6.4 173.4 151.1 194.8 784 159.4 5.8 159.6 141.6 175.6
LS‐BMD (g/cm2) Hologic QDR 4500 871 1.1 0.2 1.1 0.6 2.4 778 0.9 0.2 0.9 0.6 1.7
FN‐BMD (g/cm2) Hologic QDR 4500 869 0.8 0.1 0.8 0.4 1.3 776 0.7 0.1 0.7 0.3 1.1
10 HKOS Age (yrs) Questionnaire 0 NA NA NA NA NA 800 48.9 15.6 50.0 20.0 84.0
BMI (kg/m²) Measured 0 NA NA NA NA NA 800 22.7 3.9 22.0 15.0 40.5
Weight (kg) Measured 0 NA NA NA NA NA 800 54.7 10.2 53.2 33.5 93.5
Height (cm) Measured 0 NA NA NA NA NA 800 155 6.7 156 127 175
LS‐BMD (g/cm2) Hologic‐ Delphi W 0 NA NA NA NA NA 800 0.9 0.2 0.9 0.3 1.6
FN‐BMD (g/cm2) Hologic‐ Delphi W 0 NA NA NA NA NA 800 0.7 0.2 0.7 0.3 1.9
11 Indiana Age (yrs) Questionnaire 0 NA NA NA NA NA 1,481 33.1 7.2 33.3 20.0 50.7
BMI (kg/m²) Measured 0 NA NA NA NA NA 1,476 25.6 5.9 24.1 15.7 57.3
Weight (kg) Measured 0 NA NA NA NA NA 1,476 70.0 16.6 66.0 41.2 166.0
Height (cm) Measured 0 NA NA NA NA NA 1,476 165.5 6.1 165.3 146.8 192.3
LS‐BMD (g/cm2) GE_Lunar_Prodigy 0 NA NA NA NA NA 1,479 1.3 0.1 1.3 0.9 1.8
FN‐BMD (g/cm2) GE_Lunar_Prodigy 0 NA NA NA NA NA 1,479 1.0 0.1 1.0 0.6 1.6
12 ORCADES Age (yrs) Questionnaire 194 57.7 13.5 58.9 24.5 86.8 233 58.8 13.0 61.0 23.6 81.7
BMI (kg/m²) Measured 194 27.8 4.4 27.2 16.8 47.7 233 27.7 5.2 26.5 18.5 47.2
Weight (kg) Measured 194 84.8 14.3 83.3 42.0 147.5 233 71.5 13.7 69.3 43.0 115.4
Height (cm) Measured 194 174.7 6.6 175.2 157.9 198.6 233 160.7 6.2 160.9 139.5 181.0
LS‐BMD (g/cm2) Hologic QDR 4500 194 1.1 0.2 1.1 0.7 1.6 233 1.0 0.2 1.0 0.6 1.4
FN‐BMD (g/cm2) Hologic QDR 4500 192 0.8 0.1 0.8 0.6 1.3 229 0.8 0.1 0.7 0.5 1.0
13 RS‐I Age (yrs) Questionnaire 2,427 68.1 8.2 67.1 55.0 97.8 3,547 70.3 9.6 69.4 55.0 99.2
BMI (kg/m²) Measured 2,372 25.7 3.0 25.6 14.2 38.2 3,372 26.7 4.1 26.3 15.4 59.5
Weight (kg) Measured 2,375 78.6 10.7 77.8 41.0 122.3 3,383 69.6 11.3 68.7 40.1 146.5
Height (cm) Measured 2,372 174.8 6.8 174.6 151.0 198.0 3,375 161.3 6.6 161.5 101.0 191.5
LS‐BMD (g/cm2) GE‐lunar DPX‐L 2,116 1.2 0.2 1.2 0.5 2.0 2,798 1.0 0.2 1.0 0.5 1.7
FN‐BMD (g/cm2) GE‐lunar DPX‐L 2,106 0.9 0.1 0.9 0.4 1.4 2,799 0.8 0.1 0.8 0.4 1.5
14 RS‐II Age (yrs) Questionnaire 785 63.7 6.8 61.5 55.1 89.3 902 63.8 7.4 61.4 55.1 92.3
BMI (kg/m²) Measured 785 26.9 3.3 26.8 16.8 40.5 902 27.4 4.4 26.8 16.7 45.5
Weight (kg) Measured 785 83.5 11.4 82.5 54.0 126.8 902 72.8 12.5 71.2 44.1 125.3
Height (cm) Measured 785 176.0 6.5 175.9 156.8 203.0 902 162.9 6.2 163.0 141.5 189.6
LS‐BMD (g/cm2) GE‐lunar DPX‐L 781 1.2 0.2 1.2 0.7 1.9 898 1.1 0.2 1.1 0.5 2.0
FN‐BMD (g/cm2) GE‐lunar DPX‐L 779 1.0 0.1 1.0 0.6 1.6 888 0.9 0.1 0.9 0.5 1.4
15 RS‐III Age (yrs) Questionnaire 528 56.1 5.5 56.3 45.9 84.2 683 56.1 5.4 56.6 45.8 87.9
BMI (kg/m²) Measured 525 28.0 4.0 27.3 19.5 46.7 683 27.6 5.0 26.7 14.0 48.2




Study Trait Assessment method N mean sd median min max N mean sd median min max
Men Women
Height (cm) Measured 525 178.8 6.7 178.6 160.5 197.5 683 165.0 6.2 164.8 146.5 184.5
LS‐BMD (g/cm2) GE‐lunar DPX‐L 437 1.2 0.2 1.2 0.8 1.8 583 1.2 0.2 1.2 0.7 1.9
FN‐BMD (g/cm2) GE‐lunar DPX‐L 511 1.0 0.1 1.0 0.6 1.5 666 0.9 0.1 0.9 0.6 1.5
16 TUK‐1 Age (yrs) Questionnaire 0 NA NA NA NA NA 1,523 49.8 13.1 51.2 16.6 80.9
BMI (kg/m²) Measured 0 NA NA NA NA NA 1,523 25.2 4.8 24.2 17.4 40.1
Weight (kg) Measured 0 NA NA NA NA NA 1,523 67.5 12.7 65.2 35.1 128.3
Height (cm) Measured 0 NA NA NA NA NA 1,523 162.1 6.3 162.0 148.0 177.0
LS‐BMD (g/cm2) Hologic QDR 4500W 0 NA NA NA NA NA 1,517 1.0 0.2 1.0 0.6 1.8
FN‐BMD (g/cm2) Hologic QDR 4500W 0 NA NA NA NA NA 1,487 0.8 0.1 0.8 0.3 1.3
17 TUK‐23 Age (yrs) Questionnaire 373 49.8 14.6 50.1 18.3 81.4 2,439 50.0 13.8 51.8 16.2 82.1
BMI (kg/m²) Measured 365 25.8 3.3 25.7 19.1 35.2 2,359 25.4 4.7 24.6 17.7 41.4
Weight (kg) Measured 373 80.4 11.8 79.8 40.5 122.7 2,439 67.6 13.0 65.5 40.0 166.0
Height (cm) Measured 365 175.1 7.1 175.0 161.0 191.0 2,359 162.2 6.3 162.0 149.0 177.0
LS‐BMD (g/cm2) Hologic QDR 4500W 371 1.0 0.2 1.0 0.6 1.5 2,427 1.0 0.1 1.0 0.5 1.6




Fracture N Non‐fracture N Fracture N Non‐fracture N
1 All fractures NA NA NA NA NA
Non‐vertebral fractures NA NA NA NA NA
Vertebral fractures NA NA NA NA NA
2 All fractures Interview with questionnaire NA NA 431 1,224
Non‐vertebral fractures Radiographic NA NA 294 1,224
Vertebral fractures NA NA NA NA NA
3 All fractures NA NA NA NA NA
Non‐vertebral fractures NA NA NA NA NA
Vertebral fractures NA NA NA NA NA
4 All fractures Medical records, radiograhic 
documentation, questionnaire 532 6,890 1,453 7,673
Non‐vertebral fractures NA NA NA NA NA
Vertebral fractures NA NA NA NA NA
5 All fractures Interview 594 721 470 1,141
Non‐vertebral fractures NA NA NA NA NA
Vertebral fractures NA NA NA NA NA
6 All fractures Medical records 143 1,478 228 1,703
Non‐vertebral fractures Medical records 119 1,502 203 1,728
Vertebral fractures NA NA NA NA NA
7 All fractures Self‐report and medical records 583 1,351 937 1,431
Non‐vertebral fractures Medical records 401 1,153 738 1,352
Vertebral fractures Radiographic 48 1,506 77 2,013
8 All fractures Radiographic doc 304 687 NA NA
Non‐vertebral fractures NA NA NA NA NA
Vertebral fractures NA NA NA NA NA
9 All fractures Radiographic 109 769 199 584
Non‐vertebral fractures Radiographic 88 790 165 618















Fracture N Non‐fracture N Fracture N Non‐fracture NStudy Trait Assessment method
Men Women
10 All fractures Medical records, Radiographic and 
Questionnaire NA NA 79 627
Non‐vertebral fractures NA NA NA NA NA
Vertebral fractures NA NA NA NA NA
11 All fractures NA NA NA NA NA
Non‐vertebral fractures NA NA NA NA NA
Vertebral fractures NA NA NA NA NA
12 All fractures NA NA NA NA NA
Non‐vertebral fractures NA NA NA NA NA
Vertebral fractures NA NA NA NA NA
13 All fractures Medical records 227 2,151 753 2,615
Non‐vertebral fractures Medical records 174 2,201 622 2,761
Vertebral fractures Medical records and Radiographic  128 1,184 201 1,470
14 All fractures Medical records 41 941 88 1,080
Non‐vertebral fractures Medical records 33 951 71 1,102
Vertebral fractures Medical records and Radiographic  9 975 22 1,151
15 All fractures NA NA NA NA NA
Non‐vertebral fractures NA NA NA NA NA
Vertebral fractures NA NA NA NA NA
16 All fractures Medical records, Radiographic and 
Questionnaire NA NA 332 1,337
Non‐vertebral fractures Medical records and Radiographic NA NA 48 1,621
Vertebral fractures NA NA NA NA NA
17 All fractures Medical records, Radiographic and 
Questionnaire 52 406 475 2,416
Non‐vertebral fractures Medical records and Radiographic 1 457 72 2,819













MAF Call rate* p for HWE MAF Imputation quality* LSBMD FNBMD
1 AFOS





BeadStudio ≥ 1% ≥ 98% > 10‐7 289,499 MACH ≥ 1% MACH R2 ≥  0.3 MACH2DAT 2,543,887 0 1,955 1.01 1.02
3 CHS
Illumina 370CNV BeadStudio > 1% ≥97% > 10‐5 306,655 BimBam ≥1% (O/E)σ2 ratio ≥  0.3 R 2,335,99 347 563 1.03 0.98
4 DeCODE
Illumina HH300 and 370CNV BeadStudio > 1% > 96% > 10‐6 281,410 IMPUTE ≥1% Prop_info >0.4 SNPTEST 2,454,808 1,136 6,469 1.00 1.00
5 EPICNOR
Afffymetrix 500K BRLMM ≥ 1% ≥ 90% > 10‐6 397,438 IMPUTE ≥1% Prop_info >0.4 SNPTEST 2,313,843 109 111 ‐ 1.00
6 ERF




BRLMM ≥ 1% ≥ 97% ≥ 10‐6 378,163 MACH ≥1% (O/E)σ2 ratio ≥  0.3 Kinship          R‐Package 2,471,285 1,554 2,090 1.03 1.02
8 GOOD
Illumina / HumanHap 610 Quad Beadstudio Genecall ≥ 1% ≥ 98% > 10‐6 521,160 MACH ≥1% MACH R2 ≥  0.3 MACH2QTL via GRIMP 2,543,887 938 0 0.99 1.01
9 HABC
Illumina/ Human 1M‐Duo  Beadstudio ≥1% ≥97% > 10‐6 914,263 MACH ≥1% MACH R2 ≥  0.3 SNPTEST 2,543,887 871 778 1.00 1.01
10 HKOS
Illumina /   Human610‐Quad Illumina's GenomeStudio ≥ 1% ≥ 95% > 10‐4 488,853 IMPUTE ≥1% Prop_info >0.4 SNPTEST 2,329,916 0 778 1.00 1.01
11 Indiana
Illumina 610Quadv1_B Beadstudio v3.2.32 ≥ 1% ≥ 95% > 10‐4 553,331 IMPUTE ≥1% Prop_info >0.4 Merlin 2,626,037 0 1,487 1.01 0.99
12 ORCADES
Illumina /   HumanHap 300K V.2 Beadstudio Genecall ≥ 1% ≥ 98.0% > 10‐6 306,207 MACH ≥1% MACH R2 ≥  0.3 R, GenABEL, ProbABEL 2,543,887 194 233 1.00 1.01
13 RS‐I Illumina /   HumanHap 550K V.3 /HumanHap 550 V.3 DUO;
Beadstudio Genecall ≥ 1% ≥ 97.5% > 10‐6 512,349 MACH ≥1% MACH R2 ≥  0.3 MACH2QTL via GRIMP 2,543,887 2,378 3,368 1.07 1.05
14 RS‐II Illumina /   HumanHap 550K V.3 /HumanHap 550 V.3 DUO;
Beadstudio Genecall ≥ 1% ≥ 97.5% > 10‐6 466,389 MACH ≥1% MACH R2 ≥  0.3 MACH2QTL via GRIMP 2,543,887 982 1,168 1.01 1.00
15 RS‐III Illumina /   HumanHap610 Beadstudio Genecall ≥ 1% ≥ 97.5% > 10‐6 514,073 MACH ≥1% MACH R2 ≥  0.3 MACH2QTL via GRIMP 2,543,887 517 695 1.00 1.00
16 TUK‐1 Illumina HumanHap 300 & 550. Illumina HumanCNV370 Duo
Beadstudio Genecall ≥ 1% ≥ 95% > 10‐6 313,575 IMPUTE ≥1% Prop_info >0.4 GenABEL 2,561,701 0 1,511 1.01 1.01











Short name Full name Study design Study base Country of origin
City/region of 
















































































4 WGHS Women's Genome Health Study Cohort Population‐based North America, 
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Short name Full name Study design Study base Country of origin
City/region of 






















Study Trait Assessment method N mean sd median min max N mean sd median min max
1 AGES Age (yrs) Questionnaire 1,351 76.5 5.3 76.0 67.0 94.0 1,865 76.3 5.6 76.0 66.0 95.0
BMI (kg/m²) Measured 1,351 27.0 3.8 26.7 15.9 40.6 1,865 27.2 4.9 26.8 14.8 48.5
Weight (kg) Measured 1,351 83.2 13.3 81.6 42.0 144.7 1,865 70.5 13.3 69.3 37.2 128.3
Height (cm) Measured 1,351 175.4 6.2 175.2 153.1 196.4 1,865 160.9 5.8 160.9 139.3 182.6
LS‐BMD (g/cm2) NA NA NA NA NA NA NA NA NA NA NA NA NA
FN‐BMD (g/cm2) NA NA NA NA NA NA NA NA NA NA NA NA NA
2 DeCODE insilico Age (yrs) NationalRegistry 832 54.8 16.3 54.6 20.3 89.0 2,046 57.1 14.3 56.8 20.0 91.7
BMI (kg/m²) Calculated 831 26.4 3.7 26.1 16.6 42.0 2,045 25.9 4.5 25.2 16.2 47.2
Weight (kg) Measured 831 84.1 13.4 82.7 46.6 129.3 2,045 70.2 12.9 68.1 34.5 124.2
Height (cm) Measured 831 178.5 6.5 178.5 155.0 203.0 2,045 164.7 6.0 165.0 133.0 185.0
LS‐BMD (g/cm2) NA NA NA NA NA NA NA NA NA NA NA NA NA
FN‐BMD (g/cm2) NA NA NA NA NA NA NA NA NA NA NA NA NA
3 PROSPER/PHASE Age (yrs) Questionnaire 2,524 75.0 3.3 74.5 70.2 83.3 2,718 75.7 3.4 75.4 69.4 83.4
BMI (kg/m²) Measured 2,524 26.6 3.6 26.3 15.2 45.1 2,718 27.1 4.7 26.7 15.6 50.1
Weight (kg) Measured 2,524 78.7 11.9 78.0 40.0 127.0 2,718 68.3 12.7 67.0 35.5 138.0
Height (cm) Measured 2,524 172.1 6.7 172.0 143.0 198.0 2,718 158.8 6.6 159.0 135.0 180.0
LS‐BMD (g/cm2) NA NA NA NA NA NA NA NA NA NA NA NA NA
FN‐BMD (g/cm2) NA NA NA NA NA NA NA NA NA NA NA NA NA
4 WGHS Age (yrs) Questionnaire NA NA NA NA NA NA 22,330 54.1 7.1 52.0 38.0 89.0
BMI (kg/m²) Questionnaire NA NA NA NA NA NA 22,330 25.9 5.0 24.9 14.2 59.6
Weight (kg) Questionnaire NA NA NA NA NA NA 22,330 70.0 14.2 68.0 38.6 175.1
Height (cm) Questionnaire NA NA NA NA NA NA 22,330 164 6.0 165 13 201
LS‐BMD (g/cm2) NA NA NA NA NA NA NA NA NA NA NA NA NA




GWAS Age (yrs) Questionnaire NA NA NA NA NA NA 4,656 69.0 6.5 70.0 50.0 79.0
BMI (kg/m²) Measured NA NA NA NA NA NA 4,655 27.0 5.5 26.0 13.4 69.4
Weight (kg) Measured NA NA NA NA NA NA 4,656 70.5 14.9 68.1 37.5 171.5
Height (cm) Measured NA NA NA NA NA NA 4,656 161.6 6.5 161.5 116.0 183.4
LS‐BMD (g/cm2) NA NA NA NA NA NA NA NA NA NA NA NA NA
FN‐BMD (g/cm2) NA NA NA NA NA NA NA NA NA NA NA NA NA
6 YFS Age (yrs) Questionnaire 185 37.5 5.0 37.0 27.0 46.0 238 37.6 5.2 37.0 27.0 46.0
BMI (kg/m²) Measured 180 26.4 4.1 26.1 17.9 41.2 228 25.5 5.2 24.2 16.6 58.8
Weight (kg) Measured 180 85.7 15.2 84.0 54.0 136.0 228 70.5 15.2 66.0 47.0 166.0
Height (cm) Measured 180 179.9 6.5 180.0 164.0 197.0 228 166.3 5.6 166.0 151.0 184.0
LS‐BMD (g/cm2) Prodigy 185 1.2 0.2 1.2 0.8 1.7 238 1.2 0.2 1.2 0.8 1.6





Study Trait Assessment method Fracture N Non‐fracture N Fracture N Non‐fracture N
1 AGES All fractures Medical and radiographic records 448 892 1,011 834
Non‐vertebral fractures NA NA NA NA NA
Vertebral fractures NA NA NA NA NA
2 DeCODE insilico All fractures
Medical records, radiograhic 
documentation, questionnaire 532 6,980 1,878 7,864
Non‐vertebral fractures Medical records, questionnaire 276 418 1,785 3,736
Vertebral fractures NA NA NA NA NA
3 PROSPER/PHASE All fractures Medical records 117 2,407 309 2,409
Non‐vertebral fractures NA NA NA NA NA
Vertebral fractures NA NA NA NA NA
4 WGHS All fractures Questionnaire NA NA 1,795 20,535
Non‐vertebral fractures NA NA NA NA NA





NA NA 2,166 2,490
Non‐vertebral fractures Medical records NA NA 2,166 2,490
Vertebral fractures NA NA NA NA NA
6 YFS All fractures Medical records 96 603 106 781
Non‐vertebral fractures Medical records NA NA NA NA












1 AGES Illumina Hu370CNV BEadstudio 
Genecall
≥ 1% >97% > 10‐6 329,804 MACH ≥1% MACH R2 ≥  0.3 ProbABEL 82 1,340 1,845
2 DeCODE insilico Illumina HH300 and 370CNV BeadStudio > 1% > 96% > 10‐6 281,410 IMPUTE ≥1% MACH R2 ≥  0.3 SNPTEST 82 1,136 6,469
3 PROSPER/PHASE Illumina Beadchip 660K‐quad Beadstudio 
Genecall
≥ 1% ≥ 97.5% > 10‐6 557,192 MACH ≥1% MACH R2 ≥  0.3 PLINK 82 2,524 2,718








> 0.5% > 95% > 10‐6 499,982 MACH ≥1% MACH R2 ≥  0.3 R 82 0 4,656
6 YFS Illumina Custom BeadChip 
Human670K 
















































































































































































































































































































































































































































































































































































































































































Study Trait Assessment method N mean sd median min max N mean sd median min max
1 AOGC‐GOS Age (yrs) Questionnaire 1,322 59.3 17.9 60.4 20.0 94.0 1,600 54.3 19.6 54.1 20.3 95.5
BMI (kg/m²) Calculated 1,319 27.2 4.3 26.8 17.1 49.7 1,598 26.7 5.3 25.7 15.9 53.8
Weight (kg) Measured 1,319 82.8 14.4 81.5 41.8 154.7 1,598 68.8 14.4 66.6 35.3 138.9
Height (cm) Measured 1,321 174.2 7.2 174.3 153.6 201.0 1,598 160.5 7.0 160.9 132.3 186.0
LS‐BMD (g/cm2) Lunar 1,310 1.3 0.2 1.2 0.6 2.1 1,598 1.1 0.2 1.1 0.6 1.9
FN‐BMD (g/cm2) Lunar 1,255 1.0 0.2 1.0 0.5 1.5 1,575 0.9 0.2 0.9 0.5 1.4
2 AOGC‐SHEFFIELD Age (yrs) Questionnaire 0 NA NA NA NA NA 3,979 80.1 4.0 79.0 74.3 100.0
BMI (kg/m²) Calculated 0 NA NA NA NA NA 3,971 26.8 4.4 26.3 15.1 47.1
Weight (kg) Measured 0 NA NA NA NA NA 4,008 65.1 11.3 64.3 35.8 116.3
Height (cm) Measured 0 NA NA NA NA NA 3,971 155.9 6.0 155.7 134.3 178.0
LS‐BMD (g/cm2) Hologic QDR4500A 0 NA NA NA NA NA 0 NA NA NA NA NA
FN‐BMD (g/cm2) Hologic QDR4500A 0 NA NA NA NA NA 4,001 0.6 0.1 0.6 0.3 1.0
3 APOSS Age (yrs) Questionnaire 0 NA NA NA NA NA 3,268 48.5 2.4 48.1 44.2 56.3
BMI (kg/m²) Calculated 0 NA NA NA NA NA 3,261 25.4 4.4 24.5 15.2 56.9
Weight (kg) Measured 0 NA NA NA NA NA 3,264 66.0 12.0 63.5 40.0 146.0
Height (cm) Measured 0 NA NA NA NA NA 3,264 161.3 5.9 161.0 136.0 185.0
LS‐BMD (g/cm2) Norland 0 NA NA NA NA NA 3,264 1.1 0.2 1.0 0.6 2.0
FN‐BMD (g/cm2) Norland 0 NA NA NA NA NA 3,263 0.9 0.1 0.9 0.5 1.4
4 AROS Age (yrs) Social security 176 54.3 15.7 55.0 19.0 85.0 621 61.8 12.9 65.0 20.0 87.0
BMI (kg/m²) Calculated 143 25.2 3.7 24.7 17.4 36.5 547 24.4 4.1 23.9 15.7 51.2
Weight (kg) Measured 145 78.1 12.4 76.2 54.5 119.0 551 63.8 11.0 62.8 38.6 118.4
Height (cm) Measured 144 176.2 7.4 176.0 158.0 203.0 548 161.7 6.7 162.0 143.0 194.0
LS‐BMD (g/cm2) Hologic and Norland 173 0.9 0.2 0.9 0.5 1.4 603 0.8 0.2 0.8 0.5 1.5
FN‐BMD (g/cm2) Hologic and Norland 173 0.7 0.1 0.7 0.5 1.2 600 0.7 0.1 0.6 0.3 1.1
5 AUSTRIOS‐A Age (yrs) Questionnaire 271 56.6 12.0 58.0 22.0 77.0 534 47.1 15.8 45.5 18.0 85.0
BMI (kg/m²) Calculated 268 26.7 3.6 26.0 18.9 37.8 496 23.7 3.9 22.8 16.0 39.0
Weight (kg) Measured 268 83.4 12.1 82.0 58.0 125.0 496 63.9 10.6 62.0 36.0 106.0
Height (cm) Measured 268 176.7 6.6 177.0 160.0 197.0 496 164.2 6.3 164.0 148.0 183.0
LS‐BMD (g/cm2) Hologic 262 1.0 0.2 1.0 0.7 1.5 522 0.9 0.1 0.9 0.5 1.7
FN‐BMD (g/cm2) Hologic 265 0.8 0.1 0.8 0.6 1.2 522 0.7 0.1 0.7 0.3 1.2
6 AUSTRIOS‐B Age (yrs) Questionnaire 327 84.3 5.7 85.0 69.0 101.0 1,737 83.9 6.2 85.0 68.0 103.0
BMI (kg/m²) Calculated 311 25.1 4.0 24.7 15.0 37.3 1,637 25.7 4.8 25.2 13.8 46.1
Weight (kg) Measured 314 68.2 12.5 67.0 39.0 113.0 1,648 60.4 12.2 60.0 31.0 111.0
Height (cm) Measured 312 164.9 8.2 166.0 140.0 185.0 1,645 153.3 7.4 154.0 125.0 198.0
LS‐BMD (g/cm2) NA 0 NA NA NA NA NA 0 NA NA NA NA NA
FN‐BMD (g/cm2) NA 0 NA NA NA NA NA 0 NA NA NA NA NA
7 BARCOS Age (yrs) Questionnaire 0 NA NA NA NA NA 1,451 65.5 9.1 65.0 35.0 100.0
BMI (kg/m²) Calculated 0 NA NA NA NA NA 1,441 26.4 4.1 26.0 17.3 52.3
Weight (kg) Measured 0 NA NA NA NA NA 1,443 65.0 10.5 64.0 41.0 134.0
Height (cm) Measured 0 NA NA NA NA NA 1,442 156.8 6.3 156.0 135.0 180.0
LS‐BMD (g/cm2) Hologic 0 NA NA NA NA NA 1,443 0.9 0.1 0.8 0.5 1.4
FN‐BMD (g/cm2) Hologic 0 NA NA NA NA NA 1,351 0.7 0.1 0.7 0.4 1.2
8 CABRIO‐C Age (yrs) Questionnaire 543 63.9 8.5 63.0 50.0 92.0 907 62.0 9.8 59.0 42.0 94.0
BMI (kg/m²) Calculated 543 28.7 3.2 28.5 18.8 41.0 887 28.3 4.7 27.6 17.7 47.1
Weight (kg) Measured 543 81.5 11.0 80.0 44.5 118.4 887 68.7 12.0 67.0 42.0 119.0
Height (cm) Measured 543 168.2 6.1 168.0 150.0 189.0 889 155.9 6.0 156.0 138.0 188.0
LS‐BMD (g/cm2) Hologic 535 1.0 0.2 1.0 0.6 1.7 896 0.9 0.1 0.9 0.6 1.4
FN‐BMD (g/cm2) Hologic 529 0.8 0.1 0.8 0.4 1.2 897 0.7 0.1 0.7 0.4 1.1





Study Trait Assessment method N mean sd median min max N mean sd median min max
Men Women
BMI (kg/m²) Calculated 326 28.1 3.5 27.9 17.1 41.8 991 27.1 4.2 26.8 16.0 45.8
Weight (kg) Measured 326 78.1 11.4 78.0 46.0 137.0 995 65.0 10.4 64.0 36.0 110.0
Height (cm) Measured 326 166.7 6.8 167.0 145.0 192.0 992 154.7 6.1 155.0 138.0 178.0
LS‐BMD (g/cm2) Hologic 279 1.0 0.1 1.0 0.5 1.4 923 0.8 0.2 0.8 0.5 1.4
FN‐BMD (g/cm2) Hologic 280 0.8 0.1 0.8 0.5 1.3 926 0.7 0.1 0.7 0.4 1.1
10 CAIFOS Age (yrs) Questionnaire 0 NA NA NA NA NA 1,347 80.2 2.7 80.0 75.0 87.0
BMI (kg/m²) Measured 0 NA NA NA NA NA 1,135 27.2 4.7 26.8 15.7 48.2
Weight (kg) Measured 0 NA NA NA NA NA 1,135 67.6 12.1 65.9 39.6 114.4
Height (cm) Measured 0 NA NA NA NA NA 1,137 157.5 6.0 158.0 115.0 178.0
LS‐BMD (g/cm2) Hologic 0 NA NA NA NA NA 1,082 1.0 0.2 0.9 0.5 1.7
FN‐BMD (g/cm2) Hologic 0 NA NA NA NA NA 1,043 0.7 0.1 0.7 0.4 1.1
11 CALEX Age (yrs) Questionnaire 190 55.2 15.1 52.3 19.9 87.3 457 46.0 19.0 47.4 18.0 91.7
BMI (kg/m²) Measured 190 26.3 3.3 26.1 18.3 37.0 457 25.3 4.5 24.6 16.0 47.2
Weight (kg) Measured 190 81.4 10.7 80.8 56.8 108.6 457 68.1 12.3 66.5 46.1 127.0
Height (cm) Measured 190 175.9 6.5 176.0 154.0 194.0 457 164.2 6.2 164.0 148.0 180.0
LS‐BMD (g/cm2) Lunar 189 1.2 0.2 1.2 0.8 1.9 451 1.2 0.2 1.2 0.7 1.8
FN‐BMD (g/cm2) Lunar 189 1.0 0.2 1.0 0.7 1.5 450 1.0 0.1 1.0 0.6 1.5
12 CAMOS Age (yrs) Questionnaire 705 65.4 16.6 69.0 18.0 95.0 1,616 67.3 14.9 70.0 18.0 99.0
BMI (kg/m²) Measured 701 26.9 3.8 26.6 18.0 40.6 1,600 26.9 5.2 26.2 16.5 64.3
Weight (kg) Measured 701 81.7 13.4 80.7 47.7 126.5 1,601 69.4 13.7 67.4 38.2 158.5
Height (cm) Measured 701 174.1 7.1 174.0 151.0 198.0 1,600 160.6 6.4 160.0 141.0 182.9
LS‐BMD (g/cm2) Hologic or Lunar 705 1.0 0.2 1.0 0.6 1.6 1,603 1.0 0.2 1.0 0.5 1.6
FN‐BMD (g/cm2) Hologic or Lunar 704 0.8 0.1 0.8 0.5 1.4 1,599 0.7 0.1 0.7 0.4 1.3
13 DECODErep Age (yrs) National registry 910 55.5 16.3 55.6 20.3 89.0 2,228 57.5 14.3 57.7 20.0 97.0
BMI (kg/m²) Measured 910 26.4 3.7 26.2 16.6 42.0 2,228 25.9 4.5 25.3 14.8 47.2
Weight (kg) Measured 910 84.3 13.5 83.0 46.6 129.3 2,228 70.1 12.7 68.5 34.5 124.2
Height (cm) Measured 910 178.5 6.5 178.5 155.0 203.0 2,228 164.7 5.9 165.0 133.0 185.0
LS‐BMD (g/cm2) Hologic 779 1.0 0.2 1.0 0.6 1.6 1,877 1.0 0.2 1.0 0.5 1.6
FN‐BMD (g/cm2) Hologic 763 0.8 0.2 0.8 0.4 1.3 1,857 0.8 0.1 0.7 0.4 1.2
14 DOES Age (yrs) Questionnaire 569 75.6 5.5 75.0 61.0 90.0 888 76.2 6.3 76.0 60.0 99.0
BMI (kg/m²) Measured 569 26.7 4.0 26.3 17.7 44.4 888 26.1 5.0 25.8 14.3 56.0
Weight (kg) Measured 569 78.4 13.2 77.0 43.0 128.0 888 65.2 13.1 65.0 33.0 128.0
Height (cm) Measured 569 171.3 6.3 171.0 154.0 196.0 888 157.8 6.1 158.0 139.0 186.0
LS‐BMD (g/cm2) Lunar DPX and Prodigy 567 1.3 0.2 1.3 0.7 2.1 883 1.0 0.2 1.0 0.4 1.8
FN‐BMD (g/cm2) Lunar DPX and Prodigy 557 0.9 0.2 0.9 0.4 1.5 872 0.7 0.1 0.7 0.4 1.1
15 DOPS Age (yrs) Social security 0 NA NA NA NA NA 1,716 50.6 2.8 50.5 43.7 59.0
BMI (kg/m²) Calculated 0 NA NA NA NA NA 1,715 25.0 4.3 24.2 12.8 48.3
Weight (kg) Measured 0 NA NA NA NA NA 1,715 67.7 11.8 65.6 34.0 135.5
Height (cm) Measured 0 NA NA NA NA NA 1,715 164.5 6.0 164.5 147.0 189.0
LS‐BMD (g/cm2) Hologic 0 NA NA NA NA NA 1,710 1.0 0.1 1.0 0.6 1.6
FN‐BMD (g/cm2) Hologic 0 NA NA NA NA NA 1,702 0.8 0.1 0.8 0.5 1.3
16 EDOS Age (yrs) Questionnaire 370 62.4 13.6 62.4 18.3 93.1 1,645 66.2 12.4 67.6 20.5 94.3
BMI (kg/m²) Measured 354 26.4 5.3 26.0 14.9 51.6 1,603 26.0 5.1 25.1 14.9 52.5
Weight (kg) Measured 354 77.3 17.2 76.0 40.6 144.8 1,603 65.1 13.7 63.2 40.0 128.9
Height (cm) Measured 357 170.6 8.8 171.0 100.8 200.0 1,631 158.0 7.1 158.0 128.5 190.0
LS‐BMD (g/cm2) Hologic 353 0.9 0.2 0.8 0.4 1.6 1,613 0.8 0.2 0.8 0.4 1.5
FN‐BMD (g/cm2) Hologic 309 0.7 0.1 0.7 0.3 1.2 1,453 0.6 0.1 0.6 0.3 1.2
17 EPIC Norfolk Age (yrs) Questionnaire 680 72.5 3.1 72.1 66.9 79.3 719 72.4 3.2 72.3 60.0 85.0




Study Trait Assessment method N mean sd median min max N mean sd median min max
Men Women
Weight (kg) Measured 680 79.6 10.9 78.8 48.0 128.5 710 67.9 11.3 66.8 43.0 105.5
Height (cm) Measured 680 172.3 6.3 172.0 153.0 196.0 714 159.1 5.9 159.0 139.0 178.0
LS‐BMD (g/cm2) NA 0 NA NA NA NA NA 0 NA NA NA NA NA
FN‐BMD (g/cm2) Hologic QDR 1000W 674 0.8 0.1 0.8 0.5 1.5 698 0.7 0.1 0.7 0.3 1.1
18 EPOLOS Age (yrs) Questionnaire 317 50.4 16.5 50.9 19.8 80.9 398 55.5 15.6 58.5 20.0 81.6
BMI (kg/m²) Measured 317 26.6 4.0 26.3 17.1 39.4 397 26.7 4.9 26.4 16.4 40.9
Weight (kg) Measured 317 80.0 12.7 80.0 48.0 120.0 397 68.0 12.3 67.0 40.0 109.0
Height (cm) Measured 317 173.3 7.4 173.0 151.0 190.0 398 159.6 6.4 160.0 128.0 176.0
LS‐BMD (g/cm2) Lunar DPX 297 1.1 0.2 1.0 0.5 2.1 367 1.0 0.2 1.0 0.5 1.7
FN‐BMD (g/cm2) Lunar DPX 298 0.9 0.2 0.9 0.4 1.6 366 0.8 0.1 0.8 0.4 1.2
19 EPOS Age (yrs) Questionnaire 719 62.9 8.2 62.5 43.9 90.4 1,373 63.4 8.8 62.6 40.5 95.0
BMI (kg/m²) Measured 661 27.6 3.7 27.4 18.2 41.4 1,176 27.5 4.7 27.0 16.8 52.9
Weight (kg) Measured 661 78.7 11.5 78.7 47.0 120.0 1,177 68.1 11.5 67.0 41.3 115.0





238 1.0 0.2 1.0 0.6 1.6 482 0.9 0.2 0.9 0.5 1.6
FN‐BMD (g/cm2) Hologic (7 centres) /Lunar 513 0.8 0.1 0.8 0.4 1.4 926 0.7 0.1 0.7 0.3 1.3
20 FLOS Age (yrs) Questionnaire 161 53.9 14.7 56.0 20.0 78.0 839 60.9 12.0 62.0 19.0 89.0
BMI (kg/m²) Measured 161 26.2 3.6 26.0 18.5 54.1 839 24.1 3.5 23.9 15.0 44.2
Weight (kg) Measured 161 80.8 13.6 80.0 60.0 185.0 839 61.8 9.3 60.3 37.0 116.0
Height (cm) Measured 161 175.6 7.0 176.0 156.0 192.0 839 160.0 6.7 160.0 138.0 181.0
LS‐BMD (g/cm2) Hologic 158 1.0 0.1 1.0 0.7 1.6 835 0.9 0.2 0.9 0.4 1.6
FN‐BMD (g/cm2) Hologic 139 0.8 0.2 0.8 0.3 1.1 781 0.7 0.2 0.7 0.3 1.3
21 GEOS Age (yrs) Questionnaire 0 NA NA NA NA NA 2,379 53.8 9.6 54.0 18.0 84.0
BMI (kg/m²) Measured 0 NA NA NA NA NA 2,372 25.8 4.6 25.0 15.2 46.7
Weight (kg) Measured 0 NA NA NA NA NA 2,374 65.0 11.9 63.0 40.2 118.8
Height (cm) Measured 0 NA NA NA NA NA 2,377 158.6 6.0 159.0 130.0 184.0
LS‐BMD (g/cm2) Lunar 0 NA NA NA NA NA 2,377 1.1 0.2 1.1 0.6 1.8
FN‐BMD (g/cm2) Lunar 0 NA NA NA NA NA 2,376 0.9 0.1 0.9 0.4 1.4
22 GEVUR Age (yrs) Questionnaire 134 59.2 12.9 59.0 19.0 83.0 839 62.2 8.2 61.0 40.0 85.0
BMI (kg/m²) Measured 96 26.2 4.9 25.2 15.4 40.6 830 27.8 4.9 27.3 14.2 45.2
Weight (kg) Measured 96 76.2 14.0 76.0 49.0 120.0 830 70.6 13.2 70.0 40.0 128.0
Height (cm) Measured 97 170.8 7.5 170.0 156.0 192.0 833 159.3 6.3 159.0 134.0 185.0
LS‐BMD (g/cm2) Hologic 105 0.9 0.2 0.9 0.4 1.4 194 0.9 0.2 0.9 0.5 1.4
FN‐BMD (g/cm2) Hologic 99 0.9 0.2 0.8 0.3 1.2 373 0.8 0.2 0.8 0.3 1.3
23 GROS Age (yrs) Questionnaire 83 70.2 12.8 72.0 43.0 90.0 523 69.1 11.7 70.0 43.0 95.0
BMI (kg/m²) Measured 83 26.3 3.9 26.0 17.3 37.9 521 27.5 4.7 27.0 16.4 45.8
Weight (kg) Measured 83 71.5 12.3 71.0 40.0 120.0 521 71.7 10.9 69.0 40.0 112.0
Height (cm) Measured 83 164.8 10.4 167.0 121.0 182.0 523 161.8 7.3 162.0 146.0 182.0
LS‐BMD (g/cm2) Varius (Lunar, Hologic) 21 0.9 0.2 0.9 0.5 1.5 272 0.8 0.2 0.8 0.5 1.5
FN‐BMD (g/cm2) Varius (Lunar, Hologic) 6 0.8 0.2 0.9 0.5 1.0 55 0.8 0.1 0.8 0.5 1.2
24 HCS Age (yrs) Questionnaire 1,571 65.7 2.9 65.8 59.2 72.6 1,356 66.7 2.7 66.5 60.9 73.1
BMI (kg/m²) Measured 1,562 27.1 3.7 26.8 16.1 49.2 1,354 27.5 4.8 27.0 15.2 48.1
Weight (kg) Measured 1,563 82.4 12.6 81.0 45.5 144.5 1,354 71.2 13.2 70.0 40.0 135.5
Height (cm) Measured 1,564 174.1 6.5 174.3 149.6 195.6 1,354 160.9 5.9 160.8 140.9 180.8
LS‐BMD (g/cm2) Hologic 495 1.1 0.2 1.1 0.7 1.6 440 0.9 0.2 0.9 0.4 1.4




Study Trait Assessment method N mean sd median min max N mean sd median min max
Men Women
25 HK Age (yrs) Questionnaire 1,888 72.4 5.0 72.0 65.0 92.0 1,984 72.6 5.4 72.0 65.0 98.0
BMI (kg/m²) Measured 1,888 23.5 3.1 23.5 13.1 36.3 1,984 23.9 3.5 23.7 12.7 40.3
Weight (kg) Measured 1,888 62.4 9.4 62.4 35.9 103.1 1,984 54.5 8.5 54.2 28.8 89.0
Height (cm) Measured 1,888 163.1 5.8 163.1 141.9 187.2 1,984 150.9 5.3 150.8 133.7 170.3
LS‐BMD (g/cm2) Hologic 1,853 0.9 0.2 0.9 0.4 1.6 1,934 0.8 0.1 0.7 0.3 1.3
FN‐BMD (g/cm2) Hologic 1,884 0.7 0.1 0.7 0.4 1.1 1,977 0.6 0.1 0.6 0.3 1.0
26 KorAMC Age (yrs) Questionnaire 0 NA NA NA NA NA 1,397 59.5 7.4 59.0 45.0 87.0
BMI (kg/m²) Measured 0 NA NA NA NA NA 1,397 23.4 2.8 23.3 14.4 35.5
Weight (kg) Measured 0 NA NA NA NA NA 1,397 56.2 7.2 56.0 27.0 86.0




0 NA NA NA NA NA 1,387 0.9 0.2 0.9 0.4 1.5
FN‐BMD (g/cm2) Hologic, QDR4500A, Expe 0 NA NA NA NA NA 1,387 0.7 0.1 0.7 0.3 1.1
27 LASA Age (yrs) Questionnaire 464 72.4 6.5 72.2 61.9 85.6 485 72.6 6.6 72.1 61.8 85.3
BMI (kg/m²) Measured 438 25.8 3.2 25.9 17.4 39.1 441 27.8 4.5 27.4 16.9 45.8
Weight (kg) Measured 440 77.9 11.3 77.0 47.0 119.0 449 71.6 12.0 70.5 42.0 120.5
Height (cm) Measured 438 173.4 6.7 173.4 156.4 195.3 442 160.5 6.3 160.4 141.9 177.6
LS‐BMD (g/cm2) Hologic QDR 2000 253 1.0 0.2 1.0 0.5 1.8 262 0.9 0.2 0.9 0.6 1.4
FN‐BMD (g/cm2) Hologic QDR 2000 252 0.7 0.1 0.7 0.3 1.1 251 0.7 0.1 0.6 0.4 1.0
28 MANMC Age (yrs) Questionnaire 0 NA NA NA NA NA 1,105 56.4 8.6 57.0 27.0 86.0
BMI (kg/m²) Measured 0 NA NA NA NA NA 0 NA NA NA NA NA
Weight (kg) Measured 0 NA NA NA NA NA 0 NA NA NA NA NA
Height (cm) Measured 0 NA NA NA NA NA 0 NA NA NA NA NA
LS‐BMD (g/cm2) NA 0 NA NA NA NA NA 0 NA NA NA NA NA
FN‐BMD (g/cm2) NA 0 NA NA NA NA NA 0 NA NA NA NA NA
29 MrOS Sweden Age (yrs) Questionnaire 2,922 75.4 3.2 75.4 69.9 81.0 0 NA NA NA NA NA
BMI (kg/m²) Measured 2,922 26.4 3.5 26.2 13.3 44.6 0 NA NA NA NA NA
Weight (kg) Measured 2,922 80.7 12.1 79.9 37.0 138.3 0 NA NA NA NA NA




2,893 1.2 0.2 1.1 0.6 2.0 0 NA NA NA NA NA
FN‐BMD (g/cm2) Hologic (Gothenburg), Lun 2,814 0.9 0.1 0.8 0.4 1.4 0 NA NA NA NA NA
30 NOSOS Age (yrs) Questionnaire 0 NA NA NA NA NA 1,268 69.7 5.5 69.3 60.2 82.2
BMI (kg/m²) Measured 0 NA NA NA NA NA 1,291 27.0 4.6 26.6 16.2 55.2
Weight (kg) Measured 0 NA NA NA NA NA 1,291 67.8 12.3 66.5 40.0 132.5
Height (cm) Measured 0 NA NA NA NA NA 1,293 158.4 6.0 158.0 131.0 177.0
LS‐BMD (g/cm2) Lunar 0 NA NA NA NA NA 1,278 1.1 0.2 1.1 0.5 1.8
FN‐BMD (g/cm2) Lunar 0 NA NA NA NA NA 1,243 0.8 0.1 0.8 0.4 1.3
31 OAS Age (yrs) Questionnaire 600 68.1 4.2 68.0 60.0 76.0 0 NA NA NA NA NA
BMI (kg/m²) Measured 593 27.6 4.0 27.2 15.7 54.3 0 NA NA NA NA NA
Weight (kg) Measured 593 83.7 12.5 82.5 48.0 137.9 0 NA NA NA NA NA
Height (cm) Measured 593 174.3 6.7 174.3 128.4 191.8 0 NA NA NA NA NA
LS‐BMD (g/cm2) Hologic 589 1.0 0.2 1.0 0.6 1.6 0 NA NA NA NA NA
FN‐BMD (g/cm2) Hologic 584 0.8 0.1 0.8 0.5 1.2 0 NA NA NA NA NA
32 OSTEOS Age (yrs) Questionnaire 0 NA NA NA NA NA 626 60.5 10.4 60.0 35.0 90.0
BMI (kg/m²) Measured 0 NA NA NA NA NA 627 27.4 5.0 26.3 17.4 46.7
Weight (kg) Measured 0 NA NA NA NA NA 627 66.8 11.7 65.0 42.0 119.5




Study Trait Assessment method N mean sd median min max N mean sd median min max
Men Women
LS‐BMD (g/cm2) Lunar 0 NA NA NA NA NA 599 1.0 0.2 1.0 0.4 1.6
FN‐BMD (g/cm2) Lunar 0 NA NA NA NA NA 342 0.8 0.1 0.8 0.5 1.1
33 PERF Age (yrs) Questionnaire 0 NA NA NA NA NA 3,927 64.1 7.9 64.9 45.2 80.8
BMI (kg/m²) Measured 0 NA NA NA NA NA 3,973 25.2 3.4 24.9 14.9 43.8
Weight (kg) Measured 0 NA NA NA NA NA 3,973 66.1 9.7 65.2 36.1 116.6
Height (cm) Measured 0 NA NA NA NA NA 3,973 161.8 6.0 162.0 134.3 190.0
LS‐BMD (g/cm2) Lunar, Hologic 0 NA NA NA NA NA 3,927 0.9 0.2 0.9 0.4 1.5
FN‐BMD (g/cm2) Lunar, Hologic 0 NA NA NA NA NA 3,915 0.7 0.1 0.7 0.3 1.1
34 SLOPREVAL Age (yrs) Questionnaire 123 67.9 6.5 66.0 55.0 89.0 593 62.1 10.6 62.0 38.0 93.0
BMI (kg/m²) Measured 123 27.7 3.9 27.4 19.6 43.4 593 26.9 4.5 26.0 18.9 44.9
Weight (kg) Measured 123 81.6 12.6 80.0 55.0 130.0 593 69.1 12.2 67.0 45.0 115.0
Height (cm) Measured 123 171.7 6.3 171.0 159.0 192.0 593 160.4 6.3 160.0 137.0 181.0
LS‐BMD (g/cm2) Hologic 123 1.0 0.2 1.0 0.7 1.5 588 0.9 0.2 0.8 0.4 1.5
FN‐BMD (g/cm2) Hologic 96 0.8 0.2 0.8 0.5 1.3 566 0.7 0.1 0.7 0.3 1.2
35 UFO‐1 Age (yrs) Questionnaire 1,011 54.2 7.7 59.7 29.5 71.5 3,306 58.6 7.6 59.9 29.6 76.9
BMI (kg/m²) Measured 997 26.4 3.6 25.9 17.3 55.8 3,175 25.5 4.2 24.8 10.1 62.5
Weight (kg) Measured 998 82.4 12.7 81.0 40.0 163.2 3,187 68.0 11.6 66.0 25.0 164.0
Height (cm) Measured 997 176.6 6.3 176.0 152.0 197.0 3,200 163.4 5.9 163.0 122.0 191.0
LS‐BMD (g/cm2) Lunar 0 NA NA NA NA NA 385 1.0 0.2 0.9 0.4 1.6
FN‐BMD (g/cm2) Lunar 0 NA NA NA NA NA 415 0.8 0.1 0.8 0.5 1.2
35 UFO‐2 Age (yrs) Questionnaire 421 48.2 10.3 50.0 24.0 70.0 1,601 53.3 10.2 54.0 19.0 80.0
BMI (kg/m²) Measured 421 25.9 3.2 25.5 18.7 41.6 1,601 25.3 4.3 24.6 14.3 46.6
Weight (kg) Measured 421 82.1 11.4 81.0 51.0 129.0 1,601 68.1 12.1 66.0 36.0 127.0
Height (cm) Measured 421 177.9 6.1 178.0 152.0 198.0 1,601 164.0 6.1 164.0 130.0 190.0
LS‐BMD (g/cm2) Lunar 0 NA NA NA NA NA 0 NA NA NA NA NA
FN‐BMD (g/cm2) Lunar 0 NA NA NA NA NA 0 NA NA NA NA NA
36
WHI GeCHIP ‐ 
BMD Age (yrs) Questionnaire 0 NA NA NA NA NA 3,929 64.5 7.1 65.0 50.0 79.0
BMI (kg/m²) measured 0 NA NA NA NA NA 3,908 27.7 6.0 26.5 14.3 67.9
Weight (kg) measured 0 NA NA NA NA NA 3,923 72.4 16.5 69.4 36.0 176.5
Height (cm) measured 0 NA NA NA NA NA 3,910 1.6 0.1 1.6 1.0 1.9
LS‐BMD (g/cm2) Hologic QDR 2000, 
2000+, or 4500W 0 NA NA NA NA NA 3,761 1.0 0.2 1.0 0.5 1.8




Study Trait Assessment method Fracture N Non‐fracture N Fracture N Non‐fracture N
1 AOGC‐GOS All fractures Questionnaire, radiography 335 670 239 1,093
Non‐vertebral fractures Questionnaire, radiography 74 670 167 1,093
Vertebral fractures NA NA NA NA NA
2 AOGC‐SHEFFIELD All fractures Questionnaire, radiography lateral 
morphometry
NA NA 1,373 2,013
Non‐vertebral fractures Questionnaire, radiography NA NA 955 2,027
Vertebral fractures Radiography lateral morphometry NA NA 565 3,411
3 APOSS All fractures Self‐reported NA NA 560 2,275
Non‐vertebral fractures NA NA NA NA NA
Vertebral fractures NA NA NA NA NA
4 AROS All fractures Radiographic 64 38 271 92
Non‐vertebral fractures NA NA NA NA NA
Vertebral fractures Radiographic 64 38 271 92
5 AUSTRIOS‐A All fractures Medical records, radiograhic 118 125 116 378
Non‐vertebral fractures Medical records, radiograhic 118 123 105 389
Vertebral fractures NA NA NA NA NA
6 AUSTRIOS‐B All fractures Medical records, radiograhic 144 183 816 921
Non‐vertebral fractures Medical records, radiograhic 32 295 273 1,464
Vertebral fractures Radiographic 128 199 675 1,062
7 BARCOS All fractures Medical records, radiograhic 
documentation
NA NA 179 1,258
Non‐vertebral fractures NA NA NA NA NA
Vertebral fractures NA NA NA NA NA
8 CABRIO‐C All fractures Patient‐referred, medical records 131 412 210 697
Non‐vertebral fractures NA NA NA NA NA
Vertebral fractures Radiographic documentation 68 438 127 747
9 CABRIO‐CC All fractures Patient‐referred, medical records 176 364 946 829
Non‐vertebral fractures Patient‐referred, medical records 133 378 658 925
Vertebral fractures Radiographic documentation 25 30 195 324
10 CAIFOS All fractures Self‐reported NA NA 749 598
Non‐vertebral fractures Self‐reported NA NA 179 1,168





Study Trait Assessment method Fracture N Non‐fracture N Fracture N Non‐fracture N
Men Women
11 CALEX All fractures Questionnaire, medical records, 
radiograhic documentation 41 110 72 301
Non‐vertebral fractures NA NA NA NA NA
Vertebral fractures NA NA NA NA NA
12 CAMOS All fractures Medical records, radiograhic 
documentation
98 559 312 1,226
Non‐vertebral fractures NA NA NA NA NA
Vertebral fractures NA NA NA NA NA
13 DECODErep All fractures NA NA NA NA NA
Non‐vertebral fractures NA NA NA NA NA
Vertebral fractures NA NA NA NA NA
14 DOES All fractures X‐ray reports 141 373 405 462
Non‐vertebral fractures NA NA NA NA NA
Vertebral fractures NA NA NA NA NA
15 DOPS All fractures Radiographic NA NA 425 1,291
Non‐vertebral fractures Radiographic NA NA 239 1,477
Vertebral fractures Radiographic NA NA 108 1,605
16 EDOS All fractures Medical records, radiograhic 
documentation
286 38 1,270 159
Non‐vertebral fractures NA NA NA NA NA
Vertebral fractures
NA NA NA NA NA
17 EPICNOR All fractures Medical records 78 602 157 562
Non‐vertebral fractures Medical records 77 603 150 569








109 208 139 259













124 595 403 970
Vertebral fractures Radiographic documentation 112 607 201 1,172
20 FLOS All fractures Medical records, radiograhic 
documentation
83 78 118 721
Non‐vertebral fractures Medical records, radiograhic 
documentation
83 78 72 767
Vertebral fractures Radiographic documentation 5 156 68 771
21 GEOS All fractures Self‐report NA NA 110 1,799
Non‐vertebral fractures NA NA NA NA NA
Vertebral fractures NA NA NA NA NA
22 GEVUR All fractures Medical records, radiograhic 
documentation
61 99 346 493
Non‐vertebral fractures Medical records, radiograhic 
documentation
52 108 324 515
Vertebral fractures NA NA NA NA NA
23 GROS All fractures Medical records, radiograhic 
documentation
54 26 340 125
Non‐vertebral fractures Medical records, radiograhic 
documentation
49 31 313 154
Vertebral fractures Radiographic documentation 5 75 28 435
24 HCS All fractures Self‐report 103 1,399 253 1,036
Non‐vertebral fractures NA NA NA NA NA
Vertebral fractures NA NA NA NA NA
25 HK All fractures Medical records, radiograhic 
documentation
316 1,572 478 1,506
Non‐vertebral fractures NA NA NA NA NA
Vertebral fractures NA NA NA NA NA
26 KorAMC All fractures Self‐report and radiographic NA NA 171 1,226
Non‐vertebral fractures Self‐report and radiographic NA NA 101 1,193
Vertebral fractures NA NA NA NA NA
27 LASA All fractures Self‐report, GP questionnaire 150 314 176 309
Non‐vertebral fractures NA NA NA NA NA




Study Trait Assessment method Fracture N Non‐fracture N Fracture N Non‐fracture N
Men Women
28 MANMC All fractures Medical records, Surgical Report, ICD‐
9 Codes NA NA 848 0
Non‐vertebral fractures NA NA NA NA NA
Vertebral fractures NA NA NA NA NA
29 MrOS Sweden All fractures Questionnaire, radiographic 
documentation
1255 1,651 NA NA
Non‐vertebral fractures Radiographic documentation 157 2,765 NA NA
Vertebral fractures Radiographic documentation 309 2,613 NA NA
30 NOSOS All fractures Self‐report NA NA 385 843
Non‐vertebral fractures NA NA NA NA NA
Vertebral fractures NA NA NA NA NA
31 OAS All fractures Incident clinical fractures+ baseline 
vertebral fractures 97 503 NA NA
Non‐vertebral fractures Incident clinical fractures 24 576 NA NA
Vertebral fractures Radiographic documentation 77 523 NA NA
32 OSTEOS All fractures NA NA NA NA NA
Non‐vertebral fractures NA NA NA NA NA
Vertebral fractures NA NA NA NA NA
33 PERF All fractures Medical records, radiograhic 
documentation
NA NA 1,051 2,405
Non‐vertebral fractures NA NA NA NA NA
Vertebral fractures NA NA NA NA NA
34 SLOPREVAL All fractures Medical records 14 56 77 116
Non‐vertebral fractures NA NA NA NA NA
Vertebral fractures NA NA NA NA NA
35 UFO‐1 All fractures Medical records, radiograhic 
documentation
493 518 1,691 1,615
Non‐vertebral fractures Medical records, radiograhic 
documentation
493 518 1,691 1,615
Vertebral fractures NA NA NA NA NA
UFO‐2 All fractures Medical records, radiograhic 
documentation
10 411 181 1,420
Non‐vertebral fractures NA NA NA NA NA










NA NA NA NA
Non‐vertebral fractures NA NA NA NA NA




















1 AOGC‐GOS AOGC 74 80% 2635 > 1% >90% > 10‐6 72
2 AOGC‐SHEFFIELD AOGC 74 80% 3817 > 1% >90% > 10‐6 71
3 APOSS KBIO 82 80% 3066 > 1% >90% > 10‐6 82
4 AROS KBIO 96 80% 789 > 1% >90% > 10‐6 96
5 AUSTRIOS‐A KBIO 82 80% 638 > 1% >90% > 10‐6 49
6 AUSTRIOS‐B KBIO 82 80% 834 > 1% >90% > 10‐6 49
7 BARCOS KBIO 96 80% 1422 > 1% >90% > 10‐6 96
8 CABRIO‐C KBIO 96 80% 1361 ≥ 1% >90% > 10‐6 96
9 CABRIO‐CC KBIO 82 80% 2178 > 1% >90% > 10‐6 82
10 CAIFOS KBIO 96 80% 1321 > 1% >90% > 10‐6 96
11 CALEX KBIO 82 80% 645 > 1% >90% > 10‐6 82
12 CAMOS KBIO 96 80% 2342 > 1% >90% > 10‐6 96
13 DECODErep DECODE 95 80% 2620 > 1% >90% > 10‐6 95
14 DOES DECODE 95 80% 1347 > 1% >90% > 10‐6 90
15 DOPS KBIO 96 80% 1670 > 1% >90% > 10‐6 96
16 EDOS KBIO 96 80% 1996 > 1% >90% > 10‐6 96
17 EPICNOR KBIO 82 80% 1377 ≥ 1% >90% > 10‐6 82
18 EPOLOS KBIO 82 80% 688 > 1% >90% > 10‐6 81
19 EPOS KBIO 82 80% 2003 ≥ 1% >90% > 10‐6 82
20 FLOS KBIO 96 80% 726 > 1% >90% > 10‐6 96
























22 GEVUR KBIO 96 80% 756 > 1% >90% > 10‐6 96
23 GROS KBIO 96 80% 459 > 1% >90% > 10‐6 96
24 HCS KBIO 82 80% 2824 > 1% >90% > 10‐6 82
25 HK DECODE 95 80% 3772 > 1% >90% > 10‐6 94
26 KorAMC DECODE 95 80% 1390 > 1% >90% > 10‐6 95
27 LASA KBIO 82 80% 891 > 1% >90% > 10‐6 82
28 MANMC KBIO 82 80% 1007 > 1% >90% > 10‐6 82
29 MrOS Sweden KBIO 96 80% 2477 > 1% >90% > 10‐6 87
30 NOSOS KBIO 82 80% 1191 > 1% >90% > 10‐6 82
31 OAS KBIO 96 80% 581 > 1% >90% > 10‐6 96
32 OSTEOS KBIO 0 Failed Failed Failed Failed Failed Failed
33 PERF DECODE 95 80% 3346 > 1% >90% > 10‐6 95
34 SLO‐PREVAL KBIO 96 80% 677 > 1% >90% > 10‐6 93
35 UFO KBIO 82 80% 5921 > 1% >90% > 10‐6 82
















































































































































1.1. De novo genotyping  
 
A total of 62,203 samples from 34 studies with either BMD and/or fracture information was 
de-novo genotyped in four main genotyping centers (KBioSciences, AOGC, deCODE and WHI) 




The majority of the studies opted for whole genome amplification (WGA) before 
genotyping. WGA was done by K-Biosciences 
(http://www.kbioscience.co.uk/lab%20services/wga/wga.html) and samples were stored in 
freezers for genotyping. We evaluated the genotype concordance between raw DNA genotypes 
and amplified DNA genotypes in a panel of 82 SNPs within 96 samples. The genotype accuracy 
before and after amplification was 99.971%. DNA from the OSTEOS study could not be 
amplified with enough quality and was therefore excluded from all analyzes. All SNPs genotyped 
by K-Biosciences (www.kbioscience.co.uk) used a competitive allele specific PCR (KASPar) 
assay. A Y-chromosome specific assay was evaluated in all samples. Sample mismatches 





AOGC samples from the Geelong Osteoporosis Study cohort and the Sheffield cohort 
were directly genotyped at the University of Queensland Diamantina Institute.  Two genotyping 
platforms were used: Applied Biosystems OpenArray (for 72 SNPs) and KBioSciences technology 
for the remaining 10 SNPs for which a taqman probe could not be designed.  Positive and 
negative controls were used on each plate. Nine SNPs failed QC (rs10048146, rs7017914, 
rs9466056, rs3736228, rs3755955, rs4240467, rs12995369, rs17040773,rs1053051; 2 using the 






1.1.3. deCODE  
 
GENOMOS samples from the PERF (Denmark), DOES (Australia), AMC (South Korea) and 
the Hong Kong elderly cohorts were directly genotyped for replication at the deCODE Genetics, 
along with additional deCODE study samples (Iceland).  The genotyping was performed on the 
Centaurus (Nanogen) platform1. The quality of each Cenaturus SNP assay was evaluated by 
genotyping each assay in the CEU HapMap samples and comparing the results with the HapMap 
data.  Assays with mismatches >1% were not used and positive and negative controls were 
present on all genotyping plates in order to ensure correct genotyping.  Functional assays 
meeting all quality criteria could not be made for the markers rs4727338, rs4869742, 
rs6959212, rs430727, rs1286083, rs6532023, rs4790881, rs12995369 and rs4792909 and these 
proxy SNPs, rs7781370, rs4870044, rs1403987, rs87938, rs1286077, rs1471403, rs11657636, 
rs11690020 and rs7220711 were genotyped instead, respectively. For the SNP rs11048046 a 
functional assay could not be made nor was there a known proxy SNP available. Nine hundred 
samples from the chip-typed deCODE discovery cohort were also directly genotyped for 
comparison with the imputed genotypes. The median of the correlation between genotyped and 




A custom Illumina (Illumina, Inc., San Diego, CA, USA) iSELECT genotyping array was 
designed to analyze 3,923 samples. From the 82 main BMD SNPs the following 15 rsIDs could 
not be included in the array given design restrictions: rs4240467, rs12821008, rs4233949, 
rs7851693, rs3736228, rs7953528, rs1566045, rs2062377, rs6426749, rs7932354, rs4869742, 
rs4727338, rs430727, rs11048046, rs7427438.  
 
1.2. Quality Control 
 
Genotyped calls from K-Biosciences, AOGC and deCODE were centrally controlled for: 
Sample call rate > 80%, SNP call rate > 90%, HWE P > 1x10-4, MAF > 1%. The following QC 
filters were applied for samples genotyped by WHI: Sample call rate > 98%, SNP call rate > 
98%, HWE P > 1x10-6, MAF > 0.5%. 
 
2. ADDITIONAL ANALYSES 
2.1. Secondary signals   
 
To evaluate the presence of multiple association signals in one locus, each stage 1 study 
repeated the primary GWA analysis using models additionally adjusted for the top 82 lead SNPs 
associated with BMD at P < 5x10-6 with the objective of identifying additional signals in the 
discovered loci. The effect estimates for each association were calculated using inverse variance 
fixed-effects meta-analysis.  Assuming that approximately 3,000 Mbp in the human genome are 
usually “genotypable” we tested ~ 5.5% of ~ 1 million tests. Hence the threshold we used for 
selecting secondary signals for replication was set to 9 x 10-7. 
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2.2. Gene x Gene interaction  
 
Each individual study extracted genotype imputation dosages for each of the top 82 lead 
SNPs to investigate potential gene-gene interaction. An R-script was provided to each individual 
study and was run using the extracted dosages. The allele coding was such that the BMD 
increasing allele (based on the Stage 1 meta-analysis) was always the dosage increasing allele. 
For the additive dosage and pair-wise interaction analyses (Y=b0+b1.A+b2.B+b3.AB+e; test of 
H0: b3 = 0), the dosages were regressed against residuals of sex-standardized Z-scores of FN-
BMD and LS-BMD, adjusted for appropriate covariates as with the primary GWA study. For each 
pair, a linear regression analysis including the two SNPs and their interaction term was 
performed. Interaction terms were deemed significant at levels of 1.5x10-5 accounting for 
(82*81)/2 =3321 interaction tests.  
 
 
2.3. Fine Mapping using 1000 Genomes Project data  
 
We imputed SNPs within the 2 Mb genomic region (1 Mb upstream and 1 Mb downstream) 
of top SNP from each of the 82 loci using the CEU or CHB/JPT as appropriate reference panels 
of the 1000 Genome Project that was released in June 2010. The imputation was performed 
using either MACH or IMPUTE in samples from 9 discovery cohorts including, AOGC (women 
only), DECODE, FHS, GOOD (men only), HEALTHABC, HKOS (women only), INDIANA (women 
only), ORCADES, RSI, RSII and RSIII. The total sample is 21,699 men and women for FN-BMD 
and 20,835 men and women for LS-BMD. A total of 495,634 SNPs with variance ratio > 0.3 in 
at least one study was imputed and used for this analysis. SNP-phenotype association was 
performed in each study and a fixed-effected inverse-variance meta-analysis was performed to 
estimate association p-values. We excluded SNPs only available in 4 or less studies. SNPs with 
higher heterogeneity (I2 > 50) were also excluded. We defined “stronger evidence of 
association” as a P-value difference of more than one order of magnitude to avoid drawing 
conclusions from random variation in the test statistics. Physical-based SNP annotation by 
categorizing according to their position relative to genes (intronic, exonic, UTR, promoter, 
flanking, inter-genic, etc.) was done using the Human GRCh37 reference genome and Ensembl 
transcripts. Pair-wise Linkage Disequilibrium (LD) was estimated using haplotype information 
from 1000 Genome Project European reference panel. Functional predictions of gene or SNPs 
have been shown to provide supportive evidence of GWAS findings and can be used to prioritize 
the GWAS top hits for further studies2. We predicted the potential functional effects on 
following types of SNPs: the premature translation termination (nonsense); the exonic SNPs 
that cause an amino acid change in conservative genomic region across multiple species (non-
conservative non-synonymous)3; the exonic SNPs that affect protein function based on 
sequence homology and the physical properties of amino acids (non-conservative non-
synonymous)4; the splicing sites that lead to a protein domain being abolished.5; synonymous 
SNPs located at exonic splicing enhancer motifs6,7 and the exonic splicing silencer motifs8; the 
transcription factor binding sites at promoter regions9-11;the 3-UTR post-transcriptional 







2.4. Gene expression 
 
Expression profiles at 55 of the 56 GWS loci were analysed within several eQTL datasets. 
We chose to omit the 17q21.31_2 locus because of the known rearrangements at this locus 
(inversion, duplications, and deletions) with resulting variable number of many of the genes at 
this locus. 
The first eQTL dataset, published by Reppe and colleagues14, tested the relationship between 
gene expressions in trans-iliacal bone biopsies and BMD in 84 unrelated postmenopausal 
women. Transcripts that located within +/- 500kb of the candidate SNPs at the GWS loci were 
queried in a dataset of eQTLs that correlated with adjusted BMD with a p-value below 0.1 in the 
published dataset, 163 uniquely mapping transcripts in total for FN- and LS-BMD.  Affymetrix 
HG U133 2.0 plus array was used for expression analysis, as previously described14.  
The second eQTL dataset used expression data from multiple publicly available and in-house 
datasets to carry out cis-association analysis: a) CEU lymphoblastoid cell lines (n=60) for 
expression QTL association15 using Illumina Sentrix Human-6 Expression BeadChip version 1 
and Genotypes from HapMap project, b) allelic expression cis-associations using llumina 
Human1M-duo BeadChip for lymphoblastoid cell lines (n=53)16 and for fibroblasts,  Illumina 
HumanRef-8 v3.0 for expression traits and Illumina HapMap 1M Duo chip for genotypes 
(Pastinen, unpublished data), and c) RNAseq CEU eQTLs, where expression values were taken 
from RNA sequencing data (Illumina GA2) and genotypes from HapMap project17 
(lymphoblastoid cell lines, n=60); d)  primary human fibroblasts (n=64) treated with 
cholesterol, resveratrol, and ethanol (Pastinen, unpublished data), and primary human 
osteoblasts (HOb) (n=104) treated with bone morphogenetic protein BMP-2, dexamethasone, 
prostaglandin E2, and control PBS using Illumina HumRef-8v2 BeadChips for expression traits 
and Illumina HapMap 550k Duo chip for genotypes18. Cis-regulatory effects were tested using 
SNPs mapping the candidate SNP +/- 500kb. For the fibroblast and osteoblast samples, due to 
limited genotype information, we imputed the genotypes (MACH 1.0) for HapMap SNPs to 
provide a larger density of SNPs to test.  Cis-associations for most datasets were carried out 
using a linear regression model implemented in the PLINK software package. Association 
analysis for the HOb datasets was carried out using MACH2QTL, using the genotype imputation 
data.  For the RNAseq CEU eQTL analysis, Spearman-rank correlation was used as implemented 
in the R (version 2.12.1) software package. Variance r2 is given for all eQTL datasets except for 
the RNAseq CEU analysis, where the rho value was calculated. 
The third eQTL dataset at deCODE Genetics utilizes expression data from adipose tissue and 
whole blood from 603 and Icelandic individuals, respectively19. Genotyping was performed using 
Infinium HumanHap300 and 370CNV BeadChips (Illumina) and genotypes imputed into HapMap 
2.5m SNPs using IMPUTE. Expression analysis was performed using an Agilent microarry of 
23,700 transcripts. The correlation between the SNPs and expression of genes at the 56 GWS 
loci (located within +/- 500kb from the candidate SNP) was tested by linear regression analysis 
of normalized expression level (age, sex, BMI and weight adjusted, and for differential cell 
count in case of whole blood) on SNP genotypes as previously described20.  
The fourth eQTL dataset is derived from circulating monocytes in 1,490 unrelated individuals, 
published by Zeller and colleagues21 (publicly available at genecanvas.ecgene.net).  All 
associations between SNPs and expressions with a p-value<5 x 10-5 were available for querying, 
using data analysed as described21, of expression traits measured on Illumina Human HT-12 
expression BeadChip (12,808 detectable expression traits) and SNPs genotyped on an 
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Affymetrix 6.0 array.  Expression of genes located within +/- 500kb from the candidate GWS 
SNPs at the 56 loci were queried for association in the dataset.  Proxy SNPs were used for 42 
SNPs that are not present on the Affymetrix 6.0 array (r2>0.7), no proxy was available for the 4 
SNPs, rs5934507 (chrX), rs13336428 (16p13.3_2), rs1566045 (16q12.1) and rs3755955 
(4p16.3) and these loci therefore not represented in this dataset. Study-wise threshold of 
significance correcting of the number of expressions tested was set at P< 5 x10-5. 
 
 
2.5. Literature-based annotation with GRAIL  
 
The Gene Relationships Across Implicated Loci (GRAIL)22 software was used to investigate 
relationships between 55 autosomal loci identified from the combined results.  Briefly, GRAIL 
evaluates connectivity and relationships between identified loci, by systematically mining 
Pubmed abstracts for shared text amongst possible genes at associated loci.  Genes from 
independently identified loci that have increased sharing of text in the scientific literature are 
more likely to be functionally related and therefore more likely to be truly involved in disease 
pathogenesis22.  As no information about the phenotype is used, the relatedness of genes at 
associated loci is not biased with respect to the phenotype.  We conducted GRAIL analysis using 
the December 2006 Pubmed data set (avoiding potential bias from investigation of candidate 
genes stimulated by GWAS), the HG18 build of the human genome, and the 55 autosomal BMD 
loci with a p-value <5 x 10-8.  
To confirm the significance of these findings, we followed a previously described strategy.22 
We applied GRAIL to 2000 random matched SNP sets; each set consisted of 55 SNPs randomly 
selected from a previously published23 set of 56,988 HapMap SNPs after LD pruning. We 
selected SNPs in LD with at least one gene, and so that in aggregate the total number of genes 
implicated was 224 +/-11 genes. These SNP sets matched the 55 SNPs associated with BMD in 
terms of total gene content, since those genes implicated 224 genes in aggregate. Then we 
individually tested each SNP test through GRAIL, noting with each run what proportion of SNPs 
demonstrated connectivity with ptext  scores ≤ 0.01. 
 
2.6. Allele Risk Modeling  
 
To estimate the cumulative effect of the genetic variants, we constructed genetic 
susceptibility scores that summed the weighted number of 55 autosomal and 8 secondary BMD-
decreasing alleles, where the weights were derived from the beta-coefficients of the relationship 
between BMD and the BMD-decreasing allele. The “osteoporosis” outcome,  was defined as 
having a FN-BMD T-score < -2.5. We used the NHANES24  (female) mean and SD (mean 0.849, 
SD 0.109) to estimate T-scores from the raw FN-BMD (T = (ZFNBMD-0.849)/0.109).  For the 
fracture risk modeling, first we used the 16 SNPs also associated with fracture risk were used to 
construct the genetic susceptibility scores and then compared the results by including the rest 
of the non-significantly associated SNPs. For this analysis, the weights were derived from the 
beta-coefficients of the relationship between fracture risk and the risk-increasing allele. 
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Models were estimated using the Prospective Epidemiological Risk Factor (PERF) study. This 
study is composed of postmenopausal women, in the age rage 55-86 years, taking part in a 
prospective epidemiological study and in various clinical trials for osteoporosis at the Center for 
Clinical and Basic Research, Copenhagen. Baseline DEXA- measurement (Hologic QDR2000) at 
the hip (total hip) and lumbar spine (L2-L4) was used.  Osteoporotic fractures included low 
trauma fractures from medical records and radiographic documentation. (Supplementary 
Methods Table 3A, 3B, 3C). A subset of 2,836 women with both FN-BMD and fracture 
information were used for this analysis.  
 
The PERF study was genotyped in Stage 2, had relatively large numbers of women with fracture 
ascertainment, and was not included in the discovery set. Furthermore, effect estimates of a 
meta-analysis excluding PERF in the Stage 2 replication samples were used to weight BMD-
decreasing alleles. Weights were transformed to have a mean=1 by dividing each effect by the 
median of the FN-BMD effects. Weights for each of the 63 SNPs are available in the 
Supplementary Tables. 
 
We performed profile scoring for each individual of the PERF study as implemented in PLINK, 
where: 
Scorei=Σj=1 to m b j xij , where 
m= number of SNPs 
b j =effect of allele at locus j 
xij=number of reference alleles of individual i at locus j 
 
The resulting genetic scores were divided in quintiles and the mean FN-BMD, osteoporosis risk 
and fracture risk estimates were computed per each quintile of weighted allele score. The 
performance of the osteoporosis and fracture prediction properties of the genetic score was 
quantified using the area under the receptor-operator characteristics (ROC) curves implemented 
in the software PredictABEL25. For this analysis the continuous weighted genotypic risk score 
was used in a regression model.  Finally, the measure of variance explained (adjusted r2) was 
estimated from a linear regression model incorporating the quantitative score as the predictor 





PLINK: http://pngu.mgh.harvard.edu/purcell/plink/   
GenABEL suite: http://www.genabel.org/ 
HapMap: http://www.hapmap.org/ 
LocusZoom: http://csg.sph.umich.edu/locuszoom/ 


























































Type of Contribution Cohort Name Overseeing (PI) Genotyping Phenotyping Data analysis
GWAS AFOS Alan R Shuldiner  X
GWAS AFOS Braxton D Mitchell X
GWAS AFOS Elizabeth  A Streeten X X
GWAS AFOS Laura M Yerges‐Armstrong X
GWAS AOGC Dana Willner X
GWAS AOGC David M Evans X
GWAS AOGC Elaine M  Dennison X
GWAS AOGC Emma L Duncan X X X
GWAS AOGC Eugene McCloskey X X
GWAS AOGC Geoffrey C Nicholson X X
GWAS AOGC Graeme Jones X X
GWAS AOGC Graeme R Clark X
GWAS AOGC Ian R Reid X X
GWAS AOGC John A Eisman X X X
GWAS AOGC John P Kemp X
GWAS AOGC Matthew A Brown X X X X
GWAS AOGC Patrick Danoy X
GWAS AOGC Paul J Leo X
GWAS AOGC Philip N Sambrook X X
GWAS AOGC Richard Eastell X X
GWAS CHS Bruce M  Psaty X
GWAS CHS Guo Li X
GWAS CHS Jerome I Rotter X X
GWAS CHS John Robbins X
GWAS CHS, HealthABC Jane A Cauley X X
GWAS deCODE Gudmar Thorleifsson X
GWAS deCODE Gunnar Sigurdsson X
GWAS deCODE Hrefna Johannsdottir X
GWAS deCODE Kari Stefansson X
GWAS deCODE Stefan Th.  Palsson X
GWAS deCODE Thorvaldur  Ingvarsson X
GWAS deCODE Unnur  Styrkarsdottir X X X X
GWAS deCODE Unnur  Thorsteinsdottir X
GWAS EPIC‐Norfolk Alireza Moayyeri X X
GWAS EPIC‐Norfolk Kay‐Tee Khaw X
GWAS EPIC‐Norfolk Nick J Wareham X X
GWAS EPIC‐Norfolk Robert Luben X X X
GWAS EPIC‐Norfolk,EPOS Jonathan Reeve X X
GWAS EPIC‐Norfolk,EPOS Stephen K Kaptoge X X
GWAS ERF Ben A  Oostra X
GWAS ERF Cornelia M van Duijn X X
GWAS ERF M. Carola Zillikens X X
GWAS ERF Najaf Amin X
GWAS ERF Yurii S Aulchenko  X
GWAS Fram Ching‐Ti Liu X
GWAS Fram David Karasik X
GWAS Fram Douglas P. Kiel X X X
GWAS Fram Kannabiran Nandakumar X
GWAS Fram L. Adrienne Cupples X X
GWAS Fram Yanhua Zhou X
GWAS Fram Yi‐Hsiang Hsu X
GWAS GOOD, MrOS Sweden Claes Ohlsson X X X
GWAS GOOD Joel Eriksson X
GWAS GOOD Liesbeth Vandenput X X
GWAS GOOD Mattias Lorentzon X X X
GWAS Health ABC Candace M. Kammerer X
GWAS Health ABC Frances A. Tylavsky X
GWAS Health ABC Ryan L. Minster X
GWAS Health ABC Steven  R. Cummings X
GWAS Health ABC Yongmei Liu X X
GWAS Health ABC,AGES Tamara B.  Harris X
GWAS HKOS Annie Wai Chee Kung X X
GWAS HKOS Pak Chung Sham X X
GWAS HKOS Su‐Mei Xiao X X X
GWAS INDIANA Daniel L Koller X
GWAS INDIANA Michael J Econs X X
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5. COHORT-SPECIFIC CONTRIBUTIONS
Type of Contribution Cohort Name Overseeing (PI) Genotyping Phenotyping Data analysis
GWAS INDIANA Munro Peacock X X
GWAS ORCADES James F Wilson X X
GWAS ORCADES,EDOS Omar ME Albagha X X
GWAS ORCADES,EDOS Stuart H Ralston X X
GWAS RS‐I, RS‐II & RS‐III Albert  Hofman X X
GWAS RS‐I, RS‐II & RS‐III Andre G. Uitterlinden X X X
GWAS RS‐I, RS‐II & RS‐III Carolina  Medina‐Gómez X
GWAS RS‐I, RS‐II & RS‐III Fernando Rivadeneira X X X X
GWAS RS‐I, RS‐II & RS‐III Huibert A.P. Pols X X
GWAS RS‐I, RS‐II & RS‐III Joyce B.J. van Meurs X X
GWAS RS‐I, RS‐II & RS‐III Karol Estrada X X
GWAS RS‐I, RS‐II & RS‐III Ling Oei X X
GWAS RS‐I, RS‐II & RS‐III Lizbeth  Herrera X
GWAS RS‐I, RS‐II & RS‐III Martha Castano‐Betancourt X
GWAS TUK1, TUK23 Frances MK  Williams X
GWAS TUK1, TUK23 Hou‐Feng Zheng X
GWAS TUK1, TUK23 J Brent Richards X X
GWAS TUK1, TUK23 Rui Li X
GWAS TUK1, TUK23 Scott G Wilson X
GWAS TUK1, TUK23 Timothy D Spector X X X
Meta‐analytical center IOANNINA Evangelia E Ntzani X
Meta‐analytical center IOANNINA Evangelos Evangelou X
Meta‐analytical center IOANNINA John P.A. Ioannidis X X
GxG GXG Analytical support Andrew R Wood X
INSILICO AGES Reykjavik study Albert V Smith X
INSILICO AGES Reykjavik study Kristin Siggeirsdottir X
INSILICO AGES Reykjavik study Melissa Garcia X
INSILICO AGES Reykjavik study Thor Aspelund X X
INSILICO AGES Reykjavik study Vilmundur Gudnason X X
INSILICO PROSPER/PHASE study Brendan M. Buckley X
INSILICO PROSPER/PHASE study Ian Ford X
INSILICO PROSPER/PHASE study J Wouter Jukema X
INSILICO PROSPER/PHASE study P Eline Slagboom X
INSILICO PROSPER/PHASE study Stella Trompet X X
INSILICO WGHS Daniel I. Chasman X X X X
INSILICO WGHS Lynda M. Rose X X
INSILICO WGHS Paul M Ridker X X
INSILICO WHI Aaron K Aragaki X X X
INSILICO WHI Andrea Z Lacroix X X X
INSILICO WHI Charles  Kooperberg X X X
INSILICO WHI David J Duggan X
INSILICO WHI Rebecca  D Jackson X X X X
INSILICO Young Finns Study Jorma Viikari X X
INSILICO Young Finns Study Marika Laaksonen X
INSILICO Young Finns Study Mika Kähönen X X
INSILICO Young Finns Study Olli Raitakari X X X
INSILICO Young Finns Study Terho Lehtimäki X X X
INSILICO Young Finns Study Ville Aalto X
De novo APOSS, NOSOS David M. Reid X
De novo APOSS, NOSOS Lynne J Hocking X
De novo AROS, DOPS Bente Lomholt Langdahl X
De novo AROS, DOPS Lise  Bjerre  Husted X
De novo AUSTRIOSA, AUSTRIOSB Barbara Obermayer‐Pietsch X X X
De novo AUSTRIOSA, AUSTRIOSB Olivia Trummer X
De novo BARCOS Natàlia Garcia‐Giralt X
De novo BARCOS Roser Urreizti X
De novo BARCOS Susana Balcells X
De novo BARCOS Xavier Nogues X X
De novo Cabrio‐C, Cabrio‐CC Jesús González‐Macías X
De novo Cabrio‐C, Cabrio‐CC José  M. Olmos X X
De novo Cabrio‐C, Cabrio‐CC José A. Riancho X X
De novo Cabrio‐C, Cabrio‐CC María  T. Zarrabeitia X
De novo AOGC,CAIFOS Richard L Prince X X X
De novo CAIFOS Joshua R Lewis X
De novo CAIFOS Kun Zhu X
De novo Calex‐family Markku Alen X
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De novo Calex‐family Sulin Cheng X X
De novo CaMos David Goltzman X
De novo CaMos Millan S. Patel X
De novo DOES Jacqueline R Center X X
De novo DOES Tuan V Nguyen X
De novo EDOS Nerea Alonso X
De novo EPOLOS Marcin  Kruk X
De novo EPOLOS Roman S Lorenc X
De novo EPOS Serena Scollen X
De novo FLOS Laura Masi X X
De novo FLOS Maria Luisa Brandi X X
De novo GEOS François Rousseau X X
De novo GEOS Sylvie Giroux X X
De novo GEVUR Elza Khusnutdinova X
De novo GEVUR Rita Khusainova X
De novo GROS Panagoula Kollia X
De novo GROS Theodora Koromila X X
De novo GROS Zoe Dailiana X
De novo HCS Cyrus Cooper X
De novo HCS Karen A. Jameson X
De novo HK Jean Woo X
De novo HK Nelson L.S. Tang X
De novo HK Ping C. Leung X
De novo KorAMC Ghi Su  Kim X
De novo KorAMC Jung‐Min Koh X X
De novo KorAMC Seung Hun  Lee X
De novo LASA Natasja  M. van Schoor X
De novo LASA Paul Lips X
De novo ManMC William D. Leslie X
De novo MrOS Sweden Dan Mellström X X
De novo MrOS Sweden Magnus Karlsson X X
De novo MrOS Sweden Östen Ljunggren X X
De novo OAS Morten Frost X X
De novo OAS Wim van Hul X X
De novo OSTEOS George Dedoussis X
De novo PERF Claus Christiansen X X
De novo SLO‐PREVAL Janez Prezelj X X X
De novo SLO‐PREVAL Janja Marc X X X X
De novo SLO‐PREVAL Simona Mencej‐Bedrac X X
De novo UFO Göran Hallmans X X
De novo UFO Olle Svensson X X
De novo UFO Ulrika Pettersson X X X
De novo deCODE Gudmar Thorleifsson X
De novo deCODE Gunnar Sigurdsson X
De novo deCODE Hrefna Johannsdottir X
De novo deCODE Kari Stefansson X
De novo deCODE Stefan Th.  Palsson X
De novo deCODE Thorvaldur  Ingvarsson X
De novo deCODE Unnur  Styrkarsdottir X X X X
De novo deCODE Unnur  Thorsteinsdottir X
EQTL eQTL analytical center (deCODE) Gudmar Thorleifsson X
EQTL eQTL analytical center (deCODE) Unnur  Styrkarsdottir X X X X
EQTL eQTL analytical center (deCODE) Unnur  Thorsteinsdottir X
EQTL eQTL analytical center (deCODE) Kari Stefansson X
EQTL eQTL analytical center (CA) Dominique Verlaan X X
EQTL eQTL analytical center (CA) Elin Grundberg X X
EQTL eQTL analytical center (CA) Tomi Pastinen X
EQTL eQTL analytical center (CA) Tony Kwan X
EQTL eQTL analytical center (NO) Kaare M. Gautvik X X X
EQTL eQTL analytical center (NO) Sjur Reppe X X X
GRAIL  Grail Analytical Support Soumya Raychaudhuri X
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Australian Cancer Research Foundation and Rebecca Cooper Foundation 
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